Modification of plant messenger packets with charged lipids

By reconstructing the plant messenger packet in the presence of synthetic charged lipids, the problem of difficult ingestion of heterologous functional agents in biological cells is solved, and efficient drug delivery is achieved, suitable for agriculture and therapeutic areas.

CN114727959BActive Publication Date: 2024-11-12FLAGSHIP PIONEERING INNOVATIONS VI LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080065212.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-02-26
Filing Date
2020-08-24
Publication Date
2024-11-12
Estimated Expiration
2040-08-24

AI Technical Summary

Technical Problem

The cellular uptake of heterologous functional agents in organisms is limited by the cell barrier and is difficult to effectively act.

Method used

The plant messenger package (LPMP) that is reconstituted and purified in the presence of synthetic charged lipids, wherein the synthetic charged lipids are selected from the group consisting of C12-200, DLin-MC3-DMA, DOTAP, etc., and the electrocharged lipids are generated by reconstruction. and use it to package heterologous polynucleotides such as mRNA, siRNA, etc. to improve cell uptake efficiency.

Benefits of technology

The cellular uptake efficiency of heterologous functional agents is significantly improved, increasing cellular uptake by at least 1% to 100%, suitable for the delivery of agricultural agents and therapeutic agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114727959B_ABST
    Figure CN114727959B_ABST
Patent Text Reader

Abstract

Disclosed herein are compositions comprising a plurality of plant messenger packets (e.g., comprising plant extracellular vesicles (EVs) or segments, portions, or extracts thereof) that are modified to have enhanced cellular uptake (e.g., animal or plant cell uptake, bacterial cell uptake, or fungal cell uptake), e.g., for use in various agricultural methods or therapeutic methods.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Sequence Listing

[0002] This application contains a sequence listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy was created on August 20, 2020, is named 51296-044WO1_Sequence_Listing_8_20_20_ST25, and is 3,013 bytes in size. Background Art

[0003] The delivery of heterologous functional agents (e.g., agricultural agents or therapeutic agents) may be limited by the extent to which the agent can penetrate cellular barriers to effectively act on the organism. For example, barriers formed by plant cell walls, bacterial cell walls, or fungal cell walls, or by the cell membrane and / or extracellular matrix of animal cells pose a challenge to the cellular uptake of agents useful in agricultural or therapeutic applications. Therefore, there is a need in the art for methods and compositions for promoting cellular uptake of agents, as well as methods for making plant messenger packets containing heterologous functional agents. Summary of the Invention

[0004] In one aspect, provided herein are methods for preparing lipid-reconstituted plant messenger packets (LPMPs), the methods comprising reconstituted a membrane comprising purified PMP lipids in the presence of a synthetic charged lipid, thereby producing a LPMP comprising the synthetic charged lipid.

[0005] In another aspect, provided herein is a method for preparing a lipid-reconstituted plant messenger packet (LPMP), the method comprising reconstructing a membrane comprising purified PMP lipids in the presence of a synthetic charged lipid, thereby producing a LPMP comprising the synthetic charged lipid, wherein the synthetic charged lipid is selected from 1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol)(C12-200), DLin-MC3-DMA (MC3), dioleoyl-3-trimethylammonium propane (DODAP), DC-cholesterol, DOTAP, ethyl PC, GL67 , DLin-KC2-DMA (KC2), MD1 (cKK-E12), OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), a cationic sulfonamide amino lipid, an amphiphilic zwitterionic amino lipid, DODAC, DOBAQ, YSK05, DOBAT, DOBAQ, DOPAT, DOMPAQ, DOAAQ, DMAP-BLP, DLinDMA, DODMA, DOTMA, DSDMA, DOSPA, DODAC, DOBAQ, DMRIE, DOTAP-cholesterol, GL67A, and 98N12-5, or a combination thereof.

[0006] In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, DC-cholesterol, DOTAP, ethyl PC, GL67, KC2, MD1, OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), a cationic sulfonamide amino lipid, and an amphiphilic zwitterionic amino lipid, or a combination thereof.

[0007] In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, and DC-cholesterol, or a combination thereof.

[0008] In some embodiments, the reconstitution is performed in the presence of a sterol, thereby producing a LPMP comprising a synthetic charged lipid and a sterol. In some embodiments, the sterol is cholesterol or sitosterol.

[0009] In some embodiments, the reconstitution is carried out in the presence of a PEGylated lipid, thereby producing a LPMP comprising a synthetic charged lipid and a PEGylated lipid. In some embodiments, the PEGylated lipid is C14-PEG2k, C18-PEG2k, or DMPE-PEG2k.

[0010] In some embodiments, reconstitution is performed in the presence of a sterol and a PEGylated lipid, thereby producing a LPMP comprising a synthetic charged lipid, a sterol, and a PEGylated lipid. In some embodiments, the synthetic charged lipid, the purified PMP lipid, the sterol, and the PEGylated lipid comprise approximately 30%-75%, approximately 10%-20%, approximately 35%-50%, and approximately 1%-3% of the lipid in the modified PMP, respectively. In some embodiments, the synthetic charged lipid, the purified PMP lipid, the sterol, and the PEGylated lipid are formulated in a molar ratio of 50:10:38.5:1.5.

[0011] In some embodiments, the LPMP comprises a heterologous polynucleotide. In some embodiments, the heterologous polynucleotide is mRNA, siRNA or a precursor thereof, microRNA (miRNA) or a precursor thereof, viral RNA, or a plasmid. In some embodiments, the LPMP has an encapsulation efficiency of at least 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or greater than 99% for the heterologous polynucleotide.

[0012] In some embodiments, LPMPs are formulated for delivery to animals.

[0013] In some embodiments, LPMPs are formulated for delivery to plants.

[0014] In another aspect, provided herein are compositions comprising a PMP modified to comprise a synthetic charged lipid.

[0015] In another aspect, provided herein are compositions comprising a PMP modified to comprise a synthetic charged lipid, wherein the synthetic charged lipid is selected from 1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol)(C12-200), DLin-MC3-DMA (MC3), dioleoyl-3-trimethylammonium propane (DODAP), DC-cholesterol, DOTAP, ethyl PC, GL67, DLin-KC2-DMA (KC2 ), MD1 (cKK-E12), OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), a cationic sulfonamide amino lipid, an amphiphilic zwitterionic amino lipid, DOBAQ, YSK05, DOBAT, DOBAQ, DOPAT, DOMPAQ, DOAAQ, DMAP-BLP, DLinDMA, DODMA, DOTMA, DSDMA, DOSPA, DODAC, DOBAQ, DMRIE, DOTAP-cholesterol, GL67A, and 98N12-5, or a combination thereof.

[0016] In another aspect, provided herein are compositions comprising a PMP modified to comprise a synthetic charged lipid, wherein the PMP is modified by reconstituting a lipid membrane comprising purified PMP lipids in the presence of the synthetic charged lipid, thereby producing a modified PMP comprising the synthetic charged lipid.

[0017] In another aspect, provided herein are compositions comprising a PMP modified to comprise a synthetic charged lipid, wherein the PMP is modified by reconstituting a lipid membrane comprising purified PMP lipids in the presence of the synthetic charged lipid, thereby producing a modified PMP comprising the synthetic charged lipid, wherein the synthetic charged lipid is selected from 1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol)(C12-200), DLin-MC3-DMA (MC3), dioleoyl-3-trimethylammoniumpropane (DODAP), DC-cholesterol, DOTA P, ethyl PC, GL67, DLin-KC2-DMA (KC2), MD1 (cKK-E12), OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipid, amphiphilic zwitterionic amino lipid, DODAC, DOBAQ, YSK05, DOBAT, DOBAQ, DOPAT, DOMPAQ, DOAAQ, DMAP-BLP, DLinDMA, DODMA, DOTMA, DSDMA, DOSPA, DODAC, DOBAQ, DMRIE, DOTAP-cholesterol, GL67A, and 98N12-5, or a combination thereof.

[0018] In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, DC-cholesterol, DOTAP, ethyl PC, GL67, KC2, MD1, OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), a cationic sulfonamide amino lipid, and an amphiphilic zwitterionic amino lipid, or a combination thereof.

[0019] In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, and DC-cholesterol, or a combination thereof.

[0020] In some embodiments, the modified PMP further comprises a sterol.

[0021] In some embodiments, the modified PMP further comprises a PEGylated lipid.

[0022] In some embodiments, the modified PMP further comprises a sterol and a PEGylated lipid.

[0023] In some embodiments, the sterol is cholesterol or sitosterol.

[0024] In some embodiments, the PEGylated lipid is C14-PEG2k, C18-PEG2k, or DMPE-PEG2k.

[0025] In some embodiments, the synthetic charged lipid, purified PMP lipid, sterol, and PEGylated lipid comprise about 30%-75%, about 10%-20%, about 35%-50%, and about 1%-3% of the lipid in the modified PMP, respectively. In some embodiments, the synthetic charged lipid, purified PMP lipid, sterol, and PEGylated lipid are formulated in a molar ratio of 50:10:38.5:1.5.

[0026] In some embodiments, the synthetic charged lipid is C12-200. In some embodiments, the lipid membrane of the modified PMP comprises 25% C12-200.

[0027] In some embodiments, the synthetic charged lipid is MC3. In some embodiments, the lipid membrane of the modified PMP comprises 40% MC3.

[0028] In some embodiments, the synthetic charged lipid is DC-cholesterol. In some embodiments, the lipid membrane of the modified PMP comprises 20% DC-cholesterol. In some embodiments, the lipid membrane of the modified PMP comprises 40% DC-cholesterol.

[0029] In some embodiments, the synthetic charged lipid is DOTAP. In some embodiments, the lipid membrane of the modified PMP comprises 25% DOTAP.

[0030] In some embodiments, the synthetic charged lipid is an ionizable lipid and the composition has a zeta potential greater than -40 mV at pH 4 (in the absence of cargo). In some embodiments, the composition has a zeta potential greater than 0 mV at pH 4 (in the absence of cargo). In some embodiments, the composition has a zeta potential greater than 20 mV at pH 4 (in the absence of cargo). In some embodiments, the composition has a zeta potential greater than 30 mV at pH 4 (in the absence of cargo). In some embodiments, the composition has a zeta potential of about 40 mV at pH 4 (in the absence of cargo). In some embodiments, the composition has a zeta potential greater than -30 mV (in the absence of cargo). In some embodiments, the composition has a zeta potential greater than -20 mV (in the absence of cargo). In some embodiments, the composition has a zeta potential greater than -5 mV (in the absence of cargo). In some embodiments, the composition has a zeta potential greater than 0 mV (in the absence of cargo). In some embodiments, the composition has a zeta potential of about 30 mV (in the absence of cargo).

[0031] In some embodiments, the modified PMP comprises a heterologous functional agent. In some embodiments, the heterologous functional agent is encapsulated by the modified PMP. In some embodiments, the heterologous functional agent is embedded on the surface of the modified PMP. In some embodiments, the heterologous functional agent is conjugated to the surface of the modified PMP.

[0032] In some embodiments, the heterologous functional agent is a polynucleotide. In some embodiments, the polynucleotide is selected from mRNA, siRNA or siRNA precursor, microRNA (miRNA) or miRNA precursor, plasmid, Dicer substrate small interfering RNA (dsiRNA), short hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), peptide nucleic acid (PNA), morpholino, locked nucleic acid (LNA), piwi interacting RNA (piRNA), ribozyme, deoxyribozyme (DNAzyme), aptamer, circular RNA (circRNA), guide RNA (gRNA), or a DNA molecule encoding any of these RNAs. In some embodiments, the polynucleotide is mRNA. In some embodiments, the polynucleotide is siRNA or its precursor. In some embodiments, the polynucleotide is a plasmid. In some embodiments, the encapsulation efficiency of the modified PMP for the polynucleotide is at least 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or more than 99%.

[0033] In some embodiments, the modified PMP is a lipid-reconstituted PMP (LPMP). In some embodiments, the LPMP is produced by a method comprising lipid extrusion. In some embodiments, the LPMP is produced by a method comprising treating a solution comprising a lipid extract of the PMP in a microfluidic device comprising an aqueous phase, thereby producing the LPMP. In some embodiments, the aqueous phase comprises a heterologous functional agent.

[0034] In some embodiments, the modified PMP has increased cellular uptake. In some embodiments, the increased cellular uptake is at least 1%, 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% increased cellular uptake relative to cellular uptake of the unmodified PMP. In some embodiments, the cell is a mammalian cell. In some embodiments, the mammalian cell is a human cell. In some embodiments, the cell is a plant cell. In some embodiments, the cell is a bacterial cell. In some embodiments, the cell is a fungal cell.

[0035] In another aspect, provided herein are methods for delivering a PMP to a target cell, the method comprising introducing into the target cell a composition comprising a PMP comprising a synthetic charged lipid.

[0036] In another aspect, provided herein is a method for delivering a PMP to a target cell, the method comprising introducing into the target cell a composition comprising a PMP comprising a synthetic charged lipid, wherein the synthetic charged lipid is selected from 1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol)(C12-200), DLin-MC3-DMA (MC3), dioleoyl-3-trimethylammonium propane (DODAP), DC-cholesterol, DOTAP, ethyl PC, GL67, DLin-KC2 -DMA (KC2), MD1 (cKK-E12), OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipid, amphiphilic zwitterionic amino lipid, DODAC, DOBAQ, YSK05, DOBAT, DOBAQ, DOPAT, DOMPAQ, DOAAQ, DMAP-BLP, DLinDMA, DODMA, DOTMA, DSDMA, DOSPA, DODAC, DOBAQ, DMRIE, DOTAP-cholesterol, GL67A, and 98N12-5, or a combination thereof.

[0037] In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, DC-cholesterol, DOTAP, ethyl PC, GL67, KC2, MD1, OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipids, and amphiphilic zwitterionic amino lipids, or a combination thereof. In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, and DC-cholesterol, or a combination thereof.

[0038] In some embodiments, the PMP further comprises a sterol. In some embodiments, the PMP further comprises a PEGylated lipid.

[0039] In some embodiments, the PMP further comprises a sterol and a PEGylated lipid. In some embodiments, the sterol is cholesterol or sitosterol. In some embodiments, the PEGylated lipid is C14-PEG2k, C18-PEG2k, or DMPE-PEG2k. In some embodiments, the synthetic charged lipid, purified PMP lipid, sterol, and PEGylated lipid comprise approximately 30%-75%, approximately 10%-20%, approximately 35%-50%, and approximately 1%-3% of the lipids in the PMP, respectively. In some embodiments, the synthetic charged lipid, purified PMP lipid, sterol, and PEGylated lipid are formulated in a molar ratio of 50:10:38.5:1.5.

[0040] In some embodiments, the synthetic charged lipid is C12-200. In some embodiments, the lipid membrane of the modified PMP comprises 25% C12-200.

[0041] In some embodiments, the synthetic charged lipid is MC3. In some embodiments, the lipid membrane of the modified PMP comprises 40% MC3.

[0042] In some embodiments, the synthetic charged lipid is DC-cholesterol. In some embodiments, the lipid membrane of the modified PMP comprises 20% DC-cholesterol. In some embodiments, the lipid membrane of the modified PMP comprises 40% DC-cholesterol.

[0043] In some embodiments, the synthetic charged lipid is DOTAP. In some embodiments, the lipid membrane of the modified PMP comprises 25% DOTAP.

[0044] In some embodiments, the synthetic charged lipid is an ionizable lipid, and the composition comprising the PMP has a zeta potential greater than -40 mV at pH 4 (in the absence of cargo). In some embodiments, the composition comprising the PMP has a zeta potential greater than 0 mV at pH 4 (in the absence of cargo). In some embodiments, the composition comprising the PMP has a zeta potential greater than 20 mV at pH 4 (in the absence of cargo). In some embodiments, the composition comprising the PMP has a zeta potential greater than 30 mV at pH 4 (in the absence of cargo). In some embodiments, the composition comprising the PMP has a zeta potential of about 40 mV at pH 4 (in the absence of cargo). In some embodiments, the composition comprising the PMP has a zeta potential greater than -30 mV (in the absence of cargo). In some embodiments, the composition comprising the PMP has a zeta potential greater than -20 mV (in the absence of cargo). In some embodiments, the composition comprising the PMP has a zeta potential greater than -5 mV (in the absence of cargo). In some embodiments, the composition comprising the PMP has a zeta potential greater than 0 mV (in the absence of cargo). In some embodiments, the composition comprising the PMP has a zeta potential (in the absence of cargo) of about 30 mV.

[0045] In some embodiments, the PMP comprises a heterologous functional agent. In some embodiments, the heterologous functional agent is encapsulated by the PMP. In some embodiments, the heterologous functional agent is embedded on the surface of the PMP. In some embodiments, the heterologous functional agent is conjugated to the surface of the PMP.

[0046] In some embodiments, the heterologous functional agent is a polynucleotide. In some embodiments, the polynucleotide is selected from mRNA, siRNA or siRNA precursor, miRNA or miRNA precursor, plasmid, dsiRNA, shRNA, aiRNA, PNA, morpholino, LNA, piRNA, ribozyme, DNAzyme, aptamer, circRNA, gRNA, or a DNA molecule encoding any of these RNAs. In some embodiments, the polynucleotide is mRNA. In some embodiments, the polynucleotide is siRNA or its precursor. In some embodiments, the polynucleotide is a plasmid. In some embodiments, the encapsulation efficiency of the PMP for the polynucleotide is at least 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or greater than 99%.

[0047] In some embodiments, the PMP is a lipid-remodeled PMP (LPMP).

[0048] In some embodiments, the PMP has increased cellular uptake. In some embodiments, the increased cellular uptake is at least 1%, 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% increased cellular uptake relative to cellular uptake of the unmodified PMP. In some embodiments, the cell is a mammalian cell. In some embodiments, the mammalian cell is a human cell. In some embodiments, the cell is a plant cell. In some embodiments, the cell is a bacterial cell. In some embodiments, the cell is a fungal cell.

[0049] In another aspect, provided herein is a method of increasing the fitness of a plant, comprising delivering to the plant an effective amount of any one of the compositions described above, wherein the method increases the fitness of the plant relative to an untreated plant.

[0050] In some embodiments, the modified PMP comprises an agricultural agent.

[0051] In some embodiments, the plant is a plant of agricultural or horticultural importance. In some embodiments, the plant is a soybean plant, a wheat plant, or a corn plant.

[0052] In another aspect, provided herein is a method of reducing the fitness of a plant, comprising delivering to the plant an effective amount of any one of the above-described compositions, wherein the method reduces the fitness of the plant relative to an untreated plant.

[0053] In some embodiments, the modified PMP comprises an agricultural agent.

[0054] In some embodiments, the plants are weeds.

[0055] In some embodiments, the composition is delivered to a leaf, seed, embryo, ovule, meristem, microspore, root, fruit, bud, pollen, or flower of a plant.

[0056] In another aspect, provided herein is a method of increasing the fitness of a mammal, comprising delivering to the mammal an effective amount of any one of the compositions described above, wherein the method increases the fitness of the mammal relative to an untreated mammal.

[0057] In some embodiments, the modified PMP comprises a heterologous therapeutic agent.

[0058] In some embodiments, the mammal is a human.

[0059] In another aspect, provided herein are compositions comprising modified PMPs having a zeta potential greater than or equal to -30 mV (in the absence of cargo).

[0060] In another aspect, provided herein are compositions comprising modified PMPs having a zeta potential greater than -40 mV at pH 4 (in the absence of cargo).

[0061] In some embodiments, the composition has a net positive zeta potential (in the absence of cargo).

[0062] In certain embodiments, the composition comprises an exogenous lipid. In certain embodiments, the exogenous lipid is an ionizable lipid. In certain embodiments, the ionizable lipid is C12-200. In certain embodiments, the ionizable lipid is MC3. In certain embodiments, the exogenous lipid is a cationic lipid. In certain embodiments, the cationic lipid is DOTAP. In certain embodiments, the cationic lipid is DC-cholesterol.

[0063] In some embodiments, the composition has a zeta potential (in the absence of a cargo) greater than 0 mV at pH 4. In some embodiments, the composition has a zeta potential (in the absence of a cargo) greater than 20 mV at pH 4. In some embodiments, the composition has a zeta potential (in the absence of a cargo) of about 40 mV at pH 4.

[0064] In some embodiments, the modified PMP further comprises a cargo. In some embodiments, the cargo is a heterologous functional agent. In some embodiments, the heterologous functional agent is a polynucleotide. In some embodiments, the polynucleotide is selected from mRNA, siRNA or siRNA precursor, miRNA or miRNA precursor, plasmid, dsiRNA, shRNA, aiRNA, PNA, morpholino, LNA, piRNA, ribozyme, DNAzyme, aptamer, circRNA, gRNA, or a DNA molecule encoding any of these RNAs.

[0065] In some embodiments, zeta potential is measured by electrophoretic light scattering.

[0066] In another aspect, provided herein are methods for delivering a cargo to a cell, the method comprising contacting the cell with any one of the compositions provided herein.

[0067] In another aspect, provided herein are methods for increasing cellular uptake of a cargo, the method comprising contacting a cell with any one of the compositions provided herein.

[0068] In another aspect, provided herein are methods for fusing a composition with a cell, the method comprising contacting the cell with any one of the compositions provided herein.

[0069] In another aspect, provided herein are methods for delivering a composition to a cell wall, the method comprising contacting a cell with any one of the compositions provided herein.

[0070] In another aspect, provided herein are methods for modulating gene expression in a cell, the method comprising contacting the cell with any one of the compositions provided herein.

[0071] In another aspect, provided herein are compositions comprising a plurality of lipid-reconstituted PMPs (LPMPs), wherein the LPMPs are produced by a method comprising the steps of: (a) providing a plurality of purified PMPs; (b) processing the plurality of PMPs to produce a lipid membrane; (c) reconstitute the lipid membrane in an organic solvent, wherein the organic solvent is dimethylformamide:methanol (DMF:MeOH), thereby producing a lipid solution; and (d) processing the lipid solution of step (c) in a microfluidic device comprising an aqueous phase, thereby producing the LPMPs.

[0072] In some embodiments, the LPMP further comprises an exogenous lipid. In some embodiments, the exogenous lipid is added to the formulation prior to step (b). In some embodiments, the exogenous lipid is a synthetic charged lipid. In some embodiments, the synthetic charged lipid is selected from 1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol)(C12-200), DLin-MC3-DMA (MC3), dioleoyl-3-trimethylammonium propane (DODAP), DC-cholesterol, DOTAP, ethyl PC, GL67, DLin-KC2-DMA (KC2), MD1 (cKK-E12), OF2, E PC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipids, amphiphilic zwitterionic amino lipids, DODAC, DOBAQ, YSK05, DOBAT, DOBAQ, DOPAT, DOMPAQ, DOAAQ, DMAP-BLP, DLinDMA, DODMA, DOTMA, DSDMA, DOSPA, DODAC, DOBAQ, DMRIE, DOTAP-cholesterol, GL67A, and 98N12-5, or a combination thereof. In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, DC-cholesterol, DOTAP, ethyl PC, GL67, KC2, MD1, OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipids, and amphiphilic zwitterionic amino lipids, or a combination thereof. In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, and DC-cholesterol, or a combination thereof.

[0073] In some embodiments, the aqueous phase comprises citrate buffer at a pH of about 3.2.

[0074] In some embodiments, the aqueous phase and the lipid solution are mixed at a volume ratio of 3:1.

[0075] In some embodiments, the LPMP comprises a heterologous functional agent. In some embodiments, the heterologous functional agent is a polynucleotide. In some embodiments, the polynucleotide is selected from mRNA, siRNA or siRNA precursor, miRNA or miRNA precursor, plasmid, dsiRNA, shRNA, aiRNA, PNA, morpholino, LNA, piRNA, ribozyme, DNAzyme, aptamer, circRNA, gRNA, or a DNA molecule encoding any of these RNAs.

[0076] In some embodiments, the heterologous functional agent is comprised of an aqueous phase.

[0077] In some embodiments, the LPMP further comprises a sterol. In some embodiments, the LPMP further comprises a PEGylated lipid. In some embodiments, the LPMP further comprises a sterol and a PEGylated lipid. In some embodiments, the sterol is cholesterol or sitosterol. In some embodiments, the PEGylated lipid is C14-PEG2k, C18-PEG2k, or DMPE-PEG2k.

[0078] In another aspect, provided herein is a method for preparing LPMPs, comprising (a) providing a plurality of purified PMPs; (b) processing the plurality of PMPs to produce a lipid membrane; (c) reconstituting the lipid membrane in an organic solvent, wherein the organic solvent is dimethylformamide:methanol (DMF:MeOH), thereby producing a lipid solution; and (d) processing the lipid solution of step (c) in a microfluidic device comprising an aqueous phase, thereby producing LPMPs.

[0079] In some embodiments, the LPMP further comprises an exogenous lipid.

[0080] In some embodiments, exogenous lipids are added to the formulation prior to step (b).

[0081] In some embodiments, the exogenous lipid is a synthetic charged lipid. In some embodiments, the synthetic charged lipid is selected from 1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol)(C12-200), DLin-MC3-DMA (MC3), dioleoyl-3-trimethylammonium propane (DODAP), DC-cholesterol, DOTAP, ethyl PC, GL67, DLin-KC2-DMA (KC2), MD1 (cKK-E12), OF2, E PC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipids, amphiphilic zwitterionic amino lipids, DODAC, DOBAQ, YSK05, DOBAT, DOBAQ, DOPAT, DOMPAQ, DOAAQ, DMAP-BLP, DLinDMA, DODMA, DOTMA, DSDMA, DOSPA, DODAC, DOBAQ, DMRIE, DOTAP-cholesterol, GL67A, and 98N12-5, or a combination thereof. In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, DC-cholesterol, DOTAP, ethyl PC, GL67, KC2, MD1, OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipids, and amphiphilic zwitterionic amino lipids, or a combination thereof. In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, and DC-cholesterol, or a combination thereof.

[0082] In some embodiments, the aqueous phase comprises water, PBS, or citrate buffer.

[0083] In some embodiments, the aqueous phase and the lipid solution are mixed at a volume ratio of 3:1.

[0084] In some embodiments, the LPMP comprises a heterologous functional agent. In some embodiments, the heterologous functional agent is a polynucleotide. In some embodiments, the polynucleotide is selected from mRNA, siRNA or siRNA precursor, miRNA or miRNA precursor, plasmid, dsiRNA, shRNA, aiRNA, PNA, morpholino, LNA, piRNA, ribozyme, DNAzyme, aptamer, circRNA, gRNA, or a DNA molecule encoding any of these RNAs.

[0085] In some embodiments, the heterologous functional agent is comprised of an aqueous phase.

[0086] In some embodiments, the LPMP further comprises a sterol. In some embodiments, the LPMP further comprises a PEGylated lipid. In some embodiments, the LPMP further comprises a sterol and a PEGylated lipid. In some embodiments, the sterol is cholesterol or sitosterol. In some embodiments, the PEGylated lipid is C14-PEG2k, C18-PEG2k, or DMPE-PEG2k.

[0087] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

[0088] definition

[0089] As used herein, an "agriculturally acceptable" carrier or excipient is one that is suitable for use in agriculture, e.g., for use in plants. In certain embodiments, an agriculturally acceptable carrier or excipient has no unnecessary adverse side effects on plants, the environment, or humans or animals that consume the agricultural product produced therefrom commensurate with a reasonable benefit / risk ratio.

[0090] As used herein, "delivering" or "contacting" refers to applying a PMP composition to a plant, animal, fungus, or bacterium directly on or adjacent to the plant, animal, fungus, or bacterium in an area where the composition is effective to alter the fitness of the plant, animal, fungus, or bacterium. In methods where the composition is brought into direct contact with the plant, animal, fungus, or bacterium, the composition can be brought into contact with the entire plant, animal, fungus, or bacterium or only a portion of the plant, animal, fungus, or bacterium.

[0091] As used herein, "reducing the fitness of a plant" refers to any disruption of the physiology of a plant (e.g., weed) resulting from the application of a composition described herein (e.g., a PMP composition comprising a modified PMP, optionally comprising a heterologous functional agent), including, but not limited to, reducing the plant (e.g., weed) population by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 100% or more. A reduction in the fitness of a plant can be determined as compared to a plant to which the composition has not been applied.

[0092] As used herein, the terms "effective amount," "effective concentration," or "a concentration effective at" refer to an amount of a modified PMP or a heterologous functional agent therein that is sufficient to affect a stated outcome or achieve a target level (e.g., a predetermined or threshold level) in or on a target organism.

[0093] As used herein, "increasing the fitness of a plant" refers to better plant production, such as increased yield, improved plant vigor, or improved quality of products harvested from the plant, as a result of applying a composition described herein (e.g., a PMP composition comprising a modified PMP, optionally comprising a heterologous functional agent). Improved plant yield refers to an increase in the yield of a plant's product in a measurable amount (e.g., as measured by plant biomass, grain, seed or fruit yield, protein content, carbohydrate or oil content, or leaf area) relative to the yield of the same product of a plant produced under the same conditions but without the application of the composition of the invention, or compared to the application of conventional agricultural agents. For example, the yield can be increased by at least about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, or greater than 100%. Productive rate can be represented by weight or volumetric measurement of the product of plant or plant on a certain basis.Basis can be represented by the weight of the plant of time, growing area, production or the amount of raw materials used.The increase of plant fitness also can be measured by other means, such as relative to the same factors of the plant produced under the same conditions but without using the present composition or using conventional agricultural agents, with the increase or improvement of vigor grade, plant density (stand) (number of plants / unit area) increase, plant height increases, stalk girth increases, plant canopy increases, outward appearance (for example, as the greener leaf color of visual measurement) improves, root grade improves, emerges increase, protein content, leaf size increases, leaf number increases, still less dead basal leaves, tillering intensity increases, nutrition or fertilizer requirement reduce, seed germination increases, tillering productivity increases, flowering increases, seed or grain maturity or seed maturity increase, still less plant section (verse) (lodging), the increase of bud growth or any combination of these factors, measure by measurable or perceptible amount.

[0094] As used herein, the term "heterologous" refers to an agent that is (1) exogenous to the plant (e.g., derived from a source other than the plant that produces the PMP) or (2) endogenous to the plant that produces the PMP, but is present in the PMP (e.g., using loading, genetic engineering, in vitro, or in vivo methods) at a concentration greater than that found in nature (e.g., as found in naturally occurring plant extracellular vesicles).

[0095] As used herein, the term "functional agent" refers to an agent (e.g., an agricultural agent (e.g., a pesticide, fertilizer, herbicide, plant modifier) ​​or a therapeutic agent (e.g., an antifungal, antibacterial, viricide, antiviral, insecticide, nematicide, antiparasitic, or insect repellent)) that is or can be associated with a PMP (e.g., loaded into or loaded onto (e.g., encapsulated by, embedded in, or conjugated to) a PMP using an in vivo or in vitro method and is capable of affecting a described outcome (e.g., increasing or decreasing the fitness of a plant, plant pest, plant symbiont, animal (e.g., human) pathogen, or animal pathogen vector) according to the compositions or methods of the invention. In some aspects, the functional agent is a polynucleotide.

[0096] As used herein, the term "agricultural agent" refers to an agent that can act on plants, plant pests, or plant symbionts, such as a pesticide, a pest repellent, a fertilizer, a plant modifier, or a plant symbiont modifier.

[0097] As used herein, the term "fertilizing agent" refers to an agent capable of increasing the fitness of a plant (eg, a plant nutrient or plant growth regulator) or a plant symbiont (eg, a nucleic acid or peptide).

[0098] As used herein, the term "pesticide" refers to an agent, composition, or substance therein that controls or reduces the fitness (e.g., kills or inhibits the growth, proliferation, division, reproduction, or spread) of agricultural, environmental, or domestic / household pests (e.g., insects, molluscs, nematodes, fungi, bacteria, weeds, or viruses). Pesticides are understood to include naturally occurring or synthetic insecticides (larvicides or adulticides), insect growth regulators, acaricides (miticides), molluscicides, nematocides, ectoparasiticides, bactericides, fungicides, or herbicides. The term "pesticide" may further encompass other bioactive molecules, such as antibiotics, antivirals, pesticides, antifungals, anthelmintics, nutrients, and / or agents that stop or slow insect movement.

[0099] As used herein, the term "plant modifying agent" refers to an agent that alters the genetic characteristics (e.g., increases gene expression, decreases gene expression, or otherwise changes the nucleotide sequence of DNA or RNA), epigenetic characteristics, or biochemical characteristics of a plant in a manner that results in a change (e.g., an increase or decrease) in the fitness of the plant.

[0100] As used herein, the term "therapeutic agent" refers to an agent (e.g., an antifungal agent, an antibacterial agent, a viricide, an antiviral agent, an insecticide, a nematicide, an antiparasitic agent, or an insect repellent) that acts on an animal (e.g., a mammal, such as a human), an animal pathogen, or a pathogen vector.

[0101] As used herein, the term "formulated for delivery to a plant" refers to a PMP composition comprising an agriculturally acceptable carrier. As used herein, an "agriculturally acceptable" carrier or excipient is one that is suitable for use in agriculture, commensurate with a reasonable benefit / risk ratio, and does not have excessive adverse side effects on the plant, the environment, or humans or animals that consume the agricultural product derived therefrom. Non-limiting examples of agriculturally acceptable carriers or excipients are known in the art; see, for example, Compedium of Herbicide Adjuvants, ppp[dot]purdue[dot]edu / wp-content / uploads / 2016 / 11 / PPP-115[dot]pdf.

[0102] As defined herein, the terms "nucleic acid" and "polynucleotide" are interchangeable and refer to linear or branched, single-stranded or double-stranded RNA or DNA, or hybrids thereof, regardless of length (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 150, 200, 250, 500, 1000, or more nucleic acids). The term also encompasses RNA / DNA hybrids. Nucleotides are typically linked in nucleic acids by phosphodiester bonds, although the term "nucleic acid" also encompasses nucleic acid analogs with other types of connections or backbones (e.g., phosphoramide, phosphorothioate, phosphorodithioate, O-methylphosphoramidate, morpholino, locked nucleic acid (LNA), glycerol nucleic acid (GNA), threose nucleic acid (TNA), and peptide nucleic acid (PNA) connections or backbones, etc.). Nucleic acids can be single-stranded, double-stranded, or contain portions of both single-stranded and double-stranded sequences. Nucleic acids can contain any combination of deoxyribonucleotides and ribonucleotides, and any combination of bases including, for example, adenine, thymine, cytosine, guanine, uracil, and modified or atypical bases including, for example, hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine, and 5-hydroxymethylcytosine.

[0103] As used herein, the term "pest" refers to an organism that causes damage to plants or other organisms, exists where they are not desired, or is otherwise detrimental to humans, such as by negatively affecting human agricultural methods or products. Pests can include, for example, invertebrates (e.g., insects, nematodes, or molluscs); microorganisms (e.g., plant pathogens, endophytes, obligate parasites, facultative parasites, or facultative saprophytes) such as bacteria, fungi, or viruses; or weeds.

[0104] As used herein, the term "pesticidal agent" or "pesticide" refers to an agent, composition, or substance therein that controls or reduces the fitness (e.g., kills or inhibits the growth, proliferation, division, reproduction, or spread) of agricultural, environmental, or domestic / household pests (such as insects, molluscs, nematodes, fungi, bacteria, weeds, or viruses). Pesticides are understood to encompass naturally occurring or synthetic insecticides (larvicides or adulticides), insect growth regulators, acaricides (miticides), molluscicides, nematocides, ectoparasiticides, bactericides, fungicides, or herbicides. The term "pesticide" may further encompass other biologically active molecules, such as antibiotics, antivirals, pesticides, antifungals, anthelmintics, nutrients, and / or agents that stop or slow insect movement.

[0105] The pesticide can be heterologous. As used herein, the term "heterologous" refers to an agent (e.g., a polynucleotide or pesticide) that is (1) exogenous to the plant (e.g., derived from a source other than the plant or plant part that produces the PMP) (e.g., added to the PMP using the loading methods described herein) or (2) endogenous to the plant cells or tissue that produces the PMP, but is present in the PMP (e.g., added to the PMP using the loading methods described herein, genetic engineering, in vitro or in vivo methods) at a concentration greater than that found in nature (e.g., greater than that found in naturally occurring plant extracellular vesicles).

[0106] As used herein, the term "repellent" refers to an agent, composition, or substance therein that prevents pests from approaching or remaining on a plant. A repellent can, for example, reduce the number of pests on or near a plant, but does not necessarily kill or reduce the fitness of the pest.

[0107] As used herein, the terms "peptide," "protein," or "polypeptide" encompass any chain of naturally or non-naturally occurring amino acids (D- or L-amino acids), regardless of length (e.g., at least 2, 3, 4, 5, 6, 7, 10, 12, 14, 16, 18, 20, 25, 30, 40, 50, 100 or more amino acids), the presence or absence of post-translational modifications (e.g., glycosylation or phosphorylation), or the presence of one or more non-aminoacyl groups (e.g., sugars, lipids, etc.) covalently attached to the peptide, and include, for example, naturally occurring proteins, synthetic or recombinant polypeptides and peptides, hybrid molecules, peptoids, or peptidomimetics.

[0108] As used herein, the "percent identity" between two sequences is determined by the BLAST 2.0 algorithm (described in Altschul et al., (1990) J. Mol. Biol. 215:403-410). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.

[0109] As used herein, the term "plant" refers to whole plant, plant organ, plant tissue, seed, plant cell, seed and their progeny. Plant cell includes but is not limited to cells from seed, suspension culture, embryo, meristematic region, callus, leaf, root, branch, gametophyte, sporophyte, pollen and microspore. Plant parts include differentiated and undifferentiated tissue, including but not limited to the following: root, stem, bud, leaf, pollen, seed, fruit, production of results, tumor tissue, juice (for example, xylem sap and phloem sap) and various forms of cell and culture (for example, unicellular, protoplast, embryo and callus). Plant tissue can be in plant or in plant organ, tissue or cell culture.

[0110] As used herein, the term "modified PMP" refers to a composition comprising a plurality of PMPs, wherein the PMPs comprise one or more heterologous agents (e.g., one or more exogenous lipids, such as charged lipids (e.g., ionizable and / or cationic lipids, e.g., PMPs comprising charged lipids and sterols and / or pegylated lipids) that are capable of increasing cellular uptake (e.g., animal cell uptake, plant cell uptake, bacterial cell uptake, or fungal cell uptake) of the PMP or a portion or component thereof (e.g., a heterologous functional agent carried by the PMP); capable of allowing or increasing the delivery of the heterologous functional agent (e.g., an agricultural agent or therapeutic agent) to cells by the PMP, and / or capable of allowing or increasing the loading (e.g., loading efficiency or loading capacity) of the heterologous functional agent (e.g., an agricultural agent or therapeutic agent) relative to an unmodified PMP. PMPs can be modified in vitro or in vivo.

[0111] As used herein, the term "unmodified PMP" refers to a composition comprising PMPs that lack a heterologous cellular uptake agent capable of increasing cellular uptake (eg, animal, plant, bacterial, or fungal) of the PMPs.

[0112] As used herein, the term "cellular uptake" refers to the uptake of a PMP or a portion or component thereof (e.g., a heterologous functional agent carried by a PMP) by a cell (e.g., an animal cell, a plant cell, a bacterial cell, or a fungal cell). For example, uptake can involve the transfer of a portion of the PMP or its component from the extracellular environment to or through the cell membrane, cell wall, extracellular matrix, or to the intracellular environment of the cell. Cellular uptake of a PMP can occur via active or passive cellular mechanisms. Cellular uptake includes aspects in which the entire PMP (e.g., LPMP) is taken up by the cell, for example, by endocytosis. In embodiments, after endocytosis and endosomal escape, one or more heterologous functional agents (e.g., polynucleotides) are exposed to the cytoplasm of the target cell. In embodiments, a modified PMP (e.g., a PMP comprising a charged lipid (e.g., an ionizable lipid and / or a cationic lipid), e.g., a PMP comprising a charged lipid and a sterol and / or a pegylated lipid) has an increased endosomal escape rate relative to an unmodified PMP. Cellular uptake also includes aspects in which the PMP (e.g., LPMP) fuses with the target cell membrane. In embodiments, after membrane fusion, one or more heterologous functional agents (e.g., polynucleotides) are exposed to the cytoplasm of the target cell. In embodiments, the modified PMP (e.g., a PMP comprising a charged lipid (e.g., an ionizable lipid and / or a cationic lipid), e.g., a PMP comprising a charged lipid and a sterol and / or a pegylated lipid) has an increased rate of fusion with the target cell membrane relative to the unmodified PMP.

[0113] As used herein, the term "cell permeating agent" refers to an agent that alters the properties (e.g., permeability) of the cell wall, extracellular matrix, or cell membrane of a cell (e.g., an animal cell, a plant cell, a bacterial cell, or a fungal cell) in a manner that promotes increased cellular uptake relative to cells that have not been contacted with the agent.

[0114] As used herein, the term "plant extracellular vesicle," "plant EV," or "EV" refers to a closed lipid bilayer structure naturally present in plants. Optionally, the plant EV comprises one or more plant EV markers. As used herein, the term "plant EV marker" refers to a component naturally associated with a plant, such as a plant protein, a plant nucleic acid, a plant small molecule, a plant lipid, or a combination thereof, including but not limited to any plant EV marker listed in the Appendix. In some cases, the plant EV marker is an identification marker for a plant EV, but is not a pesticide. In some cases, the plant EV marker is an identification marker for a plant EV and is also a pesticide (e.g., associated with or encapsulated by multiple PMPs, or not directly associated with or encapsulated by multiple PMPs).

[0115] As used herein, the term "plant messenger packet" or "PMP" refers to a lipid structure (e.g., a lipid bilayer, a monolayer, a multilayer structure; e.g., a vesicular lipid structure) having a diameter of about 5-2000 nm (e.g., at least 5-1000 nm, at least 5-500 nm, at least 400-500 nm, at least 25-250 nm, at least 50-150 nm, or at least 70-120 nm) that is derived from (e.g., enriched, isolated, or purified from) a plant source, or a segment, part, or extract thereof, including lipid or non-lipid components (e.g., peptides, nucleic acids, or small molecules) associated therewith, and that has been enriched, isolated, or purified from a plant, plant part, or plant cell, the enrichment or isolation removing one or more contaminants or undesirable components from the source plant. The PMP can be a highly purified preparation of naturally occurring EVs. Preferably, at least 1% (e.g., at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 45%, 50%, 55%, 60%, 70%, 80%, 90%, 95%, 96%, 98%, 99%, or 100%) of the contaminants or undesirable components from the source plant are removed, such as plant cell wall components; pectin; plant organelles (e.g., mitochondria; plastids, such as chloroplasts, leucoplasts, or amyloplasts; and nuclei); plant chromatin (e.g., plant chromosomes); or plant molecular aggregates (e.g., protein aggregates, protein-nucleic acid aggregates, lipoprotein aggregates, or lipid-protein structures). Preferably, the PMP is at least 30% pure (e.g., at least 40% pure, at least 50% pure, at least 60% pure, at least 70% pure, at least 80% pure, at least 90% pure, at least 99% pure, or 100% pure) with respect to the one or more contaminants or undesirable components from the source plant, as measured by weight (w / w), spectral imaging (% transmittance), or conductivity (S / m).

[0116] In some cases, the PMP is a lipid reconstituted PMP (LPMP). As used herein, the terms "lipid reconstituted PMP" and "LPMP" refer to a PMP derived from a lipid structure (e.g., a lipid bilayer, a monolayer, a multilayer structure; e.g., a vesicular lipid structure) derived from (e.g., enriched, isolated, or purified from) a plant source, wherein the lipid structure is disrupted (e.g., by lipid extraction) and reassembled or reconstituted (using standard methods, e.g., by methods including lipid film hydration and / or solvent injection) in a liquid phase (e.g., a liquid phase containing a cargo) to produce a LPMP, as described herein. If desired, the method can further include sonication, freeze / thaw treatment, and / or lipid extrusion, e.g., to reduce the size of the reconstituted PMP. Alternatively, a microfluidic device (e.g., IGNITE TM LPMPs are produced using a microfluidics instrument (Precision NanoSystems). PMPs (e.g., LPMPs) can comprise between 10% and 100% lipids derived from plant-derived lipid structures, for example, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% lipids derived from plant-derived lipid structures. PMPs (e.g., LPMPs) can comprise all or a portion of the lipid species present in plant-derived lipid structures, for example, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% of the lipid species present in plant-derived lipid structures. PMPs (e.g., LPMPs) can comprise none, some, or all of the protein species present in lipid structures from plant sources, for example, 0%, less than 1%, less than 5%, less than 10%, less than 15%, less than 20%, less than 30%, less than 40%, less than 50%, less than 60%, less than 70%, less than 80%, less than 90%, less than 100%, or 100% of the protein species present in lipid structures from plant sources. In some cases, the lipid bilayer of a PMP (e.g., LPMP) does not comprise protein. In some cases, the lipid structure of a PMP (e.g., LPMP) contains a reduced amount of protein relative to a lipid structure from a plant source.

[0117] The PMP (e.g., LPMP) can optionally include an exogenous lipid, e.g., a lipid that is exogenous to the plant (e.g., derived from a source other than the plant or plant part that produces the PMP) (e.g., the PMP is added using the methods described herein). The lipid composition of the PMP can include 0%, less than 1%, or at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more than 95% exogenous lipid. Exemplary exogenous lipids include charged lipids (e.g., ionizable and / or cationic lipids). Exogenous lipids can be cell permeabilizing agents that may be able to increase the delivery of heterologous functional agents (e.g., agricultural agents or therapeutic agents) to cells by the PMP, and / or may be able to increase the loading (e.g., loading efficiency or loading capacity) of heterologous functional agents (e.g., agricultural agents or therapeutic agents). Additional exemplary exogenous lipids include sterols and pegylated lipids.

[0118] The PMP may optionally contain additional agents, such as heterologous functional agents, e.g., cell permeants, pesticides, fertilizers, plant modifiers, therapeutic agents, polynucleotides, polypeptides, or small molecules. The PMP may carry or associate with additional agents (e.g., heterologous functional agents) in a variety of ways to enable delivery of the agents to the target plant, e.g., by encapsulating the agents, incorporating the agents into lipid bilayer structures, or associating the agents (e.g., by conjugation) with the surface of lipid bilayer structures. Heterologous functional agents may be incorporated into the PMP in vivo (e.g., in planta) or in vitro (e.g., in tissue culture, in cell culture, or synthetically incorporated).

[0119] As used herein, the term "charged lipid" refers to an amphiphilic molecule (e.g., lipid or lipidoid, e.g., synthetic lipid or lipidoid) containing a group (e.g., head group) that is charged (e.g., cationic) or can be ionized to produce one or more charged species under given conditions (e.g., pH). Charged lipids include ionizable lipids and cationic lipids. In some embodiments, the charged lipid is a positively charged lipid. Exemplary synthetic charged lipids include 1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazine-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), DLin-MC3-DMA (MC3), dioleoyl-3-trimethylammonium propane (DODAP), DC-cholesterol, DOTAP, ethyl PC, GL67, DLin-KC2-DMA (KC2), MD1 (cKK-E12), OF2, E PC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipid, amphiphilic zwitterionic amino lipid, DODAC, DOBAQ, YSK05, DOBAT, DOBAQ, DOPAT, DOMPAQ, DOAAQ, DMAP-BLP, DLinDMA, DODMA, DOTMA, DSDMA, DOSPA, DODAC, DOBAQ, DMRIE, DOTAP-cholesterol, GL67A, and 98N12-5.

[0120] As used herein, the term "ionizable lipid" refers to an amphiphilic molecule (e.g., a lipid or lipidoid, e.g., a synthetic lipid or lipidoid) containing a group (e.g., a head group) that can be ionized (e.g., dissociated to produce one or more charged species) under given conditions (e.g., pH). Exemplary synthetic ionizable lipids include, but are not limited to, [1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol)](C12-200), [(6Z,9Z,28Z,31Z)-heptatriacontria-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate] (DLin-MC3-DMA (MC3)), and 18:1 DAP 1,2-dioleoyl-3-dimethylammonium-propane (DODAP).

[0121] As used herein, the term "cationic lipid" refers to an amphiphilic molecule (e.g., a lipid or lipidoid, e.g., a synthetic lipid or lipidoid) containing a cationic group (e.g., a cationic head group). Exemplary synthetic cationic lipids include, but are not limited to, DC-cholesterol, dioleoyl-3-trimethylammonium propane (DOTAP), 1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (chloride) (ethyl PC), and N- 4 -Cholesteryl-spermine HCl salt (GL67).

[0122] As used herein, the term "lipidoid" refers to a molecule having one or more characteristics of a lipid.

[0123] As used herein, the term "stable PMP composition" (e.g., a composition comprising a loaded or unloaded PMP) refers to a composition that is stable for a period of time (e.g., at least 24 hours, at least 48 hours, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 30 days, at least 60 days, or at least 90 days), optionally under a defined temperature range (e.g., at least 24°C (e.g., at least 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, or 30°C), at least 20°C (e.g., at least 20°C, 21°C, 22°C, or 23°C), at least 4°C (e.g., at least 4°C, 2 ... For example, a temperature of at least -5°C, 10°C, or 15°C), at least -20°C (e.g., at least -20°C, -15°C, -10°C, -5°C, or 0°C), or -80°C (e.g., at least -80°C, -70°C, -60°C, -50°C, -40°C, or -30°C) retains at least 5% (e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 15 ... 0%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%) of the PMP composition; or optionally at a defined temperature range (e.g., at least 24°C (e.g., at least 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, or 30°C), at least 20°C (e.g., at least 20°C, 21°C, 22°C, or 23°C), at least 4°C (e.g., at least 5°C, 10°C, or 15°C), at least -20°C (e.g., at least -20°C, -15°C, -10°C, -5°C, or 0°C), ), or -80°C (e.g., at least -80°C, -70°C, -60°C, -50°C, -40°C, or -30°C)) retains at least 5% (e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%) of its activity (e.g., cell wall penetration activity and / or pesticidal and / or repellent activity) relative to the initial activity of the PMP (e.g., at the time of production or formulation).

[0124] As used herein, the term "formulated for delivery to an animal" refers to a PMP composition comprising a pharmaceutically acceptable carrier. As used herein, a "pharmaceutically acceptable" carrier or excipient is a carrier or excipient that is suitable for administration to an animal (e.g., a human) and, for example, does not have undue adverse side effects on the animal (e.g., a human).

[0125] As used herein, the term "untreated" refers to a plant, animal, fungus, or bacteria that has not been contacted with or delivered a PMP composition herein, including a plant, animal, fungus, or bacteria alone to which a PMP composition has not been delivered, the same plant, animal, fungus, or bacteria subjected to a treatment evaluated at a time point prior to delivery of a PMP composition, or the same plant, animal, fungus, or bacteria subjected to a treatment evaluated on an untreated portion of the plant, animal, fungus, or bacteria. BRIEF DESCRIPTION OF THE DRAWINGS

[0126] Figure 1 is a schematic diagram showing the workflow for preparing lipid-reconstituted PMPs (LPMPs) from grapefruit and lemon PMPs.

[0127] Figure 2 is a graph showing the relative frequency of particles of a given size (nm) in unmodified LPMP, LPMP supplemented with MC3, and LPMP supplemented with C12-200. Data were acquired by NanoFCM using concentration and size standards provided by the manufacturer.

[0128] Figure 3A is a graph showing the zeta potential (mV) of LPMP without added lipid (LPMP) (pH 7), LPMP containing 40% MC3 (pH 4 and pH 7), and LPMP containing 25% C12-200 (pH 4 and pH 7). Data are expressed as mean ± SD.

[0129] Figure 3B Is a bar graph showing the percentage of ATTO 550 labeled TracrRNA input recovered from LPMP after loading with LPMP containing lemon lipids (LPMP) (pH 7) without added lipids, LPMP containing 40% MC3 (pH 4 and pH 9), and LPMP containing 25% C12-200 (pH 4 and pH 9). Data are expressed as mean ± SD.

[0130] Figure 3C is a bar graph showing the difference between samples that have not been treated or have been treated with Triton TM sgRNA concentration (μg / mL) in LPMP containing 25% C12-200, lysed with X-100 and heparin (+TX+heparin), as measured using Quant-iT TM Analyze what is measured.

[0131] Figure 4Is a set of micrographs showing phase contrast (left column), ATTO 550 fluorescence (middle column), and merged views of black Mexican sweet (BMS) corn cells treated with LPMPs from lemon lipids without added lipids (middle row) and LPMPs containing 25% C12-200 (bottom row). Cells treated with HO alone are provided as a negative control (top row). The presence of TracrRNA ATTO 550 signal in cells indicates cellular uptake of LPMPs or LPMPs modified with C12-200. Scale bar: 100 μm.

[0132] Figure 5A : is a bar graph showing the hydrodynamic diameter (in nanometers (nm)) of lipid-reconstituted PMPs (LPMPs) from grapefruit (GF) and lemon (LM) formulated using microfluidics (NanoAssemblr) in the organic phase solvents ethanol (EtOH) or dimethylformamide:methanol (DMF:MeOH), as measured using DLS. Data are expressed as mean ± SD.

[0133] Figure 5B is a bar graph showing the polydispersity of LPMPs from grapefruit (GF) and lemon (LM) formulated in EtOH or DMF:MeOH using microfluidics (NanoAssemblr), as measured using DLS. Data are presented as mean ± SD.

[0134] Figure 6A is a bar graph showing the total mRNA concentration (μg / mL) in LPMPs containing C12-200 that have been formulated with 35 μg firefly luciferase (Fluc) mRNA per 1 mg PMP lipid using extrusion or microfluidics, as measured using Quant-iT TM The measured data were expressed as mean ± SD.

[0135] Figure 6B is a bar graph showing Figure 8A The mRNA encapsulation efficiency of LPMP (intact and cleaved (+ The percentage difference in mRNA concentration between vesicles containing (X-100 + heparin) was expressed as mean ± SD.

[0136] Figure 6C: is a bar graph showing the expression of firefly luciferase (Fluc) mRNA (mean luminescence normalized to viability ± SD; n = 4) delivered to A549 cells by C12-200 modified LPMPs or a commercial transfection reagent (MessengerMax). Cells were transfected with 50 ng, 100 ng, or 200 ng of FLuc mRNA for 24 h.

[0137] Figure 6D is a bar graph showing cell viability (%) after transfection with C12-200-modified LPMP or a commercial transfection reagent (MessengerMax) containing Fluc mRNA.

[0138] Figure 7 : is a bar graph showing the uptake / association of lipid-reconstituted PMPs and original PMPs from lemon (LM) and grapefruit (GF) into human adenocarcinoma (A549) cells, as quantified by the median fluorescence intensity of PKH67 dye using flow cytometry (MACSQuant Analyzer 10). Free PKH67 dye was used as a control. Data are expressed as mean relative fluorescence ± SD; n = 3.

[0139] Figure 8A is a bar graph showing the size of PMP compositions composed of C12-200, broccoli PMP lipid, cholesterol or sitosterol, and PEGylated lipid in a molar ratio of 50:10:38.5:1.5, respectively (bars; left axis), and the effect of PMP on Percent entrapment of firefly luciferase (FLuc) mRNA (dots; right axis). Lipid nanoparticle (LNP) compositions containing DOPE or DSPC instead of PMP lipids were provided as positive controls. The lipid:mRNA ratio (w:w) for each composition was 20:1. Formulations AF are described in Table 11 herein.

[0140] Figure 8B is a bar graph showing the size of PMP compositions consisting of C12-200 (optimized:optimized ratio) or MC3, broccoli PMP lipid, cholesterol or sitosterol, and PEGylated lipid in a molar ratio of 50:10:38.5:1.5, respectively (bars; left axis), and the effect of PMP on Percent capture of FLuc mRNA (dots; right axis). LNP compositions containing DOPE or DSPC instead of PMP lipids were provided as positive controls. The lipid:mRNA ratio (w:w) for each composition was 20:1. Formulations A'-J' are described in Table 12 herein.

[0141] Figure 9is a bar graph showing the expression of luciferase (relative luminescence units (RLU)) in Caco-2 cells contacted with PMP compositions composed of broccoli PMP lipid, cholesterol, C12-200 or MC3, and DMPE-PEG2k and loaded with FLuc mRNA. LNP compositions containing the synthetic phospholipid (PL) DOPE or DSPC instead of PMP lipid were provided as positive controls. Formulations AF are described in Table 11 herein.

[0142] Figure 10 is a bar graph showing the expression of luciferase (RLU) in HeLa cells contacted with PMP compositions composed of broccoli or grapefruit (GRAF) PMP lipids, cholesterol, C12-200 or MC3, and DMPE-PEG2k at the indicated molar ratios and loaded with gWiz TM -Luc (plasmid encoding luciferase). Compositions containing DOPE or DSPC instead of PMP lipids were provided as positive controls.

[0143] Figure 11 is a bar graph showing the expression of luciferase (RLU) in MCF7 cells contacted with PMP compositions consisting of broccoli PMP lipid, cholesterol or sitosterol, C12-200 or MC3, and DMPE-PEG2k at the indicated molar ratios and loaded with gWiz TM Compositions containing DOPE or DSPC instead of PMP lipids were provided as positive controls.

[0144] Figure 12 is a graph showing the relative frequency of particles of a given size (nm) in LPMPs; LPMPs with added DC-cholesterol (DC-Chol); and LPMPs with added DOTAP (DOTAP). Data were acquired by NanoFCM using concentration and size standards provided by the manufacturer.

[0145] Figure 13A is a cryo-electron micrograph showing LPMP reconstituted from extracted lemon PMP lipids. Scale bar: 500 nm.

[0146] Figure 13B is a graph showing the relative frequency of particles of a given equivalent spherical diameter (nm) in LPMPs reconstituted from extracted lemon lipids, as measured using cryo-electron microscopy.

[0147] Figure 14Ais a graph showing the zeta potential (mV) of LPMP without added lipid (LPMP) and LPMP containing 25% or 40% DOTAP or DC-cholesterol, as measured using dynamic light scattering (DLS). Data are presented as mean ± SD.

[0148] Figure 14B is a bar graph showing the percentage of Alexa Fluor 555-labeled siRNA input recovered from LPMPs after loading LPMPs from grapefruit lipids containing no added lipids (LPMPs) and LPMPs from grapefruit lipids containing 20% ​​DOTAP.

[0149] Figure 14C is a bar graph showing the percentage of ATTO-labeled TracrRNA input recovered from LPMPs after loading LPMPs from lemon lipids containing no added lipids (LPMPs) and LPMPs from lemon lipids containing 40% DC-cholesterol (DC-Chol).

[0150] Figure 14D is a bar graph showing the difference between samples that have not been treated or have been treated with Triton TM TracrRNA concentration (μg / mL) in LPMP containing 40% DC-cholesterol, lysed with X-100 and heparin (+TX+heparin), as measured using Quant-iT TM Analyze what is measured.

[0151] Figure 15 A set of micrographs showing DAPI (top row) and PKH67 (middle row) fluorescence in COLO697 cells treated with PKH67-labeled LPMPs derived from grapefruit lipids without added lipids (middle column) and LPMPs containing 20% ​​DOTAP (right column). The bottom panel shows a merged image containing DAPI and PKH67 signals. Cells treated with PKH67 dye are shown as a control. Scale bar: 50 μm.

[0152] Figure 16 Is a set of micrographs showing phase contrast (left column), ATTO 550 fluorescence (middle column) and merged views of black Mexican sweet corn (BMS) cells treated with LPMP (middle row) without added lipids and LPMP containing 40% DC-cholesterol (DC-Chol). Cells treated with HO alone served as a negative control (upper panel). Cellular uptake of LPMP or LPMP modified with DC-cholesterol is indicated by the presence of TracrRNA ATTO 550 signals in the cells. Scale bar: 100 μm.

[0153] Figure 17A is a bar graph showing the total mRNA concentration (μg / mL) in LPMPs containing DC cholesterol that have been formulated with 35 μg firefly luciferase (Fluc) mRNA / 1 mg PMP lipid using extrusion or microfluidics, as measured using Quant-iT TM The measured data were expressed as mean ± SD.

[0154] Figure 17B is a bar graph showing Figure 8A The mRNA encapsulation efficiency of LPMP (intact and cleaved (+ The percentage difference in mRNA concentration between vesicles containing (X-100 + heparin) was expressed as mean ± SD.

[0155] Figure 17C : is a bar graph showing the expression of firefly luciferase (Fluc) mRNA (mean luminescence normalized to viability ± SD; n = 4) delivered to A549 cells by DC-cholesterol-modified LPMPs or a commercial transfection reagent (MessengerMax). Cells were transfected with 50 ng, 100 ng, or 200 ng of FLuc mRNA for 24 h.

[0156] Figure 17D is a bar graph showing cell viability (%) after transfection with DC-cholesterol-modified LPMP or a commercial transfection reagent (MessengerMax) containing Fluc mRNA.

[0157] Figure 18 : is a bar graph showing human adenocarcinoma (A549) cell uptake / association of reconstituted LM (recLM) PMPs containing 40% DOTAP or DC-cholesterol, as quantified by median fluorescence intensity of PKH67 dye using flow cytometry (MACSQuant Analyzer 10). Free PKH67 dye was used as a control. Data are expressed as mean relative fluorescence ± SD; n = 3.

[0158] Figure 19A is a bar graph showing the total siRNA concentration (μg / mL) in lemon (LM) LPMPs modified with GL67 or ethyl PC (EPC) using extrusion, which had been formulated with 25 μg (approximately 1.5 nmol) siRNA / 1 mg PMP lipid, as measured using Quant-iT TM The measured data were expressed as mean ± SD.

[0159] Figure 19Bis a bar graph showing Figure 19A siRNA encapsulation efficiency of LPMP (intact and cleaved (+ The data are presented as mean ± SD. DETAILED DESCRIPTION

[0160] The present invention features modified plant messenger packages (PMPs). PMPs are lipid modules produced in whole or in part from plant extracellular vesicles (EVs) or segments, portions, or extracts thereof. PMPs can optionally contain additional agents (e.g., heterologous functional agents, (e.g., heterologous agricultural agents (e.g., pesticides, fertilizers, herbicides, plant modifiers) or heterologous therapeutic agents (e.g., antifungals, antibacterials, virucides, antivirals, insecticides, nematicides, antiparasitics, or insect repellents)). The modified PMPs and related compositions and methods described herein can be used in a variety of agricultural and therapeutic methods.

[0161] I. Modified Plant Messenger Packet Compositions

[0162] The PMP compositions described herein comprise a plurality of modified plant messenger packets (PMPs). PMPs are lipid (e.g., lipid bilayers, monolayers or multilayer structures) structures comprising plant EVs or their segments, parts or extracts (e.g., lipid extracts). Plant EVs refer to a closed lipid bilayer structure that naturally occurs in plants and has a diameter of about 5-2000 nm. Plant EVs can be derived from a variety of plant biosynthetic pathways. In nature, plant EVs can be found in intracellular compartments and extracellular compartments of plants, such as plant apoplasts (compartments located outside the plasma membrane and formed by continuous cell walls and extracellular spaces). Alternatively, PMPs can be enriched plant EVs found in cell culture media after secretion from plant cells. Plant EVs can be isolated from plants by the various methods further described herein, thereby providing PMPs. In addition, the PMP can optionally include a heterologous functional agent (e.g., a heterologous agricultural agent (e.g., a pesticide, a fertilizer, a herbicide, a plant modifier) ​​or a heterologous therapeutic agent (e.g., a cell permeating agent, an antifungal agent, an antibacterial agent, a viricide, an antiviral agent, an insecticide, a nematicide, an antiparasitic agent, or an insect repellent)) that can be introduced in vivo or in vitro. In some aspects, the heterologous functional agent is at least one nucleic acid (e.g., DNA or RNA, e.g., mRNA or siRNA) or a small molecule.

[0163] The PMPs may comprise plant EVs or segments, parts or extracts thereof. Optionally, in addition to lipids derived from plant EVs, the PMPs may also comprise exogenous lipids (e.g., sterols (e.g., cholesterol or sitosterol), charged lipids (e.g., ionizable lipids and / or cationic lipids), and / or pegylated lipids). In some embodiments, the diameter of the plant EVs is about 5-1000 nm. For example, the PMPs may comprise an average diameter of about 5-50 nm, about 50-100 nm, about 100-150 nm, about 150-200 nm, about 200-250 nm, about 250-300 nm, about 300-350 nm, about 350-400 nm, about 400-450 nm, about 450-500 nm, about 500-550 nm, about 550-600 nm, about 600-650 nm. 0 nm, about 650-700 nm, about 700-750 nm, about 750-800 nm, about 800-850 nm, about 850-900 nm, about 900-950 nm, about 950-1000 nm, about 1000-1250 nm, about 1250-1500 nm, about 1500-1750 nm, or about 1750-2000 nm of plant EVs or their segments, parts or extracts. In some cases, the PMPs comprise plant EVs or segments, parts or extracts thereof having an average diameter of about 5-950 nm, about 5-900 nm, about 5-850 nm, about 5-800 nm, about 5-750 nm, about 5-700 nm, about 5-650 nm, about 5-600 nm, about 5-550 nm, about 5-500 nm, about 5-450 nm, about 5-400 nm, about 5-350 nm, about 5-300 nm, about 5-250 nm, about 5-200 nm, about 5-150 nm, about 5-100 nm, about 5-50 nm, or about 5-25 nm. In some cases, the plant EVs or segments, parts or extracts thereof have an average diameter of about 50-200 nm. In some cases, the plant EVs or segments, parts or extracts thereof have an average diameter of about 50-300 nm. In some cases, the average diameter of the plant EV, or a segment, part, or extract thereof, is about 200-500 nm. In some cases, the average diameter of the plant EV, or a segment, part, or extract thereof, is about 30-150 nm.

[0164] In some cases, the PMPs may comprise plant EVs, or segments, portions, or extracts thereof, having an average diameter of at least 5 nm, at least 50 nm, at least 100 nm, at least 150 nm, at least 200 nm, at least 250 nm, at least 300 nm, at least 350 nm, at least 400 nm, at least 450 nm, at least 500 nm, at least 550 nm, at least 600 nm, at least 650 nm, at least 700 nm, at least 750 nm, at least 800 nm, at least 850 nm, at least 900 nm, at least 950 nm, or at least 1000 nm. In some cases, the PMPs comprise plant EVs or segments, parts or extracts thereof having an average diameter of less than 1000 nm, less than 950 nm, less than 900 nm, less than 850 nm, less than 800 nm, less than 750 nm, less than 700 nm, less than 650 nm, less than 600 nm, less than 550 nm, less than 500 nm, less than 450 nm, less than 400 nm, less than 350 nm, less than 300 nm, less than 250 nm, less than 200 nm, less than 150 nm, less than 100 nm, or less than 50 nm. The particle size of the plant EVs or segments, parts or extracts thereof can be measured using a variety of standard methods in the art (e.g., dynamic light scattering methods).

[0165] In some cases, the PMP may comprise an average surface area of ​​77 nm. 2 to 3.2x10 6 nm 2 (e.g., 77-100nm 2 , 100-1000nm 2 , 1000-1x10 4 nm 2 , 1x10 4 -1x10 5 nm 2 , 1x10 5 -1x10 6 nm 2 , or 1x10 6 -3.2x10 6 nm 2 ) of plant EVs or segments, parts or extracts thereof. In some cases, the PMPs may comprise an average volume of 65 nm 3 to 5.3x10 8 nm 3 (e.g., 65-100 nm 3 , 100-1000nm 3 , 1000-1x10 4 nm 3 , 1x10 4 -1x10 5 nm3 , 1x10 5 -1x10 6 nm 3 , 1x10 6 -1x10 7 nm 3 , 1x10 7 -1x10 8 nm 3 , 1x10 8 -5.3x10 8 nm 3 ) of a plant EV or a segment, part or extract thereof. In some cases, the PMP may comprise a mean surface area of ​​at least 77 nm 2 (For example, at least 77nm 2 , at least 100nm 2 , at least 1000nm 2 , at least 1x10 4 nm 2 , at least 1x10 5 nm 2 , at least 1x10 6 nm 2 , or at least 2x10 6 nm 2 ) of a plant EV or a segment, part or extract thereof. In some cases, the PMP may comprise an average volume of at least 65 nm 3 (For example, at least 65nm 3 , at least 100nm 3 , at least 1000nm 3 , at least 1x10 4 nm 3 , at least 1x10 5 nm 3 , at least 1x10 6 nm 3 , at least 1x10 7 nm 3 , at least 1x10 8 nm 3 , at least 2x10 8 nm 3 , at least 3x10 8 nm 3 , at least 4x10 8 nm 3 , or at least 5x10 8 nm 3 Plant EVs or their segments, parts or extracts.

[0166] In some cases, the size of the PMP can be the same as that of the plant EV or a segment, extract or portion thereof. Alternatively, the size of the PMP can be different from that of the initial plant EV from which the PMP is produced. For example, the diameter of the PMP can be about 5-2000 nm in diameter. For example, the average diameter of the PMP can be about 5-50 nm, about 50-100 nm, about 100-150 nm, about 150-200 nm, about 200-250 nm, about 250-300 nm, about 300-350 nm, about 350-400 nm, about 400-450 nm, about 450-500 nm, about 500-550 nm, about 550-600 nm, about 60 ... In some embodiments, the present invention relates to a nanostructured carbonyl group comprising: a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, a nanostructured carbonyl group, In some cases, the average diameter of the PMP can be at least 5 nm, at least 50 nm, at least 100 nm, at least 150 nm, at least 200 nm, at least 250 nm, at least 300 nm, at least 350 nm, at least 400 nm, at least 450 nm, at least 500 nm, at least 550 nm, at least 600 nm, at least 650 nm, at least 700 nm, at least 750 nm, at least 800 nm, at least 850 nm, at least 900 nm, at least 950 nm, at least 1000 nm, at least 1200 nm, at least 1400 nm, at least 1600 nm, at least 1800 nm, or about 2000 nm. The particle size of the PMP can be measured using a variety of standard methods in the art (e.g., dynamic light scattering methods). In some cases, the size of the PMP is determined after loading a heterologous functional agent or after other modifications of the PMP.

[0167] In some cases, the average surface area of ​​the PMPs can be 77 nm 2 to 1.3x10 7 nm 2 (e.g., 77-100nm 2 , 100-1000nm 2 , 1000-1x10 4 nm 2 , 1x10 4 -1x10 5 nm 2 , 1x10 5 -1x10 6 nm 2 , or 1x10 6 -1.3x107 nm 2 In some cases, the average volume of the PMP can be 65 nm. 3 to 4.2x10 9 nm 3 (e.g., 65-100 nm 3 , 100-1000nm 3 , 1000-1x10 4 nm 3 , 1x10 4 -1x10 5 nm 3 , 1x10 5 -1x10 6 nm 3 , 1x10 6 -1x10 7 nm 3 , 1x10 7 -1x10 8 nm 3 , 1x10 8 -1x10 9 nm 3 , or 1x10 9 -4.2x10 9 nm 3 ). In some cases, the average surface area of ​​the PMP is at least 77 nm 2 (For example, at least 77nm 2 , at least 100nm 2 , at least 1000nm 2 , at least 1x10 4 nm 2 , at least 1x10 5 nm 2 , at least 1x10 6 nm 2 , or at least 1x10 7 nm 2 ). In some cases, the average volume of the PMP is at least 65 nm 3 (For example, at least 65nm 3 , at least 100nm 3 , at least 1000nm 3 , at least 1x10 4 nm 3 , at least 1x10 5 nm 3 , at least 1x10 6 nm 3 , at least 1x10 7 nm 3 , at least 1x10 8nm 3 , at least 1x10 9 nm 3 , at least 2x10 9 nm 3 , at least 3x10 9 nm 3 , or at least 4x10 9 nm 3 ).

[0168] In some cases, the PMP may comprise a complete plant EV. Alternatively, the PMP may comprise a segment, portion, or extract of the entire surface area of ​​a vesicle of a plant EV (e.g., a segment, portion, or extract comprising less than 100% (e.g., less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 10%, less than 5%, or less than 1%) of the entire surface area of ​​the vesicle). The segment, portion, or extract may be of any shape, such as a circular segment, a spherical segment (e.g., a hemisphere), a curved segment, a linear segment, or a flat segment. In the case where the segment is a spherical segment of a vesicle, the spherical segment may represent a spherical segment produced by splitting a spherical vesicle along a pair of parallel lines or a spherical segment produced by splitting a spherical vesicle along a pair of non-parallel lines. Thus, a plurality of PMPs may comprise a plurality of whole plant EVs, a plurality of plant EV segments, parts or extracts, or a mixture of whole plant EVs and segmented plant EVs. It will be understood by those skilled in the art that the ratio of whole plant EVs to segmented plant EVs will depend on the specific separation method used. For example, grinding or blending a plant or a portion thereof can produce PMPs containing a higher percentage of plant EV segments, parts or extracts compared to non-destructive extraction methods such as vacuum infiltration.

[0169] In cases where the PMP comprises a segment, part or extract of a plant EV, the EV segment, part or extract may have an average surface area that is less than the average surface area of ​​an intact vesicle, for example less than 77 nm 2 , 100nm 2 , 1000nm 2 , 1x10 4 nm 2 , 1x10 5 nm 2 , 1x10 6 nm 2 , or 3.2x10 6 nm 2 In some cases, the surface area of ​​the EV segment, fraction, or extract is less than 70 nm. 2 , 60nm 2 , 50nm2 , 40nm 2 , 30nm 2 , 20nm 2 , or 10nm 2 In some cases, the PMPs may comprise a vesicle having an average volume less than the average volume of an intact vesicle (e.g., less than 65 nm). 3 , 100nm 3 , 1000nm 3 , 1x10 4 nm 3 , 1x10 5 nm 3 , 1x10 6 nm 3 , 1x10 7 nm 3 , 1x10 8 nm 3 , or 5.3x10 8 nm 3 average volume of plant EVs or their segments, parts or extracts).

[0170] In the case where the PMP comprises an extract of a plant EV, for example, in the case where the PMP comprises lipids extracted (e.g., with chloroform) from plant EVs, the PMP may comprise at least 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or greater than 99% of lipids extracted (e.g., with chloroform) from plant EVs. The PMPs in the plurality may comprise plant EV segments and / or plant EV extracted lipids or mixtures thereof.

[0171] Details regarding methods for producing modified PMPs, plant EV markers that can associate with PMPs, and formulations for compositions comprising PMPs are further outlined herein.

[0172] A. Production Method

[0173] PMPs can be produced from plant EVs or segments, parts or extracts thereof (e.g., lipid extracts), where PMPs are naturally present in plants or parts thereof (including plant tissues or plant cells). Exemplary methods for producing PMPs include (a) providing an initial sample from a plant or a part thereof, wherein the plant or a part thereof comprises EVs; and (b) isolating a crude PMP fraction from the initial sample, wherein the crude PMP fraction has a reduced level of at least one contaminant or undesirable component from the plant or a part thereof relative to the level in the initial sample. The method may further include the additional step of (c) purifying the crude PMP fraction, thereby producing a plurality of pure PMPs, wherein the plurality of pure PMPs have a reduced level of at least one contaminant or undesirable component from the plant or a part thereof relative to the level in the crude EV fraction. Each of the production steps will be discussed in further detail below. Exemplary methods for the isolation and purification of PMPs are found, for example, in Rutter and Innes, Plant Physiol. 173(1):728-741, 2017; Rutter et al., Bio. Protoc. 7(17):e2533, 2017; Regente et al., J of Exp. Biol. 68(20):5485-5496, 2017; Mu et al., Mol. Nutr. Food Res., 58, 1561-1573, 2014, and Regente et al., FEBS Letters. 583:3363-3366, 2009, each of which is incorporated herein by reference.

[0174] In some cases, a plurality of PMPs can be isolated from a plant by a method comprising the steps of: (a) providing an initial sample from a plant or a portion thereof, wherein the plant or portion thereof comprises EVs; (b) isolating a crude PMP fraction from the initial sample, wherein the crude PMP fraction has a reduced level (e.g., a reduction of at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 45%, 50%, 55%, 60%, 70%, 80%) of at least one contaminant or undesirable component from the plant or portion thereof relative to the level in the initial sample; , 90%, 95%, 96%, 98%, 99%, or 100% of the level); and (c) purifying the crude PMP fraction to produce a plurality of pure PMPs, wherein the plurality of pure PMPs have a reduced level of at least one contaminant or undesirable component from the plant or a portion thereof relative to the level in the crude EV fraction (e.g., a level reduced by at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 45%, 50%, 55%, 60%, 70%, 80%, 90%, 95%, 96%, 98%, 99%, or 100%).

[0175] The PMPs provided herein may comprise plant EVs produced from a variety of plants, or segments, parts or extracts thereof. PMPs may be produced from any genus of plant (vascular or non-vascular), including but not limited to angiosperms (monocots and dicots), gymnosperms, ferns, selaginellae, horsetails, naked ferns, lycophytes, algae (e.g., unicellular or multicellular, such as primitive plastid organisms) or mosses. In some cases, PMPs may be produced using vascular plants, such as monocots or dicots or gymnosperms. For example, PMPs may be produced using alfalfa, apple, Arabidopsis, banana, barley, Brassica species (e.g., Arabidopsis thaliana or Brassica napus). napus), canola, castor bean, chicory, chrysanthemum, clover, cocoa, coffee, cotton, cottonseed, corn, crambe, cranberry, cucumber, dendrobium, yam, eucalyptus, fescue, flax, gladiolus, lily family, linseed, millet, melon, mustard, oats, oil palm, rapeseed, papaya, peanuts, pineapple, ornamentals, beans, potatoes, rapeseed, rice, rye, ryegrass, safflower, sesame, sorghum, soybeans, sugar beets, sugarcane, sunflower, strawberry, tobacco, tomato, turf grass, wheat, or vegetable crops (such as lettuce, celery, broccoli, cauliflower , gourd); fruit and nut trees, such as apple, pear, peach, orange, grapefruit, lemon, lime, almond, pecan, walnut, and hazelnut; vines, such as grapes, kiwi, and hops; fruit shrubs and raspberries, such as raspberries, blackberries, and currants; forest trees, such as ash, pine, fir, maple, oak, chestnut, and poplar (popular); and alfalfa, canola, castor bean, corn, cotton, crambe, flax, linseed, mustard, oil palm, rapeseed, peanuts, potatoes, rice, safflower, sesame, soybeans, sugar beets, sunflower, tobacco, tomatoes, or wheat.

[0176] PMPs can be produced using the following: whole plants (e.g., entire rosettes or seedlings) or alternatively produced from one or more plant parts (e.g., leaves, seeds, roots, fruits, vegetative parts, pollen, phloem sap, or xylem sap). For example, PMPs can be produced using the following: shoot vegetative organs / structures (e.g., leaves, stems, or tubers), roots, flowers and floral organs / structures (e.g., pollen, bracts, sepals, petals, stamens, carpels, anthers, or ovules), seeds (including embryos, endosperms, or embryos), fruits (mature ovaries), sap (e.g., phloem or xylem sap), plant tissues (e.g., vascular tissue, ground tissue, tumor tissue, etc.), and cells (e.g., single cells, protoplasts, embryos, callus tissue, guard cells, egg cells, etc.), or progeny thereof. For example, the isolation step can involve (a) providing a plant or a part thereof. In some instances, the plant part is an Arabidopsis leaf. The plant can be at any developmental stage. For example, PMPs can be produced using seedlings, such as 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 week old seedlings (e.g., Arabidopsis seedlings). Other exemplary PMPs can be produced using roots (e.g., ginger root), fruit juices (e.g., grapefruit juice), vegetables (e.g., broccoli), pollen (e.g., olive pollen), phloem sap (e.g., Arabidopsis phloem sap), or xylem sap (e.g., tomato plant xylem sap).

[0177] Plants or parts thereof can be used to produce PMPs by a variety of methods. Any method that allows the release of a plant's apoplast fraction containing EVs, or other extracellular fractions (e.g., cell culture media) containing PMPs containing secreted EVs, is suitable for use in the methods of the present invention. EVs can be isolated from plants or plant parts by destructive (e.g., grinding or blending the plant or any plant part) or non-destructive (washing or vacuum infiltration of the plant or any plant part) methods. For example, the plant or a part thereof can be vacuum infiltrated, ground, blended, or a combination thereof to isolate EVs from the plant or plant part, thereby producing PMPs. For example, the separation step can involve vacuum infiltration of the plant (e.g., with a vesicle separation buffer) to release and collect the apoplast fraction. Alternatively, the separation step can involve grinding or blending the plant to release the EVs, thereby producing PMPs.

[0178] After isolating the plant EVs (thereby producing PMPs), the PMPs can be separated or collected into a crude PMP fraction (e.g., an apoplast fraction). For example, the separation step can involve separating multiple PMPs into a crude PMP fraction using centrifugation (e.g., differential centrifugation or ultracentrifugation) and / or filtration to separate the fraction containing the plant PMPs from large contaminants (including plant tissue fragments or plant cells). As a result, the crude PMP fraction will have a reduced number of large contaminants, including plant tissue fragments or plant cells, compared to the initial sample from the plant or plant part. Depending on the method used, the crude PMP fraction may additionally contain reduced levels of plant organelles (e.g., nuclei, mitochondria, or chloroplasts) compared to the initial sample from the plant or plant part.

[0179] In some cases, the separation step can involve separating the plurality of PMPs into a crude PMP fraction using centrifugation (e.g., differential centrifugation or ultracentrifugation) and / or filtration to separate the PMP-containing fraction from plant cells or cell debris. In such cases, the crude PMP fraction will have a reduced number of plant cells or cell debris compared to the initial sample from the source plant or plant part.

[0180] The crude PMP fraction can be further purified by additional purification methods to produce a plurality of pure PMPs. For example, the crude PMP fraction can be separated from other plant components by ultracentrifugation, for example using a density gradient (iodixanol or sucrose) and / or using other methods that remove aggregated components (e.g., precipitation or size exclusion chromatography). The resulting pure PMPs can have reduced levels of contaminants or other undesirable components from the source plant (e.g., one or more non-PMP components, such as protein aggregates, nucleic acid aggregates, protein-nucleic acid aggregates, free lipoproteins, lipid-protein structures), nuclei, cell wall components, cellular organelles, or combinations thereof) relative to one or more fractions produced in an earlier separation step, or relative to a predetermined threshold level (e.g., a commercial release specification). For example, a purified PMP can have reduced levels (e.g., about 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%; or about 2x-fold, 4x-fold, 5x-fold, 10x-fold, 20x-fold, 25x-fold, 50x-fold, 75x-fold, 100x-fold, or greater than 100x-fold) of plant organelles or cell wall components relative to the levels in the initial sample. In some cases, a purified PMP is substantially free (e.g., has undetectable levels) of one or more non-PMP components, such as protein aggregates, nucleic acid aggregates, protein-nucleic acid aggregates, free lipoproteins, lipid-protein structures), nuclei, cell wall components, cellular organelles, or combinations thereof. Additional examples of release and separation steps can be found in Example 1. The concentration of the PMP can be, for example, 1x10 9 , 5x10 9 , 1x10 10 , 5x10 10 , 5x10 10 , 1x10 11 , 2x10 11 , 3x10 11 , 4x10 11 , 5x10 11 , 6x10 11 , 7x10 11 , 8x10 11 , 9x10 11 , 1x10 12 , 2x10 12 , 3x10 12 , 4x10 12 , 5x10 12 , 6x10 12 , 7x10 12 , 8x10 12 , 9x10 12 , 1x10 13, or greater than 1x10 13 PMP / mL.

[0181] For example, protein aggregates can be removed from PMPs. For example, PMPs can be subjected to a range of pH values ​​(e.g., as measured using a pH probe) to precipitate protein aggregates in solution. The pH can be adjusted to, for example, pH 3, pH 5, pH 7, pH 9, or pH 11 by adding, for example, sodium hydroxide or hydrochloric acid. Once the solution is at a specified pH, it can be filtered to remove particulates. Alternatively, PMPs can be flocculated using charged polymers such as Polymin-P or Praestol 2640. Briefly, Polymin-P or Praestol 2640 is added to the solution and mixed with an impeller. The solution can then be filtered to remove particulates. Alternatively, aggregates can be solubilized by increasing the salt concentration. For example, NaCl can be added to the PMPs until it reaches, for example, 1 mol / L. The solution can then be filtered to separate the PMPs. Alternatively, aggregates can be solubilized by increasing the temperature. For example, the PMPs can be heated with mixing until the solution reaches a uniform temperature of, for example, 50°C for 5 minutes. The PMP mixture can then be filtered to separate the PMPs. Alternatively, soluble contaminants can be separated from the PMP solution by size exclusion chromatography according to standard procedures, with the PMPs eluting in the first fraction and proteins and ribonucleoproteins and some lipoproteins eluting later. The efficiency of protein aggregate removal can be determined by measuring and comparing protein concentrations before and after removal of protein aggregates via BCA / Bradford protein quantification.

[0182] Any production method described herein can be supplemented with any quantitative or qualitative method known in the art to characterize or identify PMPs at any step of the production process. PMPs can be characterized by a variety of analytical methods that estimate PMP yield, PMP concentration, PMP purity, PMP composition, or PMP size. PMPs can be evaluated by many methods known in the art that can visualize, quantify, or qualitatively characterize (e.g., composition identification) PMPs, such as microscopy (e.g., transmission electron microscopy), dynamic light scattering, nanoparticle tracking, spectroscopy (e.g., Fourier transform infrared analysis), or mass spectrometry (protein and lipid analysis). In some cases, methods (e.g., mass spectrometry) can be used to identify plant EV markers present on PMPs, such as the markers disclosed in the appendix. In order to help analyze and characterize PMP fractions, PMPs can be additionally labeled or stained. For example, PMPs can be labeled or stained with 3,3'-dihexyloxacarbocyanine iodide (DIOC6) (fluorescent lipophilic dye, PKH67 (Sigma Aldrich); Alexa Fluor 500; ... 488 (ThermoFisher Scientific), or DyLight TM 800 (Thermo Fisher) staining. In the absence of complex forms of nanoparticle tracking, this relatively simple method quantifies total membrane content and can be used to indirectly measure the concentration of PMPs (Rutter and Innes, Plant Physiol. [Plant Physiology] 173 (1): 728-741, 2017; Rutter et al., Bio. Protoc. [Biological Program] 7 (17): e2533, 2017). For more accurate measurements and to evaluate the size distribution of PMPs, nanoparticle tracking can be used.

[0183] During production, the PMPs can optionally be prepared such that the PMPs have an increased concentration relative to the EV levels in a control or initial sample (e.g., an increase of about 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%; or an increase of about 2x-fold, 4x-fold, 5x-fold, 10x-fold, 20x-fold, 25x-fold, 50x-fold, 75x-fold, 100x-fold, or greater than 100x-fold). The PMPs can comprise from about 0.1% to about 100% of the PMP composition, such as from about 0.01% to about 100%, from about 1% to about 99.9%, from about 0.1% to about 10%, from about 1% to about 25%, from about 10% to about 50%, from about 50% to about 99%, or from about 75% to about 100%. In some cases, the composition comprises at least 0.1%, 0.5%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more of any of PMPs, e.g., as measured by wt / vol percent PMP protein composition and / or percent lipid composition (e.g., by measuring fluorescently labeled lipids; see, e.g., Example 3). In some cases, concentrated formulations are used as commercial products, e.g., end users can use diluted formulations having significantly lower concentrations of active ingredients. In some embodiments, the composition is formulated as an agricultural concentrate formulation, e.g., an ultra-low volume concentrate formulation.

[0184] As demonstrated in Example 1, PMPs can be produced using a variety of plants or parts thereof (e.g., leaf apoplasts, seed apoplasts, roots, fruits, vegetative parts, pollen, phloem, or xylem sap). For example, PMPs can be released from apoplast fractions of plants, such as leaf apoplasts (e.g., Arabidopsis leaf apoplasts) or seed apoplasts (e.g., sunflower seed apoplasts). Other exemplary PMPs can be produced using roots (e.g., ginger root), juices (e.g., grapefruit juice), plants (e.g., broccoli), pollen (e.g., olive pollen), phloem sap (e.g., Arabidopsis phloem sap), xylem sap (e.g., tomato plant xylem sap), or cell culture supernatants (e.g., BY2 tobacco cell culture supernatants). This example further demonstrates the production of PMPs from these various plant sources.

[0185] As demonstrated in Example 2, PMPs can be purified by a variety of methods, such as by using a density gradient (iodixanol or sucrose) in combination with ultracentrifugation and / or methods to remove aggregated contaminants (e.g., precipitation or size exclusion chromatography). For example, Example 2 demonstrates the purification of PMPs obtained by the separation steps outlined in Example 1. Additionally, PMPs can be characterized according to the methods demonstrated in Example 3.

[0186] PMPs may be modified prior to use, as further outlined herein.

[0187] B. Modified PMPs and PMP Compositions

[0188] After production of the PMP, the PMP can be modified by loading or formulating with a heterologous agent (e.g., a cell permeating agent) that increases cellular uptake (e.g., animal cell uptake (e.g., mammalian cell uptake, such as human cell uptake)), plant cell uptake, bacterial cell uptake, or fungal cell uptake relative to the unmodified PMP. For example, the modified PMP can include (e.g., loaded, such as encapsulated or conjugated to) or be formulated with (e.g., suspended or resuspended in a solution containing) a plant cell permeating agent, such as a charged lipid (e.g., an ionizable lipid and / or a cationic lipid). Each of the modified PMPs can contain at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater than 90% charged lipid (e.g., ionizable lipid and / or cationic lipid).

[0189] In some cases, the heterologous agent is a charged lipid (e.g., a synthetic charged lipid, e.g., an ionizable lipid and / or a cationic lipid). In some embodiments, the synthetic charged lipid is selected from 1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), DLin-MC3-DMA (MC3), dioleoyl-3-trimethylammonium propane (DODAP), DC-cholesterol, DOTAP, ethyl PC, GL67, DLin-KC2-DMA (KC2), MD1 (cKK-E12), OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipids, amphiphilic zwitterionic amino lipids, DODAC, DOBAQ, YSK05, DOBAT, DOBAQ, DOPAT, DOMPAQ, DOAAQ, DMAP-BLP, DLinDMA, DODMA, DOTMA, DSDMA, DOSPA, DODAC, DOBAQ, DMRIE, DOTAP-cholesterol, GL67A, and 98N12-5, or a combination thereof. In some embodiments, the synthetic charged lipid is selected from C12-200, MC3, DODAP, DC-cholesterol, DOTAP, ethyl PC, GL67, KC2, MD1, OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipids, and amphiphilic zwitterionic amino lipids, or a combination thereof. In some embodiments, the charged lipid of synthesis is selected from C12-200, MC3, DODAP and DC-cholesterol or its combination. In some cases, the charged lipid is an ionizable lipid. In some embodiments, the ionizable lipid is 1,1 '-((2-(4-(2-((2-bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazine-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200) or (6Z, 9Z, 28Z, 31Z)-triacontac-6,9,28,31-tetraene-19-yl 4-(dimethylamino)butyrate, DLin-MC3-DMA (MC3). In some cases, the charged lipid is a cationic lipid. In some embodiments, the cationic lipid is DC-cholesterol or dioleoyl-3-trimethylammonium propane (DOTAP).

[0190] In some cases, the PMP comprises at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater than 90% charged lipids (e.g., ionizable lipids and / or cationic lipids).

[0191] In some cases, the PMP comprises a molar ratio of at least 0.1%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more than 90% charged lipids (e.g., ionizable lipids and / or cationic lipids), for example, 1%-10%, 10%-20%, 20%-30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, 70%-80%, or 80%-90% charged lipids, for example, about 30%-75% charged lipids (e.g., about 30%-75% charged lipids). In some embodiments, the PMP comprises 25% C12-200. In some embodiments, the PMP comprises 35% C12-200 by mole. In some embodiments, the PMP comprises 50% C12-200 by mole. In some embodiments, the PMP comprises 40% MC3. In some embodiments, the PMP comprises 50% C12-200 by mole. In some embodiments, the PMP comprises 20% or 40% DC-cholesterol. In some embodiments, the PMP comprises 25% or 40% DOTAP.

[0192] The agent may increase the uptake of the PMP as a whole or may increase the uptake of a portion or component of the PMP, such as a heterologous functional agent carried by the PMP (e.g., a heterologous agricultural agent (e.g., a pesticide, fertilizer, herbicide, plant modifier) ​​or a heterologous therapeutic agent (e.g., an antifungal agent, an antibacterial agent, a viricide, an antiviral agent, an insecticide, a nematicide, an antiparasitic agent, or an insect repellent)). The degree of increase in cellular uptake (e.g., plant cell uptake, bacterial cell uptake, or fungal cell uptake) may depend on the plant or plant part to which the composition is delivered, the PMP formulation, and other modifications made to the PMP. For example, The modified PMP can have at least 1%, 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% increased cellular uptake (e.g., animal cell uptake, plant cell uptake, bacterial cell uptake, or fungal cell uptake) relative to the unmodified PMP. In some cases, the increased cellular uptake (e.g., animal cell uptake, plant cell uptake, bacterial cell uptake, or fungal cell uptake) is at least 2x-fold, 4x-fold, 5x-fold, 10x-fold, 100x-fold, or 1000x-fold increased cellular uptake relative to the unmodified PMP.

[0193] In some embodiments, PMPs modified with charged lipids (e.g., ionizable lipids and / or cationic lipids) more effectively encapsulate negatively charged heterologous functional agents (e.g., polynucleotides) than PMPs not yet modified with charged lipids. In some aspects, PMPs modified with charged lipids have altered biodistribution relative to PMPs not yet modified with charged lipids. In some aspects, PMPs modified with charged lipids have altered (e.g., increased) fusion with target cell endosomal membranes relative to PMPs not yet modified with charged lipids.

[0194] In another aspect, the PMPs can be further modified with other components (e.g., lipids, e.g., sterols such as cholesterol; or small molecules) to further alter the functional and structural characteristics of the PMPs. For example, the PMPs can be further modified with stabilizing molecules that increase the stability of the PMPs (e.g., for at least one day at room temperature and / or for at least one week at 4°C).

[0195] In some embodiments, the PMP is modified with a sterol. In some embodiments, the sterol is cholesterol or sitosterol. In some cases, the PMP comprises a sterol (e.g., cholesterol or sitosterol) in a molar ratio of at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or greater than 60%, for example, 1%-10%, 10%-20%, 20%-30%, 30%-40%, 40%-50%, or 50%-60% sterol. In some embodiments, the PMP comprises a sterol (e.g., cholesterol or sitosterol) in a molar ratio of about 35%-50%, for example, about 36%, 38.5%, 42.5%, or 46.5% sterol. In some embodiments, the PMP comprises a sterol in a molar ratio of about 20%-40%.

[0196] In some embodiments, the PMP that has been modified with a sterol has altered stability (e.g., increased stability) relative to a PMP that has not been modified with a sterol. In some aspects, the PMP that has been modified with a sterol has a greater rate of fusion with the target cell membrane relative to a PMP that has not been modified with a sterol.

[0197] In some embodiments, the PMP is modified with a PEGylated lipid. The polyethylene glycol (PEG) length can vary from 1 kDa to 10 kDa; in some aspects, a PEG of 2 kDa is used. In some embodiments, the PEGylated lipid is C14-PEG2k, C18-PEG2k, or DMPE-PEG2k. In some cases, the PMP comprises a molar ratio of at least 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, 3.5%, 4%, 4.5%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 10%, 20%, 30%, 40%, 50%, or greater than 50% PEGylated lipid (e.g., C14-PEG2k, C18-PEG2k, or DMPE-PEG2k), for example, 0.1%-0.5%, 0.5%-1%, 1%-1.5%, 1.5%-2.5%, 2.5%-3.5%, 3.5%-5%, 5%-10%, 10%-20%, 20%-30%, 30%-40%, or 30%-50% PEGylated lipid. In some embodiments, the PMP comprises a molar ratio of about 0.1% to 10% PEGylated lipid (e.g., C14-PEG2k, C18-PEG2k, or DMPE-PEG2k), for example, about 1% to 3% PEGylated lipid, for example, about 1.5% or about 2.5% PEGylated lipid. In some embodiments, the PMP modified with PEGylated lipid has altered stability (e.g., increased stability) relative to a PMP not yet modified with PEGylated lipid. In some embodiments, the PMP modified with PEGylated lipid has an altered particle size relative to a PMP not yet modified with PEGylated lipid. In some embodiments, the PMP modified with PEGylated lipid is less likely to be phagocytosed than the PMP not yet modified with PEGylated lipid. Adding PEGylated lipids can also affect the stability of the GI tract and enhance the migration of particles through mucus. PEG can be used as a method of attaching a targeting moiety.

[0198] In some embodiments, the PMP is modified with an ionizable lipid (e.g., C12-200 or MC3) and one or both of a sterol (e.g., cholesterol or sitosterol) and a pegylated lipid (e.g., C14-PEG2k, C18-PEG2k, or DMPE-PEG2k). In embodiments, the modified PMP comprises a molar ratio of about 5%-50% PMP lipid (e.g., about 10%-20% PMP lipid, e.g., about 10%, 12.5%, 16%, or 20% PMP lipid); about 30%-75% ionizable lipid (e.g., about 35% or about 50% ionizable lipid); about 35%-50% sterol (e.g., about 36%, 38.5%, 42.5%, or 46.5% sterol); and about 0.1%-10% PEGylated lipid (e.g., about 1%-3% PEGylated lipid, e.g., about 1.5% or about 2.5% PEGylated lipid).

[0199] In some embodiments, PMPs modified with cationic lipids and sterols and / or pegylated lipids are more efficient at encapsulating negatively charged cargo (e.g., nucleic acids) than PMPs that have not been modified with cationic lipids and sterols and / or pegylated lipids. The modified PMPs can have an encapsulation efficiency of at least 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or greater than 99% for cargo (e.g., nucleic acids, e.g., RNA or DNA), for example, 5%-30%, 30%-50%, 50%-70%, 70%-80%, 80%-90%, 90%-95%, or 95%-100%.

[0200] Cellular uptake of modified PMPs can be measured by a variety of methods known in the art. For example, the PMP or a component thereof can be labeled with a marker detectable in isolated cells (e.g., a fluorescent marker) to confirm uptake. For example, cellular uptake can be detected based on measurements of fitness (e.g., the fitness of the animal, plant, bacteria, or fungus containing the treated cells). For example, the efficacy of the compositions and methods of the present invention can be determined by comparing the change in fitness of an organism treated with a modified PMP of the present invention relative to treatment with a composition lacking the modified PMP.

[0201] In some embodiments, the PMP compositions provided herein comprise two or more different modified PMPs, e.g., modified PMPs derived from different unmodified PMPs (e.g., unmodified PMPs from two or more different plant sources), and / or modified PMPs containing different types and / or different ratios of charged lipids (e.g., ionizable lipids and / or cationic lipids), sterols, and / or PEGylated lipids.

[0202] C. Plant EV markers

[0203] The PMPs of the compositions and methods of the present invention may have a series of markers that identify the PMPs as being produced using plant EVs and / or comprising segments, parts, or extracts thereof. As used herein, the term "plant EV marker" refers to a component that is naturally associated with a plant and incorporated into or on a plant EV within the plant, such as a plant protein, a plant nucleic acid, a plant small molecule, a plant lipid, or a combination thereof. Examples of plant EV markers can be found, for example, in Rutter and Innes, Plant Physiol. 173(1):728-741, 2017; Raimondo et al., Oncotarget. 6(23):19514, 2015; Ju et al., Mol. Therapy 21(7):1345-1357, 2013; Wang et al., Molecular Therapy 22(3):522-534, 2014; and Regente et al., J of Exp. Biol. 68(20):5485-5496, 2017; each of which is incorporated herein by reference. Additional examples of plant EV markers are listed in the Appendix and further summarized herein.

[0204] In some cases, plant EV markers may include plant lipids. Examples of plant lipid markers that may be found in PMPs include plant sterols, campesterol, β-sitosterol, stigmasterol, avenasterol, glycosyl inositolphosphoceramide (GIPC), glycolipids (e.g., monogalactosyldiacylglycerol (MGDG) or digalactosyldiacylglycerol (DGDG)), or combinations thereof. For example, PMPs may include GIPC, which represents the main sphingolipids in plants and is one of the most abundant membrane lipids in plants. Other plant EV markers may include lipids that accumulate in plants in response to abiotic stressors or biotic stressors (e.g., bacterial infection or fungal infection), such as phosphatidic acid (PA) or phosphatidylinositol-4-phosphate (PI4P).

[0205] Alternatively, the plant EV marker may include a plant protein. In some cases, the protein plant EV marker may be an antimicrobial protein naturally produced by the plant, including a defense protein secreted by the plant in response to abiotic stressors or biotic stressors (e.g., bacterial infection or fungal infection). Plant pathogen defense proteins include soluble N-ethylmaleimide sensitive factor associated protein receptor protein (SNARE) proteins (e.g., syntaxin-121 (SYP121; GenBank accession number: NP_187788.1 or NP_974288.1), penetration 1 (PEN1; GenBank accession number: NP_567462.1)) or ABC transporter penetration 3 (PEN3; GenBank accession number: NP_191283.2). Other examples of plant EV markers include proteins that facilitate long-distance transport of RNA in plants, including phloem proteins (e.g., phloem protein 2-A1 (PP2-A1), GenBank Accession No.: NP_193719.1), calcium-dependent lipid-binding proteins, or lectins (e.g., jackfruit-related lectins, such as sunflower (Helianthus annuus) jackfruit (Helja; GenBank: AHZ86978.1). For example, the RNA binding protein can be glycine-rich RNA binding protein-7 (GRP7; GenBank Accession No.: NP_179760.1). In addition, in some cases, proteins that regulate plasmodesmata function can be found in plant EVs (including proteins such as Synap-Totgamin AA (GenBank accession number: NP_565495.1)). In some cases, plant EV markers can include proteins involved in lipid metabolism, such as phospholipase C or phospholipase D. In some cases, plant protein EV markers are cellular trafficking proteins in plants. In some cases where the plant EV marker is a protein, the protein marker may lack a signal peptide typically associated with secreted proteins. Unconventional secretory proteins appear to share several common features, such as (i) lack of a leader sequence, (ii) lack of post-translational modifications (PTMs) specific for the ER or Golgi apparatus, and / or (iii) secretion that is not affected by Brefeldin A, which blocks the classical ER / Golgi-dependent secretory pathway. Those skilled in the art can use a variety of tools that are freely available to the public (e.g., SecretomeP database; SUBA3 (SUBcellular localization database for Arabidopsis proteins)) to assess proteins for signal sequences or their lack thereof.

[0206] In some cases where the plant EV marker is a protein, the protein can have an amino acid sequence that has at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to a plant EV marker, such as the plant EV markers listed in the Appendix. For example, the protein can have an amino acid sequence that has at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to PEN1 from Arabidopsis thaliana (GenBank Accession No.: NP_567462.1).

[0207] In some cases, plant EV markers include nucleic acids encoded in plants, such as plant RNA, plant DNA, or plant PNA. For example, PMP can include dsRNA, mRNA, viral RNA, microRNA (miRNA) or miRNA precursors or small interfering RNA (siRNA) or siRNA precursors encoded by plants. In some cases, the nucleic acid can be a nucleic acid related to a protein that promotes long-distance transport of RNA in plants, as discussed herein. In some cases, nucleic acid plant EV markers can be nucleic acid plant EV markers that participate in host-induced gene silencing (HIGS), which is the process of plant silencing the foreign transcripts of plant pests (e.g., pathogens, such as fungi). For example, the nucleic acid can be a nucleic acid that silences bacterial genes or fungal genes. In some cases, the nucleic acid can be a microRNA, such as miR159 or miR166, a gene in the microRNA targeting fungal pathogen (e.g., Verticillium dahliae). In some cases, the protein can be a protein involved in carrying plant defense compounds, such as a protein involved in the transport and metabolism of glucosinolates (GSLs), including glucosinolate transporter-1-1 (GTR1; GenBank Accession No.: NP_566896.2), glucosinolate transporter-2 (GTR2; NP_201074.1), or epithiospecific modifier 1 (ESM1; NP_188037.1).

[0208] Where the plant EV marker is a nucleic acid, the nucleic acid can have a nucleotide sequence that has at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to a plant EV marker, such as those listed in the Coding Appendix for plant EV markers. For example, the nucleic acid can have a polynucleotide sequence that has at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to miR159 or miR166.

[0209] In some cases, plant EV markers include compounds produced by plants. For example, the compound can be a defense compound produced in response to an abiotic stressor or a biotic stressor, such as a secondary metabolite. One such secondary metabolite found in PMPs is glucosinolates (GSLs), which are nitrogen- and sulfur-containing secondary metabolites found primarily in plants of the Brassicaceae family. Other secondary metabolites can include allelochemicals.

[0210] In some cases, PMPs can also be identified as being produced using plant EVs based on the absence of certain markers (e.g., lipids, polypeptides, or polynucleotides) that are typically not produced by plants but are typically associated with other organisms (e.g., markers of animal EVs, bacterial EVs, or fungal EVs). For example, in some cases, PMPs lack lipids typically found in animal EVs, bacterial EVs, or fungal EVs. In some cases, PMPs lack lipids that are typical features of animal EVs (e.g., sphingomyelin). In some cases, PMPs do not contain lipids that are typical features of bacterial EVs or bacterial membranes (e.g., LPS). In some cases, PMPs lack lipids that are typical features of fungal membranes (e.g., ergosterol).

[0211] Plant EV markers can be identified using any method known in the art that is capable of identifying small molecules (e.g., mass spectrometry, mass spectrometry), lipids (e.g., mass spectrometry, mass spectrometry), proteins (e.g., mass spectrometry, immunoblotting), or nucleic acids (e.g., PCR analysis). In some cases, the PMP compositions described herein comprise a detectable amount (e.g., a predetermined threshold amount) of a plant EV marker described herein.

[0212] D. Drug Loading

[0213] PMPs can be modified to include heterologous functional agents, e.g., cell permeating agents and / or heterologous agricultural agents (e.g., pesticides, fertilizers, herbicides, plant modifiers), heterologous therapeutic agents (e.g., antifungals, antibacterials, virucides, antivirals, insecticides, nematicides, antiparasitics, or insect repellents), such as those described herein. PMPs can carry or associate with such agents by various means to enable delivery of these agents to a target organism (e.g., a target animal, target plant, target bacterium, or target fungus), e.g., by encapsulating the agent, incorporating the component into the lipid bilayer structure, or associating the component (e.g., by conjugation) with the surface of the lipid bilayer structure of the PMP. In some cases, a PMP formulation includes a heterologous functional agent (e.g., a cell permeating agent), as described in Section 1B herein.

[0214] The heterologous functional agent can be bound or loaded into or onto the PMP by any method known in the art that allows for direct or indirect association between the PMP and the agent. The heterologous functional agent can be incorporated into the PMP by in vivo methods (e.g., in planta, such as by producing the PMP from a transgenic plant containing the heterologous agent), or in vitro (e.g., in tissue culture or in cell culture), or both in vivo and in vitro methods.

[0215] In the case of loading a heterologous functional agent (e.g., a heterologous agricultural agent (e.g., a pesticide, a fertilizer, a herbicide, a plant modifier) ​​or a heterologous therapeutic agent (e.g., an antifungal agent, an antibacterial agent, a viricide, an antiviral agent, an insecticide, a nematicide, an antiparasitic agent, or an insect repellent)) into a PMP in vivo, the PMP can be produced using EVs or segments or portions thereof that have been loaded into the plant, or extracts containing EVs. In planta methods include expressing a heterologous functional agent (e.g., a heterologous agricultural agent (e.g., a pesticide, a fertilizer, a herbicide, a plant modifier) ​​or a heterologous therapeutic agent (e.g., an antifungal agent, an antibacterial agent, a viricide, an antiviral agent, an insecticide, a nematicide, an antiparasitic agent, or an insect repellent)) in a plant that has been genetically modified to express a heterologous functional agent for loading into an EV. In some cases, the heterologous functional agent is exogenous to the plant. Alternatively, the heterologous functional agent may be found naturally in the plant, but engineered to be expressed at elevated levels relative to its levels found in non-genetically modified plants.

[0216] In some cases, PMP can be loaded in vitro. The substance can be loaded onto or into PMP using, but not limited to, physical, chemical, and / or biological methods (e.g., in tissue culture or cell culture) (e.g., can be encapsulated by PMP). For example, heterologous functional agents can be introduced into PMP by one or more of electroporation, ultrasonic treatment, passive diffusion, stirring, lipid extraction, or extrusion. In some cases, heterologous functional agents are incorporated into PMP using a microfluidic device, such as using a method in which PMP lipids are provided in an organic phase, heterologous functional agents are provided in an aqueous phase, and the organic phase and the aqueous phase are combined in a microfluidic device to produce a PMP comprising a heterologous functional agent. A variety of methods can be used to evaluate the PMP loaded to confirm the presence or level of the loaded agent, such as HPLC (e.g., for evaluating small molecules), immunoblotting (e.g., for evaluating proteins); and / or quantitative PCR (e.g., for evaluating nucleotides). However, it will be appreciated by those skilled in the art that the method of loading the substance of interest into PMP is not limited to the above display.

[0217] In some cases, a heterologous functional agent can be conjugated to a PMP, wherein the heterologous functional agent is indirectly or directly connected or attached to the PMP. For example, one or more heterologous functional agents can be chemically attached to the PMP so that the one or more heterologous functional agents are directly attached (e.g., by a covalent bond or an ionic bond) to the lipid bilayer of the PMP. In some cases, the conjugation of various heterologous functional agents to the PMP can be achieved by first mixing one or more heterologous functional agents with an appropriate cross-linking agent (e.g., N-ethylcarbodiimide ("EDC"), which is commonly used as a carboxyl activator for amide bonding with primary amines and also reacts with phosphate groups) in a suitable solvent. After an incubation period sufficient to allow the heterologous functional agent to attach to the cross-linking agent, the cross-linker / heterologous functional agent mixture can then be bonded to the PMP and, after another incubation period, subjected to a sucrose gradient (e.g., 8%, 30%, 45%, and 60% sucrose gradients) to separate the free heterologous functional agent and the free PMP from the heterologous functional agent conjugated to the PMP. As part of the mixing of the mixture with the sucrose gradient and the accompanying centrifugation step, PMPs conjugated to the heterologous functional agent are then visible as bands in the sucrose gradient, allowing the conjugated PMPs to then be collected, washed, and dissolved in a suitable solution for use as described herein.

[0218] In some cases, the PMP is stably associated with the heterologous functional agent before and after the PMP is delivered to, for example, a plant. In other cases, the PMP is associated with the heterologous functional agent such that after the PMP is delivered to, for example, a plant, the heterologous functional agent becomes dissociated from the PMP.

[0219] The PMP can be loaded with various concentrations of heterologous functional agents or the PMP compositions can be formulated with various concentrations of heterologous functional agents, depending on the particular agent or use. For example, in some cases, the PMP is loaded or the PMP composition is formulated so that the PMP composition disclosed herein comprises about 0.001, 0.01, 0.1, 1.0, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 95 (or any range between about 0.001 and 95) or more wt % of the heterologous functional agent. In some cases, the PMP is loaded or the PMP composition is formulated so that the PMP composition comprises about 95, 90, 80, 70, 60, 50, 40, 30, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1.0, 0.1, 0.01, 0.001 (or any range between about 95 and 0.001) or less wt% of the heterologous functional agent. For example, the PMP composition can comprise about 0.001 to about 0.01 wt%, about 0.01 to about 0.1 wt%, about 0.1 to about 1 wt%, about 1 to about 5 wt%, or about 5 to about 10 wt%, about 10 to about 20 wt% of the heterologous functional agent. In some cases, the PMP can be loaded with about 1, 5, 10, 50, 100, 200, or 500, 1,000, 2,000 (or any range between about 1 and 2,000) or more μg / ml of a heterologous functional agent, or a PMP composition can be formulated therewith. The PMPs of the present invention can be loaded with about 2,000, 1,000, 500, 200, 100, 50, 10, 5, 1 (or any range between about 2,000 and 1) or less μg / ml of a heterologous functional agent, or a PMP composition can be formulated therewith.

[0220] In some cases, the PMP is loaded or the PMP composition is formulated such that the PMP composition disclosed herein comprises at least 0.001 wt%, at least 0.01 wt%, at least 0.1 wt%, at least 1.0 wt%, at least 2 wt%, at least 3 wt%, at least 4 wt%, at least 5 wt%, at least 6 wt%, at least 7 wt%, at least 8 wt%, at least 9 wt%, at least 10 wt%, at least 15 wt%, at least 20 wt%, at least 30 wt%, at least 40 wt%, at least 50 wt%, at least 60 wt%, at least 70 wt%, at least 80 wt%, at least 90 wt%, or at least 95 wt% of the heterologous functional agent. In some cases, the PMPs can be loaded with at least 1 μg / ml, at least 5 μg / ml, at least 10 μg / ml, at least 50 μg / ml, at least 100 μg / ml, at least 200 μg / ml, at least 500 μg / ml, at least 1,000 μg / ml, at least 2,000 μg / ml of a heterologous functional agent, or the PMP composition can be formulated therewith.

[0221] In some cases, the PMP composition is formulated with a heterologous functional agent by suspending the PMP in a solution comprising or consisting of the heterologous functional agent, e.g., suspending or resuspending the PMP by vigorous mixing. The heterologous functional agent (e.g., a cell permeating agent such as an enzyme, detergent, ion, fluorinated liquid, or zwitterionic liquid, or a charged lipid (e.g., an ionizable lipid and / or a cationic lipid)) can comprise, for example, less than 1% or at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the solution.

[0222] Examples of specific heterologous functional agents that can be loaded into PMPs are further summarized in the section entitled "Heterologous Functional Agents."

[0223] E. Production of LPMPs using microfluidics

[0224] In some aspects, the PMP composition comprises a plurality of lipid-reconstituted PMPs (LPMPs), wherein the LPMPs are produced by a method comprising the steps of: (a) providing a plurality of purified PMPs (e.g., PMPs purified as described in Section IA herein); (b) processing the plurality of PMPs to produce a lipid membrane; (c) reconstitute the lipid membrane in an organic solvent or combination of solvents, thereby producing a lipid solution; and (d) processing the lipid solution of step (c) in a microfluidic device comprising an aqueous phase, thereby producing the LPMPs.

[0225] In some cases, processing a plurality of PMPs to generate a lipid membrane comprises extracting lipids from the plurality of PMPs, e.g., extracting lipids using the Bligh-Dyer method (Bligh and Dyer, J Biolchem ​​Physiol, 37:911-917, 1959). The extracted lipids can be provided as a stock solution, e.g., a chloroform:methanol solution. Generating the lipid membrane can comprise, e.g., evaporating the solvent with a stream of inert gas (e.g., nitrogen).

[0226] LPMPs can comprise exogenous lipids, for example, charged lipids (e.g., ionizable lipids (e.g., C12-200 or MC3) and / or cationic lipids (e.g., DOTAP or DC cholesterol). In some examples, the charged lipid is selected from 1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol)(C12-2 00), DLin-MC3-DMA (MC3), dioleoyl-3-trimethylammonium propane (DODAP), DC-cholesterol, DOTAP, ethyl PC, GL67, DLin-KC2-DMA (KC2), MD1 (cKK-E12), OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5 (Moderna), cationic sulfonamide amino lipid, amphiphilic zwitterionic amino lipid, DO In some instances, the exogenous lipid is added to the preparation before step (b), for example, before step (b), the exogenous lipid is mixed with the PMP lipid extracted. The addition of exogenous lipid can reach, for example, 1% of total lipid in the preparation, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater than 90% (w / w). In some instances, the addition of exogenous lipid (for example, charged lipid, for example, ionizable lipid and / or cationic lipid) can reach 25% or 40% (w / w) of total lipid in the preparation.

[0227] In some cases, the LPMP comprises an exogenous sterol, e.g., sitosterol, dihydrositosterol, β-sitosterol, 7α-hydroxycholesterol, pregnenolone, cholesterol (e.g., ovine cholesterol or cholesterol isolated from plants), stigmasterol, campesterol, fucoxanthin, or any sterol analog (e.g., glycoside, ester, or peptide). In some instances, the exogenous sterol is added to the formulation prior to step (b), e.g., the exogenous lipid is mixed with the extracted PMP lipid prior to step (b). The exogenous sterol can be added in an amount of, e.g., 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater than 90% (w / w) of the total lipids and sterols in the formulation.

[0228] In some cases, the LPMP comprises an exogenous lipid and an exogenous sterol.

[0229] In some cases, the organic solvent for dissolving the lipid film is dimethylformamide:methanol (DMF:MeOH). Alternatively, the organic solvent or solvent combination can be, for example, acetonitrile, acetone, ethanol, methanol, dimethylformamide, tetrahydrofuran, 1-butanol, dimethyl sulfoxide, acetonitrile:ethanol, acetonitrile:methanol, acetone:methanol, methyl tert-butyl ether:propanol, tetrahydrofuran:methanol, dimethyl sulfoxide:methanol, or dimethylformamide:methanol.

[0230] The aqueous phase can be any suitable solution, for example, a citrate buffer (e.g., a citrate buffer having a pH of about 3.2), water, or phosphate buffered saline (PBS). The aqueous phase can further comprise a heterologous functional agent, for example, an agent described in Section II herein, for example, a nucleic acid (e.g., siRNA or siRNA precursor (e.g., dsRNA), miRNA or miRNA precursor, mRNA, or plasmid (pDNA)) or a small molecule.

[0231] The lipid solution and the aqueous phase can be mixed in the microfluidic device at any suitable ratio. In some examples, the aqueous phase and the lipid solution are mixed at a volume ratio of 3:1.

[0232] F. Zeta potential

[0233] A PMP composition comprising a plurality of modified PMPs containing charged lipids (e.g., ionizable lipids, e.g., C12-200 or MC3 and / or cationic lipids, e.g., DC-cholesterol or DOTAP) can have, for example, a zeta potential of greater than -30 mV in the absence of cargo, or a zeta potential of greater than -20 mV, greater than -5 mV, greater than 0 mV, or about 30 mV in the absence of cargo. In some instances, the PMP composition has a negative zeta potential, e.g., a zeta potential of less than 0 mV, less than -10 mV, less than -20 mV, less than -30 mV, less than -40 mV, or less than -50 mV (in the absence of cargo). In some instances, the PMP composition has a positive zeta potential, e.g., a zeta potential of greater than 0 mV, greater than 10 mV, greater than 20 mV, greater than 30 mV, greater than 40 mV, or greater than 50 mV (in the absence of cargo). In some instances, the PMP composition has a zeta potential of about 0.

[0234] The zeta potential of a PMP composition can be measured using any method known in the art. Zeta potential is typically measured indirectly, for example, using data (e.g., electrophoretic mobility or dynamic electrophoretic mobility) obtained using methods and techniques known in the art, calculated using a theoretical model. Electrophoretic mobility is typically measured using microelectrophoresis, electrophoretic light scattering, or tunable resistive pulse sensing. Electrophoretic light scattering is based on dynamic light scattering. Typically, zeta potential can be obtained from dynamic light scattering (DLS) measurements, also known as photon correlation spectroscopy or quasi-elastic light scattering.

[0235] G. Preparations

[0236] i.Agricultural preparations

[0237] In order to allow for easy application, handling, transport, storage, and effective activity, PMPs (e.g., modified PMPs as described herein) can be formulated with other substances. PMPs can be formulated into, for example, baits, concentrated emulsions, powders, emulsifiable concentrates, fumigants, gels, granules, microcapsules, seed treatments, suspension concentrates, suspoemulsions, tablets, water-soluble liquids, water-dispersible granules or dry flowables, wettable powders, and ultra-low volume solutions. For further information on formulation types, see "Catalogue of Pesticide Formulation Types and International Coding System," Technical Monograph no. 2, 5th edition, CropLife International (2002).

[0238] The PMP composition can be applied as an aqueous suspension or emulsion prepared from a concentrated formulation of such an agent. Such water-soluble, water-suspendable, or emulsifiable formulations are solids, commonly referred to as wettable powders or water-dispersible granules, or liquids, commonly referred to as emulsifiable concentrates or aqueous suspensions. Wettable powders, which can be compacted to form water-dispersible granules, comprise an intimate mixture of the PMP composition, a carrier, and a surfactant. The carrier is typically selected from attapulgite clay, montmorillonite clay, diatomaceous earth, or purified silicates. Effective surfactants, comprising from about 0.5% to about 10% of the wettable powder, are found in sulfonated lignin, condensed naphthalene sulfonates, naphthalene sulfonates, alkylbenzene sulfonates, alkyl sulfates, and nonionic surfactants such as ethylene oxide adducts of alkylphenols.

[0239] The emulsifiable concentrate can comprise a suitable concentration of PMP (e.g., from about 50 to about 500 g / L of liquid) dissolved in a carrier that is a mixture of a water-miscible solvent or a water-immiscible organic solvent and an emulsifier. Available organic solvents include aromatic compounds (especially xylene) and petroleum fractions (especially the high-boiling naphthalene and alkene portions of petroleum, such as heavy aromatic naphtha). Other organic solvents may also be used, such as terpene solvents including rosin derivatives, aliphatic ketones such as cyclohexanone, and complex alcohols such as 2-ethoxyethanol. Suitable emulsifiers for the emulsifiable concentrate are selected from conventional anionic and nonionic surfactants.

[0240] Aqueous suspensions include a suspension of a water-insoluble PMP composition dispersed in an aqueous carrier at a concentration of from about 5% to about 50% by weight. The suspension is prepared by finely grinding the composition and vigorously mixing it into a carrier composed of water and a surfactant. Ingredients such as inorganic salts and synthetic or natural gums may also be added to increase the density and viscosity of the aqueous carrier.

[0241] PMP compositions can also be applied in the form of granular compositions, which are particularly useful for application to soil. Granular compositions typically contain from about 0.5% to about 10% by weight of the PMP composition, dispersed in a carrier comprising clay or a similar material. Such compositions are typically prepared by dissolving the formulation in a suitable solvent and applying it to a granular carrier that has been preformed into a granular carrier of the appropriate particle size, from about 0.5 mm to about 3 mm. Such compositions can also be formulated by forming a gluten or paste of the carrier and compound, extruding, and drying to obtain the desired particle size.

[0242] Dusts containing the PMP formulations of the present invention are prepared by intimately mixing the PMP in powdered form with a suitable dusty agricultural carrier, such as kaolin clay, ground volcanic rock, etc. Dusts may suitably contain from about 1% to about 10% of the sachets. They may be applied as a seed dressing or by foliar application using a duster.

[0243] It is also practical to apply the formulations of the invention in the form of solutions in a suitable organic solvent, generally petroleum oil, such as the spray oils widely used in agrochemistry.

[0244] PMPs can also be used in the form of aerosol compositions. In such compositions, the packets are dissolved or dispersed in a carrier that serves as a propellant mixture to generate pressure. The aerosol composition is packaged in a container that dispenses the mixture through an atomizing valve.

[0245] Another embodiment is an oil-in-water emulsion comprising oily beads each having a lamellar liquid crystal coating and dispersed in an aqueous phase, wherein each oily bead comprises at least one agriculturally active compound and is individually coated with a monolamellar layer or multiple layers comprising: (1) at least one nonionic lipophilic surfactant, (2) at least one nonionic hydrophilic surfactant, and (3) at least one ionic surfactant, wherein the beads have an average particle size of less than 800 nanometers. More information about this embodiment is disclosed in U.S. Patent Publication No. 20070027034, published on February 1, 2007. For ease of reference, this embodiment will be referred to as "OIWE."

[0246] In addition, generally, when the molecules disclosed above are used in formulations, such formulations may also contain other components. These components include, but are not limited to (this is a non-exhaustive and non-mutually exclusive list) wetting agents, spreading agents, adhesives, penetrants, buffers, chelating agents, bleach reducers, compatibilizers, defoamers, detergents, and emulsifiers. Several components are described below.

[0247] A wetting agent is a substance that, when added to a liquid, increases the spreading or penetration of the liquid by reducing the interfacial tension between the liquid and the surface on which it is spread. Wetting agents are used in agrochemical formulations for two main functions: to increase the rate at which powders wet in water to make liquid-soluble concentrates or suspension concentrates during processing and manufacturing; and to reduce the wetting time of wettable powders and improve water penetration into water-dispersible granules during mixing of the product with water in the spray tank. Examples of wetting agents used in wettable powder, suspension concentrate, and water-dispersible granule formulations are: sodium lauryl sulfate; sodium dioctyl sulfosuccinate; alkylphenol ethoxylates; and aliphatic alcohol ethoxylates.

[0248] Dispersants are substances that adsorb onto the surface of particles and help maintain their dispersion and prevent reaggregation. Dispersants are added to agrochemical formulations to promote dispersion and suspension during manufacturing and ensure that the particles redisperse in the water in the spray tank. They are widely used in wettable powders, suspension concentrates, and water-dispersible granules. Surfactants used as dispersants have the ability to strongly adsorb onto the surface of particles and provide a charged or steric barrier to particle reaggregation. The most commonly used surfactants are anionic surfactants, nonionic surfactants, or mixtures of the two types. For wettable powder formulations, the most common dispersant is sodium lignin sulfonate. For suspension concentrates, polyelectrolytes (such as sodium naphthalenesulfonate formaldehyde condensate) are used to achieve excellent adsorption and stabilization. Tristyrylphenol ethoxylate phosphate esters are also used. Nonionic surfactants such as alkylaryl ethylene oxide condensates and EO-PO block copolymers are sometimes used in combination with anionic surfactants as dispersants for suspension concentrates. In recent years, new types of very high molecular weight polymeric surfactants have been developed as dispersants. They have a very long hydrophobic "backbone" and a large number of ethylene oxide chains that form the "teeth" of a "comb-type" surfactant. These high molecular weight polymers can impart very good long-term stability to suspension concentrates because the hydrophobic backbone has many anchor points to the particle surface. Examples of dispersants used in agrochemical formulations are: sodium lignin sulfonate; sodium naphthalenesulfonate formaldehyde condensate; tristyrylphenol ethoxylate phosphate; aliphatic alcohol ethoxylates; alkyl ethoxylates; EO-PO (ethylene oxide-propylene oxide) block copolymers; and graft copolymers.

[0249] Emulsifiers are substances that stabilize the suspension of droplets of one liquid phase in another liquid phase. In the absence of emulsifiers, the two liquids can be separated into two immiscible liquid phases. The most commonly used emulsifier blends contain alkylphenols or aliphatic alcohols with twelve or more ethylene oxide units and oil-soluble calcium dodecylbenzenesulfonate. A hydrophilic-lipophilic balance ("HLB") value of 8 to 18 will generally provide a good stable emulsion. Emulsion stability can sometimes be improved by adding a small amount of EO-PO block copolymer surfactant.

[0250] Solubilizing agents are surfactants that will form micelles in water at a concentration above the critical micelle concentration. These micelles are then able to dissolve or solubilize the water-insoluble material within the hydrophobic portion of the micelles. The types of surfactants commonly used for solubilization are nonionic surfactants, sorbitan monooleate, sorbitan monooleate ethoxylate, and methyl oleate.

[0251] Surfactants are sometimes used alone or with other additives (such as mineral or vegetable oils) as adjuvants for spray tank mixes to improve the biological performance of the PMP composition for the target. The type of surfactant used for bioenhancement generally depends on the nature and mode of action of the PMP composition. However, they are typically nonionic surfactants such as: alkyl ethoxylates; linear aliphatic alcohol ethoxylates; aliphatic amine ethoxylates.

[0252] A carrier or diluent in agricultural formulations is a material added to a PMP composition to give the product the desired strength. Carriers are typically materials with high absorptive capacity, while diluents are typically materials with low absorptive capacity. Carriers and diluents are used in the formulation of dusts, wettable powders, granules, and water-dispersible granules.

[0253] Organic solvents are primarily used to formulate emulsifiable concentrates, oil-in-water emulsions, suspoemulsions, and ultra-low volume formulations, and to a lesser extent, granular formulations. Solvent mixtures are sometimes used. The first major group of solvents is the aliphatic paraffin oils, such as kerosene or refined paraffin. The second major group (and the most commonly used) includes aromatic solvents, such as xylene and the higher molecular weight C9 and C10 aromatic solvent fractions. Chlorinated hydrocarbons can be used as cosolvents to prevent the PMP composition from crystallizing when the formulation is emulsified in water. Alcohols are sometimes used as cosolvents to increase dissolving power. Other solvents can include vegetable oils, seed oils, and esters of vegetable and seed oils.

[0254] Thickeners or gelling agents are primarily used in the formulation of suspension concentrates, emulsions, and suspoemulsions to modify the rheology or flow properties of a liquid and to prevent the separation and sedimentation of dispersed particles or droplets. Thickeners, gelling agents, and anti-settling agents are generally divided into two categories: water-insoluble particulates and water-soluble polymers. Clays and silica can be used to produce suspension concentrate formulations. Examples of these materials include, but are not limited to, montmorillonite, bentonite, magnesium aluminum silicate, and attapulgite. Water-soluble polysaccharides have been used as thickening and gelling agents for many years. The most commonly used polysaccharides are natural extracts from seeds and seaweeds or synthetic derivatives of cellulose. Examples of these materials include, but are not limited to, guar gum; locust bean gum; carrageenan; alginates; methylcellulose; sodium carboxymethylcellulose (SCMC); and hydroxyethylcellulose (HEC). Other types of anti-settling agents are based on modified starches, polyacrylates, polyvinyl alcohol, and polyethylene oxide. Another good anti-settling agent is xanthan gum.

[0255] Microorganisms can cause spoilage in formulated products. Therefore, preservatives are used to eliminate or reduce their effects. Examples of such agents include, but are not limited to: propionic acid and its sodium salt; sorbic acid and its sodium or potassium salt; benzoic acid and its sodium salt; sodium p-hydroxybenzoate; methyl p-hydroxybenzoate; and 1,2-benzothiazolin-3-one (BIT).

[0256] The presence of surfactants usually causes foaming of water-based formulations during the mixing operation in production and in applications performed by spray tanks. In order to reduce the tendency to foam, defoamers are usually added during the production stage or before filling into the bottle. Generally, there are two types of defoamers, silicones and non-silicone defoamers. Silicones are usually aqueous emulsions of dimethylpolysiloxane, while non-silicone defoamers are water-insoluble oils (such as octanol and nonanol) or silicon dioxide. In both cases, the function of the defoamer is to displace the surfactant from the air-water interface.

[0257] "Green" agents (e.g., adjuvants, surfactants, solvents) can reduce the overall environmental footprint of crop protection formulations. Green agents are biodegradable and are typically derived from natural and / or sustainable sources, such as plant and animal sources. Specific examples are: vegetable oils, seed oils, and esters thereof, and alkoxylated alkyl polyglucosides.

[0258] In some cases, the PMPs can be freeze-dried or lyophilized. See U.S. Patent No. 4,311,712. The PMPs can then be reconstituted after contact with water or another liquid. Other components can be added to the freeze-dried or reconstituted PMPs, such as other heterologous functional agents, agriculturally acceptable carriers, or other materials according to the formulations described herein.

[0259] Other optional features of the composition include a carrier or delivery vehicle that protects the PMP composition from UV and / or acidic conditions. In some cases, the delivery vehicle contains a pH buffer. In some cases, the composition is formulated to have a pH in the range of about 4.5 to about 9.0, including, for example, a pH in the range of 5.0 to about 8.0, about 6.5 to about 7.5, or about 6.5 to about 7.0.

[0260] For further information on agricultural formulations, see D.A. Knowles, ed., "Chemistry and Technology of Agrochemical Formulations," copyright 1998 by Kluwer Academic Publishers. See also A. S. Perry, I. Yamamoto, I. Ishaaya, and R. Perry, "Insecticides in Agriculture and Environment—Retrospects and Prospects," copyright 1998 by Springer-Verlag.

[0261] ii. Pharmaceutical preparations

[0262] The modified PMPs described herein can be formulated into pharmaceutical compositions, for example, for administration to animals (e.g., humans). Pharmaceutical compositions can be administered to animals (e.g., humans) with pharmaceutically acceptable diluents, carriers, and / or excipients. Depending on the mode of administration and dosage, the pharmaceutical compositions of the methods described herein can be formulated into suitable pharmaceutical compositions to allow for easy delivery. As needed, a single dose can be in unit dosage form.

[0263] The PMP compositions can be formulated for, for example, oral administration, intravenous administration (e.g., injection or infusion), or subcutaneous administration to animals. Various effective pharmaceutical carriers are known in the art for injectable formulations (see, for example, Remington: The Science and Practice of Pharmacy, 22nd ed. (2012) and Handbook on Injectable Drugs, 18th ed. (2014)).

[0264] The pharmaceutically acceptable carriers and excipients in the compositions of the present invention are nontoxic to the receptor at the dosages and concentrations used. Acceptable carriers and excipients can include buffers such as phosphates, citrates, HEPES, and TAE; antioxidants such as ascorbic acid and methionine; preservatives such as hexamethonium chloride, octadecyldimethylbenzyl ammonium chloride, resorcinol, and benzalkonium chloride; proteins such as human serum albumin, gelatin, dextran, and immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, histidine, and lysine; and carbohydrates such as glucose, mannose, sucrose, and sorbitol. The compositions can be formulated according to conventional pharmaceutical practice. The concentration of the compound in the formulation will vary depending on many factors, including the dosage of the active agent (e.g., PMP) to be administered and the route of administration.

[0265] For oral administration to animals, the PMP composition can be prepared in the form of an oral formulation. Oral formulations may include tablets, caplets, capsules, syrups, or oral liquid dosage forms containing one or more active ingredients mixed with non-toxic pharmaceutically acceptable excipients. These excipients can be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starch (including potato starch), calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate, or sodium phosphate); granulating agents and disintegrants (e.g., cellulose derivatives including microcrystalline cellulose, starch including potato starch, cross-linked sodium carboxymethyl cellulose, alginates, or alginic acid); binders (e.g., sucrose, glucose, sorbitol, gum arabic, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, sodium carboxymethyl cellulose, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, polyvinyl pyrrolidone, or polyethylene glycol); and lubricants, glidants, and anti-adherents (e.g., magnesium stearate, zinc stearate, stearic acid, silicon dioxide, hydrogenated vegetable oil, or talc). Other pharmaceutically acceptable excipients can be colorants, flavorings, plasticizers, humectants, buffers, etc. Formulations for oral use may also be provided in unit dosage form as chewable tablets, non-chewable tablets, caplets, capsules (e.g., as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent; or as soft gelatin capsules in which the active ingredient is mixed with water or an oil medium). The compositions disclosed herein may further comprise an immediate release formulation, an extended release formulation, or a delayed release formulation.

[0266] For parenteral administration to animals, the PMP composition can be formulated in the form of a liquid solution or suspension and administered by a parenteral route (e.g., subcutaneous, intravenous, or intramuscular). The pharmaceutical composition can be formulated for injection or infusion. Pharmaceutical compositions for parenteral administration can be formulated using a sterile solution or any pharmaceutically acceptable liquid as a vehicle. Pharmaceutically acceptable vehicles include, but are not limited to, sterile water, normal saline, or cell culture media (e.g., Dulbecco's Modified Eagle Medium (DMEM), α-modified Eagle Medium (α-MEM), F-12 culture medium). Formulation methods are known in the art, see, for example, Gibson (ed.) Pharmaceutical Preformulation and Formulation [drug preformulation and formulation] (2nd ed.) Taylor & Francis Group [Taylor Francis Group], CRC Press [CRC Press] (2009).

[0267] II. Heterologous Functional Agents

[0268] The PMPs manufactured herein may further comprise a heterologous functional agent, such as a heterologous functional agent (e.g., a heterologous agricultural agent (e.g., a pesticide, a fertilizer, a herbicide, a plant modifier) ​​or a heterologous therapeutic agent (e.g., an antifungal agent, an antibacterial agent, a viricide, an antiviral agent, an insecticide, a nematicide, an antiparasitic agent, or an insect repellent)). For example, the PMP may encapsulate the heterologous functional agent. Alternatively, the heterologous functional agent may be embedded on the surface of the PMP or conjugated thereto. In some cases, the PMP comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different heterologous functional agents. The heterologous functional agent may be added at any step during manufacture to effectively introduce the agent into the manufactured PMP.

[0269] In some cases, a heterologous functional agent (e.g., a heterologous agricultural agent (e.g., a pesticide, a fertilizer, a herbicide, a plant modifier, a heterologous nucleic acid, a heterologous polypeptide, or a heterologous small molecule) or a heterologous therapeutic agent (e.g., an antifungal agent, an antibacterial agent, a viricide, an antiviral agent, a nematicide, an antiparasitic agent, or an insect repellent)) can be modified. For example, the modification can be a chemical modification, such as coupling to a label, such as a fluorescent marker or a radioactive marker. In other examples, the modification can include coupling or operative linkage to a moiety that enhances the stability, delivery, targeting, bioavailability, or half-life of the agent (e.g., a lipid, a polysaccharide, a polymer (e.g., PEG), or a cationic moiety).

[0270] Examples of heterologous functional agents that can be loaded into the PMPs produced herein are summarized below.

[0271] A. Heterologous agricultural chemicals

[0272] The PMPs produced herein can include a heterologous agricultural agent (eg, an agent that affects plants or plant-associated organisms and can be loaded into the PMP), for example, a pesticide, herbicide, fertilizer, or plant modifier.

[0273] For example, in some cases, the PMP may comprise a pesticide. The pesticide may be an antifungal, antibacterial, insecticide, molluscicide, nematocide, viricide, or a combination thereof. The pesticide may be a chemical agent, such as those well known in the art. Alternatively or additionally, the pesticide may be a peptide, polypeptide, nucleic acid, polynucleotide, or small molecule. The pesticide may be an agent that can reduce the fitness of various plant pests, or may be an agent for one or more specific target plant pests (e.g., plant pests of a particular species or genus).

[0274] In some cases, the PMP may comprise one or more heterologous fertilizers. Examples of heterologous fertilizers include plant nutrients or plant growth regulators, such as those known in the art. Alternatively or additionally, the fertilizer may be a peptide, polypeptide, nucleic acid, or polynucleotide that increases the fitness of a plant symbiont. The fertilizer may be an agent that increases the fitness of various plants or plant symbionts, or may be an agent for one or more specific target plants or plant symbionts (e.g., plants or plant symbionts of a specific species or genus).

[0275] In other cases, the PMP may comprise one or more heterologous plant modifying agents. In some cases, the plant modifying agent may include a peptide or a nucleic acid.

[0276] i. Antibacterial agents

[0277] The PMP compositions described herein may further comprise an antibacterial agent. In some cases, the PMP compositions comprise two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different antibacterial agents. For example, an antibacterial agent can reduce (e.g., reduce growth or kill) the fitness of bacterial plant pests (e.g., bacterial plant pathogens). A PMP composition comprising an antibiotic as described herein can be contacted with a target pest or a plant infested with the target pest or the plant infested with the antibiotic in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of antibiotic concentration in or on the target pest; and (b) reduce the fitness of the target pest. The antibacterial agents described herein can be formulated in the PMP compositions for any of the methods described herein and, in some cases, can be associated with their PMPs.

[0278] As used herein, the term "antibacterial agent" refers to a material that kills or inhibits the growth, proliferation, division, reproduction, or spread of bacteria (such as plant pathogenic bacteria), and includes bactericides (e.g., disinfecting compounds, antibacterial compounds, or antibiotics) or bacteriostatics (e.g., compounds or antibiotics). Bactericidal antibiotics kill bacteria, while bacteriostatic antibiotics only slow their growth or reproduction.

[0279] Bactericides may include disinfectants, antimicrobials, or antibiotics. The most commonly used disinfectants may include: active chlorine (i.e., hypochlorites (e.g., sodium hypochlorite), chloramines, dichloroisocyanurates and trichloroisocyanurates, wet chlorine, chlorine dioxide, etc.), active oxygen (peroxides such as peracetic acid, potassium persulfate, sodium perborate, sodium percarbonate, and urea perhydrate), iodine (iodine povidone (povidone iodine, Betadine), Lugol's solution (Lugol's solution), and the like. solution), iodine tincture, iodinated nonionic surfactants), concentrated alcohols (mainly ethanol, 1-propanol (also called n-propanol) and 2-propanol (called isopropanol), and mixtures thereof; further, 2-phenoxyethanol and 1-phenoxypropanol and 2-phenoxypropanol are used), phenolic substances (such as phenol (also called carbolic acid), cresol (combined with liquid potassium soap to be called Lysol), halogenated (chlorinated, brominated) phenols, such as hexachlorophene, triclosan, trichlorophenol, tribromophenol, pentachlorophenol, dibromophenol and their salts), cationic surfactants, such as some quaternary ammonium cations (such as benzalkonium chloride, cetyltrimethylammonium bromide or cetyltrimethylammonium chloride, didecyldimethyl The following are some of the following: 1) alkylammonium chloride, cetylpyridinium chloride, benzethonium chloride) and other non-quaternary compounds such as chlorhexidine, saccharin protamine, octenidine dihydrochloride, etc.; 2) strong oxidants such as ozone and permanganate solution; 3) heavy metals and their salts such as colloidal silver, silver nitrate, mercuric chloride, phenylmercuric salts, copper sulfate, copper oxychloride, copper hydroxide, copper octoate, copper oxychloride sulfate, copper sulfate, copper sulfate pentahydrate, etc. Heavy metals and their salts are the most toxic and environmentally harmful bactericides, and therefore, their use has been strongly suppressed or eliminated; 4) in appropriately concentrated form strong acids (phosphoric acid, nitric acid, sulfuric acid, sulfamic acid, toluenesulfonic acid) and alkalis (sodium hydroxide, potassium hydroxide, calcium hydroxide).

[0280] As antimicrobial agents (i.e., antiseptics that can be used on the human or animal body, skin, mucous membranes, wounds, etc.), the above-mentioned disinfectants can be used under appropriate conditions (mainly concentration, pH, temperature and toxicity to humans / animals). Important among these are: appropriately diluted chlorine preparations (i.e., Daquin's solution, 0.5% sodium or potassium hypochlorite solution (pH adjusted to pH 7-8), or 0.5%-1% solution of benzenesulfonyl chloride sodium salt (chloramine B)); some iodine preparations, such as iodine povidone in various galenical preparations (ointments, solutions, wound plasters) and, in the past, Lugol's solution; peroxides as urea perhydrate solutions and pH-buffered 0.1%-0.25% peracetic acid solutions; alcohols with or without antimicrobial additives, primarily for skin antiseptics; weak organic acids, such as sorbic acid, benzoic acid, lactic acid, and salicylic acid; some phenolic compounds, such as hexachlorophene, triclosan, and Dibromol; and cationically active compounds, such as 0.05%-0.5% benzalkonium, 0.5%-4% chlorhexidine, 0.1%-2% octenidine solutions.

[0281] The PMP compositions described herein may include an antibiotic. Any antibiotic known in the art may be used. Antibiotics are generally classified based on their mechanism of action, chemical structure, or spectrum of activity.

[0282] Antibiotics described herein can target the function or growth process of any bacteria and can be bacteriostatic (for example, slowing down or preventing bacterial growth) or bactericidal (for example, killing bacteria). In some cases, antibiotic is a bactericidal antibiotic. In some cases, bactericidal antibiotic is a bactericidal antibiotic (for example, penicillin and cephalosporin) targeting bacterial cell wall;Bactericidal antibiotic (for example, polymyxin) targeting cell membrane;Or bactericidal antibiotic (for example, rifamycin, lipiarmycins, quinolones and sulfonamides) that suppresses essential bacterial enzymes. In some cases, bactericidal antibiotic is aminoglycoside (for example, kasugamycin). In some cases, antibiotic is a bacteriostatic antibiotic. In some cases, bacteriostatic antibiotic targets protein synthesis (for example, macrolides, lincosamides and tetracyclines). The antibiotic of other classes that can be used herein includes cyclic lipopeptides (such as daptomycin), glycylcycline (such as tigecycline), oxazolidinones (such as linezolid) or lipiarmycins (such as fidaxomicin). Examples of antibiotics include rifampicin, ciprofloxacin, doxycycline, ampicillin, and polymyxin B. Antibiotics described herein can have any level of target specificity (e.g., narrow spectrum or broad spectrum). In some cases, antibiotics are narrow spectrum antibiotics and therefore target specific types of bacteria, such as gram-negative bacteria or gram-positive bacteria. Alternatively, antibiotics can be broad spectrum antibiotics targeting a wide range of bacteria.

[0283] Other non-limiting examples of antibiotics are found in Table 1. One skilled in the art will recognize that the appropriate concentration of each antibiotic in the composition depends on factors such as efficacy, stability of the antibiotic, the number of different antibiotics, the formulation, and the method of application of the composition.

[0284] Table 1. Examples of antibiotics

[0285]

[0286] ii. Antifungal agents

[0287] The PMP compositions described herein may further comprise an antifungal agent. In some cases, the PMP compositions comprise two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different antifungals. For example, an antifungal agent can reduce (e.g., reduce growth or kill) the fitness of fungal plant pests. A PMP composition comprising an antifungal agent as described herein can be contacted with a target fungal pest or a plant infected therewith in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of antibiotic concentration in or on the target fungus; and (b) reduce the fitness of the target fungus. The antifungal agents described herein can be formulated in the PMP compositions for any of the methods described herein and, in some cases, can be associated with their PMPs.

[0288] As used herein, the term "fungicide" or "antifungal agent" refers to a substance that kills or inhibits the growth, proliferation, division, reproduction, or spread of fungi, such as plant pathogenic fungi. Many different types of antifungals are commercially produced. Non-limiting examples of antifungals include: azoxystrobin, maneb, prothioconazole, folpet, tebuconazole, difenoconazole, captan, pyrimidine sulfonate, or fosetyl-Al. Other exemplary fungicides include, but are not limited to, strobilurins, azoxystrobin, methicystrobin, enoxastrobin, fluoxastrobin, kresoxim-methyl, fenoxystrobin, picoxystrobin, pyraclostrobin, triflumin, orysastrobin, formamide, formanilide, benalaxyl, benalaxyl-M, mefenoxam, carboxin, mefenoxam, mefenoxam, fenhexamid, furalaxyl, furalaxyl, furazolidone, metalaxyl, metalaxyl-M (mefenoxam), furazolidone, thiopyrad, ofurace, oxaloxam, oxycarboxin, penthiopyrad, pyracarbolid, salicylanilide, chloranil, thiofuran, thiopyrad, N-biphenylamide, bixafen, boscalid, N-carboxylic acid acidmorpholide), dimethomorph, flumorph, benzamide, flumetover, fluopicolid (picobenzamid), zoxamide, formamide, cyproconazole, dimethomorph, dimethomorph, thiosilamide, azoles, triazoles, bitertaconazole, bromoconazole, cyproconazole, difenoconazole, dacrylic acid, enilconazole, epoxiconazole, fenketo, flusilazole, fluquinconazole, flutriafol, hexaconazole, imidazole, cyclopentaconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, silyconazole, tebuconazole, tetraconazole, triadimefon, triathlon, imidazole, cyazofamid, imazalil, pefurazoate, prochloraz, triflumizole, benzimidazole , benomyl, carbendazim, furanylbenzimidazole (fuberidazole), thiabendazole, ethidium, etridiazole, oxamexazole, nitrogen-containing heterocyclic compounds, pyridine, fuazinam, bifenoxanol, pyrimidine, pyrimidine sulfonate, cyprodinil, ferimzone, chlorfenapyr, mepanipyrim, flufenapyr, pyrimidine, piperazine, chlorfenapyr, pyrrole, fludioxonil, fenpiclonil, morpholine, aldimorph, dodemorph, fenpropimorph, trimorph, dicarboximide, iprodione, procymidone, vinclozolin, activated ester-S-methyl, difop-butyl, captan, captan, dazomet, dazolin,Blastamide, folpet, fenpropidin, oxadiazol, fenamidon, octhilinone, thiabendazole, propoxyquin, pyroquilon, quinoxyfen, tricyclazole, carbamate, dithiocarbamate, ferbam, maneb, maneb, maneb, methamphetamine, propineb, thiram, maneb, ziram, ethoflufencarb, flubenthiavalicarb, iprovalicarb, propamocarb, guanidine, dodine, biguanide, biguanide salts, kasugamycin, polyoxin, streptomycin, validamycin A, organometallic compounds, triphenyltin salts, sulfur-containing heterocyclic compounds compounds, rice blast, dithianon, organophosphorus compounds, kefansan, fosetyl, fosetyl aluminum, isoprenaline, pyrazophos, methyl tolclofos, organochlorine compounds, thiophanate-methyl, chlorothalonil, bacteriostatic, tolylfluanid, flusulfuron, tetrachlorophthalide, hexachlorobenzene, pencycuron, pentachloronitrobenzene, nitrophenyl derivatives, binacarb, diclofenac, chlorpyrifos, spiroxam, cyfluanid, cymoxanil, metrafenon, N-2-cyanophenyl-3,4-dichloroisothiazol-5-carboxamide (isotianil), N-(3′,4′,5′-trifluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazole-4-carboxamide, 3-[5-(4-chlorophenyl)-2,3 -dimethylisoxazolidin-3-yl]-pyridine, N-(3′,4′-dichloro-4-fluorobiphenyl-2-yl)-3-difluoromethyl-1-methylpyrazole-4-carboxamide, 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]tri-oxazolo[1,5-a]pyrimidine, 2-butoxy-6-iodo-3-propylchromen-4-one, N,N-dimethyl-3-(3-bromo-6-fluoro-2-methylindole-1-sulfonyl)-[1,2,4]triazole-1-sulfonamide, methyl-(2-chloro-5-[1-(3-methylbenzyloxyimino)ethyl]benzyl)carbamate, methyl-(2-chloro-5-[1-(6-methylpyridin-2-yl)-1-sulfonyl]benzyl)carbamate methyl]benzyl)carbamate, 3-(4-chlorophenyl)-3-(2-isopropoxycarbonylamino-3-methylbutyryl-amino)propionic acid methyl ester, 4-fluorophenyl N-(1-(1-(4-cyanophenyl)ethanesulfonyl)but-2-yl)carbamate, N-(2-(4-[3-(4-chlorophenyl)prop-2-ynyloxy]-3-methoxyphenyl)ethyl)-2-methanesulfonylamino-3-methylbutyramide, N-(2-(4-[3-(4-chlorophenyl)prop-2-ynyloxy]-3-methoxyphenyl)ethyl)-2-ethanesulfonylamino-3-methylbutyramide, N-(4′-bromobiphenyl-2-yl)-4-difluoromethyl-2-methylthiazole-5-carboxamide,N-(4′-trifluoromethylbiphenyl-2-yl)-4-difluoromethyl-2-methylthiazole-5-carboxamide, N-(4′-chloro-3′-fluorobiphenyl-2-yl)-4-difluoromethyl-2-methylthiazole-5-carboxamide, or methyl 2-(o-((2,5-dimethylphenoxy-methylene)phenyl)-3-methoxyacrylate. It will be appreciated by those skilled in the art that the appropriate concentration of each antifungal agent in the composition depends on factors such as efficacy, stability of the antifungal agent, the amount of the different antifungal agents, the formulation, and the method of application of the composition.

[0289] iii. Insecticides

[0290] The PMP compositions described herein may further comprise an insecticide. In some cases, the PMP compositions comprise two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different insecticides. For example, an insecticide can reduce (e.g., reduce growth or kill) the fitness of an insect plant pest. A PMP composition comprising an insecticide as described herein can be contacted with a target insect pest or a plant infested therewith in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of insecticide concentration in or on the target insect; and (b) reduce the fitness of the target insect. The insecticides described herein can be formulated in a PMP composition for use in any of the methods described herein, and in some cases, can be associated with its PMP.

[0291] As used herein, the term "insecticide" or "insecticidal agent" refers to a substance that kills or inhibits the growth, proliferation, reproduction, or spread of insects, such as agricultural insect pests. Non-limiting examples of insecticides are shown in Table 2. Additional non-limiting examples of suitable insecticides include biological agents, hormones or pheromones (such as azadirachtin), Bacillus species, Beauveria species, codlemone, Metarrhizium species, Paecilomyces species, thuringiensis, and Verticillium species; and active compounds with unknown or non-specific mechanisms of action, such as fumigants (such as aluminum phosphide, methyl bromide, and sulfuryl fluoride), and selective feeding inhibitors (such as cryolite, flonicamid, and pymetrozine). Those skilled in the art will recognize that the appropriate concentration of each insecticide in the composition depends on factors such as efficacy, stability of the insecticide, the amount of the different insecticides, the formulation, and the method of application of the composition.

[0292] Table 2. Examples of insecticides

[0293]

[0294]

[0295] iv. Nematicides

[0296] The PMP compositions described herein may further comprise a nematode. In some cases, the PMP compositions comprise two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different nematodes. For example, a nematode can reduce (e.g., reduce growth or kill) the fitness of a nematode plant pest. A PMP composition comprising a nematode as described herein can be contacted with a target nematode pest or a plant infested therewith in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of nematode concentration in or on the target nematode; and (b) reduce the fitness of the target nematode. The nematodes described herein can be formulated in a PMP composition for use in any of the methods described herein, and in some cases, can be associated with a PMP.

[0297] As used herein, the term "nematicide" or "nematicidal agent" refers to a substance that kills or inhibits the growth, proliferation, reproduction, or spread of nematodes (e.g., agricultural nematode pests). Non-limiting examples of nematicides are shown in Table 3. One skilled in the art will recognize that the appropriate concentration of each nematicide in the composition depends on factors such as efficacy, stability of the nematicide, the amount of the different nematicides, the formulation, and the method of application of the composition.

[0298] Table 3. Examples of nematicides

[0299]

[0300] v. Molluscicide

[0301] The PMP compositions described herein may further comprise a molluscicide. In some cases, the PMP compositions comprise two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different molluscicides. For example, a molluscicide can reduce (e.g., reduce growth or kill) the fitness of mollusc plant pests. A PMP composition comprising a molluscicide as described herein can be contacted with a target mollusc pest or a plant infested therewith in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of molluscicide concentration in or on the target mollusc; and (b) reduce the fitness of the target mollusc. The molluscicides described herein can be formulated in the PMP compositions for any of the methods described herein and, in some cases, can be associated with their PMPs.

[0302] As used herein, the term "molluscicide" or "molluscicide" refers to a substance that kills or inhibits the growth, proliferation, reproduction, or spread of mollusks, such as agricultural mollusc pests. Many chemicals can be used as molluscicides, including metal salts such as iron (III) phosphate, aluminum sulfate, and sodium ferric EDTA, [3][4] metaldehyde, methiocarb, or acetylcholinesterase inhibitors. One skilled in the art will recognize that the appropriate concentration of each molluscicide in the composition depends on factors such as efficacy, stability of the molluscicide, the amount of the different molluscicides, the formulation, and the method of application of the composition.

[0303] vi. Virucide

[0304] The PMP compositions described herein may further comprise a virucide. In some cases, the PMP composition comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different virucides. For example, a virucide can reduce (e.g., reduce or eliminate) the fitness of a viral plant pathogen. A PMP composition comprising a virucide as described herein can be contacted with a target virus or a plant infected therewith in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of virucide concentration; and (b) reduce or eliminate the target virus. The virucides described herein can be formulated in a PMP composition for use in any of the methods described herein and, in some cases, can be associated with a PMP thereof.

[0305] As used herein, the term "virucide" or "antiviral agent" refers to a substance that kills or inhibits the growth, proliferation, reproduction, development, or spread of viruses (e.g., agricultural viral pathogens). It is desirable that an agent can be used as a virucide, including a chemical or biological agent (e.g., a nucleic acid, such as dsRNA). One skilled in the art will recognize that the appropriate concentration of each virucide in the composition depends on factors such as efficacy, stability of the virucide, the number of different virucides, formulation, and method of application of the composition.

[0306] vii. Herbicides

[0307] The PMP compositions described herein can further comprise one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) herbicides. For example, the herbicides can reduce (e.g., decrease or eliminate) the fitness of weeds. A PMP composition comprising a herbicide as described herein can be contacted with a target weed in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of herbicide concentration on the plant, and (b) reduce the fitness of the weed. The herbicides described herein can be formulated in the PMP compositions used in any of the methods described herein, and in some cases, can be associated with the PMP.

[0308] As used herein, the term "herbicide" refers to a substance that kills or inhibits the growth, proliferation, reproduction, or spread of weeds. Many chemicals can be used as herbicides, including glufosinate-ammonium, sulfamethoxam, metamitron, metazachlor, pendimethalin, flufenacet, difluanid, clomazone, nicosulfuron, mesotrione, pinoxaden, sulcotrione, prosulfocarb, sulfentrazone, fenpropimorph, quinclorac, terbuthylazine, atrazine, oxyfluorfen, diuron, trifluralin, or chlorotoluron. Further examples of herbicides include, but are not limited to, benzoic acid herbicides such as dicamba esters; phenoxyalkanoic acid herbicides such as 2,4-D, MCPA, and 2,4-DB esters; aryloxyphenoxypropionic acid herbicides such as clodinafop, cyhalofop, fenoxaprop, fluazifop-butyl, haloxyfop-butyl, and quizalofop-butyl; pyridinecarboxylic acid herbicides such as aminopyralid, picloram, and clopyralid; pyrimidinecarboxylic acid herbicides, Such as cyproconazole esters; pyridyloxyalkanoic acid herbicides, such as fluoroxypyr and triclopyr esters; and hydroxybenzonitrile herbicides, such as bromoxynil and ioxynil esters; esters of arylpyridine carboxylic acids; and arylpyrimidine carboxylic acids of the general structure disclosed in U.S. Patent No. 7,314,849, U.S. Patent No. 7,300,907, and U.S. Patent No. 7,642,220, each of which is incorporated herein by reference in its entirety.In certain embodiments, the herbicide can be selected from the group consisting of 2,4-D, 2,4-DB, acetochlor, acifluorfen, alachlor, ametryn, cypermethrin, cypermethrin, atrazine, fluazifop, fluazifop, benzylsulfuron-methyl, dithiocarb, bentazon, bromocriptine, butachlor, foramsulfuron, chlorsulfuron-methyl, chlorproham, chlorsulfuron, clethodim, clomazone, clopyralid, cloransulam, chloranil, chlorpyrifos, cyclopentane, DCPA, betadine, dichlorvos, grass Fluazifop-P, fluazifop-methyl, flufenacet, fluazifop-P, flufenacet-butyl, flufenacet-butyl, fluazifop-P, flufenacet-butyl, flufenacet-butyl, fluazifop-P, flufenacet-butyl, flufenacet-butyl, fluazifop-P, flufenacet-butyl, flufenacet-butyl, fluazifop-P, flufenacet-butyl, flufenacet-butyl, fluazifop-P, flufenacet-butyl, flufenacet-butyl, fluazifop-P, flufenacet-butyl, flufenacet-butyl, fluazifop-P, flufenacet-butyl, flufenacet-butyl, fluthiacet, flufenacet-butyl, flufenacet-butyl, fluthiacet, flufenacet-butyl, flufenacet-butyl, fluthiacet, flufenacet-butyl, glufosinate, glyphosate, haloxyfop, haloxyfop , hexazinone, imazamethabenz, imazamethabenz, imazamethabenz, imazaquin, imazamethabenz, isoxazolidinone, isoxazolidinone, lactofenol, linuron, MCPA, MCPB, mesotrione, chlorpyrifos, isopropylamine-s, metribuzin, metsulfuron-methyl, chlorpyrifos, MSMA, propamide, herbicide, nicosulfuron, norsulfuron, yellow grass, oxaflor, epoxysulfuron, oxyfluorfen, paraquat, pebulate, nonanoic acid, pendimethalin, benzylpyridinium, pyralid , primisulfuron, aminfluralin, prometryn, natifenad, pyrazon, pyridaquat, pyrimsulfuron, quinclorac, quizalofop-ethyl, rimsulfuron, sethoxydim, cypermethrin, simazine, sulfentrazone, sulfensulfuron, sulfosulfuron, terbuthiuron, terbacil, thiamethoxam, thifensulfuron, tralkoxydim, wild wheat chlorpyrifos, bensulfuron-methyl, bensulfuron-methyl, triclopyr, trifluralin, trifluralin, triamcinol, and chlorpyrifos. It will be appreciated by those skilled in the art that the appropriate concentration of each herbicide in the composition depends on factors such as efficacy, stability of the herbicides, the amount of the different herbicides, the formulation, and the method of application of the composition.

[0309] viii. Repellent

[0310] The PMP compositions described herein may further comprise a repellent. In some cases, the PMP compositions comprise two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different repellents. For example, a repellent may repel any of the pests described herein (e.g., insects, nematodes, or mollusks); microorganisms (e.g., plant pathogens or endophytes, such as bacteria, fungi, or viruses); or weeds. A PMP composition comprising a repellent as described herein may be brought into contact with a target plant or a plant infected therewith in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of repellent concentration; and (b) reduce the level of pests on the plant relative to untreated plants. The repellents described herein may be formulated in a PMP composition for use in any of the methods described herein, and in some cases, may be associated with its PMP.

[0311] In some cases, the repellent is an insect repellent. Some examples of well-known insect repellents include: benzil; benzyl benzoate; 2,3,4,5-bis(but-2-ene)tetrahydrofurfural (MGK Repellent 11); butoxypolypropylene glycol; N-butylacetanilide; n-butyl-6,6-dimethyl-5,6-dihydro-1,4-pyrone-2-carboxylate (Bifurcon); dibutyl adipate; dibutyl phthalate; di-n-butyl succinate (Bifurcon); N,N-diethyl-m-toluamide (DEET); Benzyl alcohol (endo, endo)-dimethylbicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate); dimethyl phthalate; 2-ethyl-2-butyl-1,3-propanediol; 2-ethyl-1,3-hexanediol (Rutgers 612); di-n-propyl isooctanoate (MGK Repellent 326); 2-phenylcyclohexanol; p-methane-3,8-diol, and n-propyl N,N-diethylsuccinamate. Other repellents include citronella oil, dimethyl phthalate, n-butyl mesitylene oxide oxalate, and 2-ethylhexanediol-1,3-diol (see Kirk-Othmer Encyclopedia of Chemical Technology, 2nd ed., Vol. 11: 724-728; and The Condensed Chemical Dictionary, 8th ed., p. 756).

[0312] The insect repellent may be a synthetic or non-synthetic insect repellent. Examples of synthetic insect repellents include methyl anthranilate and other anthranilate-based insect repellents, benzaldehyde, DEET (N,N-diethyl-m-toluamide), chlorpyrifos, dimethyl phthalate, icaridin (i.e., picaridin, Bayrepel, and KBR 3023), chlorpyrifos (e.g., as used in the "6-2-2" mixture (60% dimethyl phthalate, 20% chlorpyrifos, 20% ethyl hexanediol), IR3535 (3-[N-butyl-N-acetyl]-aminopropionic acid, ethyl ester), metofluthrin, permethrin, SS220, or tricyclodecenyl allyl ether. Examples of natural insect repellents include callicarpa leaves, birch bark, menyanthes (Myrica spp.), and cypermethrin. Gale), catnip oil (e.g., nepetalactone), citronella oil, essential oil of lemon eucalyptus (Corymbia citriodora; e.g., p-menthane-3,8-diol (PMD)), neem oil, lemongrass, tea tree oil from Melaleuca alternifolia leaves, tobacco, or extracts thereof.

[0313] ix. Fertilizer

[0314] The PMP compositions described herein may further comprise a heterologous fertilizer agent. In some cases, the heterologous fertilizer agent is associated with the PMP. For example, the PMP may encapsulate the heterologous fertilizer agent. Additionally, or alternatively, the heterologous fertilizer agent may be embedded on the surface of the PMP or conjugated thereto.

[0315] Examples of heterologous fertilizers include plant nutrients or plant growth regulators, such as those known in the art. Alternatively or additionally, the fertilizer may be a peptide, polypeptide, nucleic acid, or polynucleotide that increases the fitness of a plant symbiont. The fertilizer may be an agent that increases the fitness of various plants or plant symbionts, or may be an agent that targets one or more specific plants or plant symbionts (e.g., plants or plant symbionts of a specific species or genus).

[0316] In some cases, the heterologous fertilizer agent can be modified. For example, the modification can be a chemical modification, such as being coupled to a label, such as a fluorescent marker or a radiolabel. In other examples, the modification can include coupling or operative connection with a portion that enhances stability, delivery, targeting, bioavailability, or the half-life of an agent (e.g., a lipid, polysaccharide, polymer (e.g., PEG), a cationic moiety).

[0317] Examples of heterologous fertilizers that can be used in the PMP compositions and methods disclosed herein are summarized below.

[0318] In some cases, heterologous fertilizer agent comprises any material of natural or synthetic origin, and it is applied on soil or plant tissue to provide one or more necessary plant nutrients for plant growth.Plant nutrients can comprise macronutrients, micronutrients or its combination.Plant macronutrients comprise nitrogen, phosphorus, potassium, calcium, magnesium and / or sulphur.Plant micronutrients comprise copper, iron, manganese, molybdenum, zinc, boron, silicon, cobalt and / or vanadium.The example of plant nutrient fertilizer comprises nitrogenous fertilizer, includes but not limited to urea, ammonium nitrate, ammonium sulfate, atmospheric nitrogen solution, ammoniacal liquor, anhydrous ammonia, ammonium thiosulfate, urea coated with sulfur, urea-formaldehyde, IBDU, urea, calcium nitrate, urea formaldehyde or methylene urea, phosphate fertilizer (such as diammonium phosphate, monoammonium phosphate, ammonium polyphosphate, triple superphosphate and triple superphosphate) or potash fertilizer (such as potassium chloride, potassium sulfate, magnesium potassium sulfate, potassium nitrate).Such composition can exist in the form of free salt or ion in composition. Fertilizers can be specified by the content of one or more of their components, such as nitrogen, phosphorus, or potassium. The content of these elements in a fertilizer can be indicated by the N-P-K value (where N = nitrogen content by weight percent, P = phosphorus content by weight percent, and K = potassium content by weight percent).

[0319] On the other hand, inorganic fertilizers are made from non-living materials and include, for example, ammonium nitrate, ammonium sulfate, urea, Repone K, potash, ammonium phosphate, anhydrous ammonia and other phosphates. Inorganic fertilizers are readily commercially available and contain the nutrients that can be used immediately for plants in soluble form. Inorganic fertilizers are usually cheap, and the unit cost of the desired element is low. It will be appreciated by those skilled in the art that the precise amount of a given element in the fertilizer formulation can be calculated and applied to plants or soil.

[0320] Fertilizer can be further classified as organic fertilizer or inorganic fertilizer.Organic fertilizer comprises the fertilizer of the molecular backbone with carbon-containing main chain, as in the composition derived from living matter.Organic fertilizer is made by the material derived from biology.Animal miscellaneous manure, compost, bone meal, feather meal and blood meal are the examples of common organic fertilizer.On the other hand, organic fertilizer typically can not be used for plant immediately, and needs soil microorganism that fertilizer component is decomposed into simpler structure before being used by plant.In addition, organic fertilizer not only can cause the growth reaction of plant as observed by common inorganic fertilizer, and natural organic fertilizer can also stimulate the growth and activity of soil microorganism colony.The increase of soil microorganism colony (for example, plant symbiont) may have significant beneficial effect to the physical and chemical properties of soil, and has increased the resistance to disease and harmful organism.

[0321] In one aspect, a PMP composition comprising a phytonutrient as described herein can be contacted with a plant in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of phytonutrient concentration in or on the plant, and (b) increase the fitness of the plant relative to untreated plants.

[0322] In another aspect, a PMP composition comprising a phytonutrient as described herein can be contacted with a plant symbiota in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of phytonutrient concentration within or on the plant symbiota (e.g., a bacterial or fungal endosymbiota), and (b) increase the fitness of the plant symbiota relative to an untreated plant symbiota.

[0323] Heterogeneous fertilizer can comprise plant growth regulator.Exemplary plant growth regulator comprises plant growth hormone, cytokinin, gibberellin and abscisic acid.In some cases, plant growth regulator is abscisic acid, acetamide, pyrimidine alcohol, 6-benzylaminopurine, brassinolide, butarin, chlormequat (chlormequat) (chlormequat chloride (chlormequatchloride)), choline chloride, cyproconazole, dimethoate, furazolidone, thiamethoxam, 2,6-lutidine, vinylphosphine, flumetramid, flurprimidol, flumethoxam, chlorforamide, gibberellic acid, antineptachlor, indole-3-acetic acid, maleic hydrazide, flusulfamide, mepiquat (mepiquat) (chlormequat chloride (mepiquatchloride)), chloranil, cyproconazole, dimethoate ... Chloride), naphthylacetic acid, N-6-benzyladenine, paclobutrazol, prohexadione (prohexadione-calcium), prohydrojasmon, thidiazuron, fenthiazolinone, tributyl trithiophosphate, 2,3,5-tri-iodobenzoic acid, trinexapac-ethyl, and uniconazole. Other plant growth regulators that can be incorporated into the seed coating composition are described in US 2012 / 0108431, which is incorporated herein by reference in its entirety.

[0324] x. Plant modifiers

[0325] The PMP compositions described herein comprise one or more heterologous plant modifiers. For example, the PMP can encapsulate the heterologous plant modifier. Alternatively or additionally, the heterologous plant modifier can be embedded or conjugated to the surface of the PMP.

[0326] In some cases, the plant modifier may include a peptide or a nucleic acid. The plant modifier may be an agent that increases the fitness of a variety of plants, or may be an agent that targets one or more specific plants (e.g., a specific species or genus of plants). Additionally, in some cases, the PMP composition comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different plant modifiers.

[0327] In addition, in some cases, the heterologous plant modifier (e.g., an agent comprising a nucleic acid molecule or peptide) can be modified. For example, the modification can be a chemical modification, such as coupling to a label, such as a fluorescent marker or a radioactive marker. In other examples, the modification can include coupling or operative linkage to a moiety that enhances the stability, delivery, targeting, bioavailability, or half-life of the agent (e.g., a lipid, a polysaccharide, a polymer (e.g., PEG), a cationic moiety).

[0328] Examples of heterologous plant modifying agents (eg, peptides or nucleic acids) that can be used in the PMP compositions and methods disclosed herein are summarized below.

[0329] B. Peptides

[0330] The PMP compositions described herein (e.g., PMPs) can include heterologous polypeptides. In some cases, the PMP compositions described herein include polypeptides or functional fragments or derivatives thereof that modify plants (e.g., to increase the fitness of a plant). For example, the polypeptide can increase the fitness of a plant. A PMP composition comprising a polypeptide as described herein can be contacted with a plant in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of polypeptide concentration; and (b) modify the plant (e.g., to increase the fitness of the plant).

[0331] Examples of polypeptides useful herein can include enzymes (e.g., metabolic recombinases, helicases, integrases, RNases, DNases, or ubiquitinated proteins), pore-forming proteins, signaling ligands, cell-penetrating peptides, transcription factors, receptors, antibodies, nanobodies, gene editing proteins (e.g., CRISPR-Cas systems, TALENs, or zinc fingers), riboproteins, protein aptamers, or chaperone proteins.

[0332] The polypeptide included herein can include naturally occurring polypeptides or recombinant variants.In some cases, the polypeptide can be its functional fragment or variant (for example, its enzymatic activity fragment or variant).For example, the polypeptide can be the functional active variant of any polypeptide as described herein, for example, in a designated region or entire sequence, there is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homogeneity with the sequence of polypeptide as described herein or naturally occurring polypeptide. In some cases, a polypeptide can be at least 50% (e.g., at least 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, or greater) identical to a protein of interest.

[0333] Polypeptide described herein can be prepared in the compositions for any purposes described herein.Compositions disclosed herein can comprise the polypeptide of any quantity or type (for example, classification), such as any one of at least about 1 polypeptide, 2, 3, 4, 5, 10, 15, 20 or more kinds of polypeptide.In compositions, the suitable concentration of every kind of polypeptide depends on the factor of the application method of the quantity, preparation and composition of different polypeptides in the stability, composition of effect, polypeptide.In some cases, in liquid composition, every kind of polypeptide is from about 0.1ng / mL to about 100mg / mL.In some cases, in solid composition, every kind of polypeptide is from about 0.1ng / g to about 100mg / g.

[0334] Methods for making polypeptides are conventional in the art. See generally Smales and James (eds.), Therapeutic Proteins: Methods and Protocols (Methods in Molecular Biology), Humana Press (2005); and Crommelin, Sindelar and Meibohm (eds.), Pharmaceutical Biotechnology: Fundamentals and Applications, Springer (2013).

[0335] Methods for producing polypeptides involve expression in plant cells, although insect cells, yeast, bacteria, mammalian cells, or other cells may also be used to produce recombinant proteins under the control of an appropriate promoter. Mammalian expression vectors may contain non-transcribed elements, such as an origin of replication, a suitable promoter and enhancer, and other 5' or 3' flanking non-transcribed sequences; and 5' or 3' non-translated sequences, such as necessary ribosome binding sites, polyadenylation sites, splice donor and acceptor sites; and termination sequences. DNA sequences derived from the SV40 viral genome, such as the SV40 origin, early promoter, enhancer, splice and polyadenylation sites, can be used to provide other genetic elements required for expression of heterologous DNA sequences. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cell hosts are described in Green & Sambrook, Molecular Cloning: A Laboratory Manual (4th ed.), Cold Spring Harbor Laboratory Press (2012).

[0336] Different mammalian cell culture systems can be used to express and manufacture recombinant polypeptide pharmaceuticals. Examples of mammalian expression systems include, but are not limited to, CHO cells, COS cells, HeLA, and BHK cell lines. Host cell culture processes for producing protein therapeutics are described in, for example, Zhou and Kantardjieff (eds.), Mammalian Cell Cultures for Biologics Manufacturing (Advances in Biochemical Engineering / Biotechnology), Springer (2014). Protein purification is described in, for example, Franks, Protein Biotechnology: Isolation, Characterization, and Stabilization (Humana Press, 2013); and Cutler, Protein Purification Protocols (Methods in Molecular Biology), Humana Press (2010). The formulation of protein therapeutics is described in Meyer (ed.), Therapeutic Protein Drug Products: Practical Approaches to formulation in the Laboratory, Manufacturing, and the Clinic, Woodhead Publishing Series (2012).

[0337] In some cases, the PMP composition comprises an antibody or an antigen-binding fragment thereof. For example, the medicament described herein can be an antibody that blocks or enhances the activity and / or function of a component of a plant. Antibodies can act as antagonists or agonists of polypeptides (e.g., enzymes or cell receptors) in plants. The manufacture and use of antibodies against target antigens are known in the art. See, for example, Zhiqiang An (ed.), Therapeutic Monoclonal Antibodies: From Bench to Clinic, 1st edition, Wiley, 2009, and Greenfield (ed.), Antibodies: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, 2013. Methods for manufacturing recombinant antibodies include antibody engineering, the use of degenerate oligonucleotides, 5'-RACE, phage display, and mutagenesis; antibody testing and characterization; antibody pharmacokinetics and pharmacodynamics; antibody purification and storage; and screening and labeling techniques.

[0338] C. Nucleic acid

[0339] In some cases, the PMPs described herein include heterologous nucleic acids (heterologous polynucleotides). Many nucleic acids are useful in the PMP compositions and methods described herein. The PMPs disclosed herein can include any number or type (e.g., category) of heterologous nucleic acids (e.g., DNA molecules (e.g., plasmids) or RNA molecules, e.g., mRNA, guide RNA (gRNA), or inhibitory RNA molecules or precursors thereof (e.g., siRNA, shRNA, or miRNA or a precursor of any of these), or hybrid DNA-RNA molecules), such as at least about 1 nucleic acid class or variant, or 2, 3, 4, 5, 10, 15, 20 or more nucleic acid classes or variants. The appropriate concentration of each nucleic acid in the composition depends on a variety of factors, such as efficacy, stability of the nucleic acid, the number of different nucleic acids, formulation, and the method of administration of the composition. Examples of nucleic acids that can be used herein include DNA molecules (e.g., plasmids), mRNA, siRNA, Dicer substrate small interfering RNA (dsiRNA), antisense RNA, short interfering RNA (siRNA) or siRNA precursor (e.g., one or more RNA strands that hybridize inter- or intramolecularly to form at least partially double-stranded RNA of at least about 20 consecutive base pairs), short hairpin (shRNA), micro RNA (miRNA) or miRNA precursor, asymmetric interfering RNA (aiRNA), peptide nucleic acid (PNA), morpholino, locked nucleic acid (LNA), piwi-interacting RNA (piRNA), ribozyme, deoxyribozyme (DNAzyme), aptamer (DNA, RNA), circular RNA (circRNA), guide RNA (gRNA), or a DNA molecule encoding any of these RNAs.

[0340] A PMP composition comprising a nucleic acid as described herein can be contacted with a plant in an amount and for a time sufficient to: (a) achieve a target level of nucleic acid concentration (e.g., a predetermined or threshold level); and (b) modify the plant (e.g., increase the fitness of the plant).

[0341] (a) Nucleic acid encoding a peptide

[0342] In some cases, the PMP comprises a heterologous nucleic acid encoding a polypeptide. The nucleic acid encoding the polypeptide can have a length of from about 10 to about 50,000 nucleotides (nts), about 25 to about 100 nts, about 50 to about 150 nts, about 100 to about 200 nts, about 150 to about 250 nts, about 200 to about 300 nts, about 250 to about 350 nts, about 300 to about 500 nts, about 10 to about 1000 nts, about 50 to about 1000 nts, about 100 to about 1000 nts, about 1000 to about 2000 nts, about 2000 to about 3000 nts, about 3000 to about 4000 nts, about 4000 to about 5000 nts. ts, about 5000 to about 6000 nts, about 6000 to about 7000 nts, about 7000 to about 8000 nts, about 8000 to about 9000 nts, about 9000 to about 10,000 nts, about 10,000 to about 15,000 nts, about 10,000 to about 20,000 nts, about 10,000 to about 25,000 nts, about 10,000 to about 30,000 nts, about 10,000 to about 40,000 nts, about 10,000 to about 45,000 nts, about 10,000 to about 50,000 nts, or any range therebetween.

[0343] PMP compositions can also include active variants of the target nucleic acid sequence. In some cases, the variant of the nucleic acid has at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence of the target nucleic acid, for example, in a specified region or throughout the entire sequence. In some cases, the present invention includes active polypeptides encoded by nucleic acid variants as described herein. In some cases, the active polypeptide encoded by the nucleic acid variant is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of the polypeptide of interest or the polypeptide sequence of a natural source, for example, over a specified region or over the entire amino acid sequence.

[0344] Certain methods for expressing protein-encoding nucleic acids can involve expression in cells, including insects, yeast cells, plant cells, bacterial cells, or other cells, under the control of an appropriate promoter. Expression vectors can include non-transcribed elements, such as an origin of replication, a suitable promoter and enhancer, and other 5' or 3' flanking non-transcribed sequences; as well as 5' or 3' non-translated sequences, such as necessary ribosome binding sites, polyadenylation sites, splice donor and acceptor sites; and termination sequences. DNA sequences derived from the SV40 viral genome, such as the SV40 origin, early promoter, enhancer, splice and polyadenylation sites, can be used to provide other genetic elements required for expression of heterologous DNA sequences. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cell hosts are described in Green et al., Molecular Cloning: A Laboratory Manual, 4th edition, Cold Spring Harbor Laboratory Press, 2012.

[0345] Genetic modification using recombinant methods is generally known in the art. Nucleic acid sequences encoding desired genes can be obtained using recombinant methods known in the art, such as by screening libraries from cells expressing the gene, by obtaining the gene from vectors known to include the gene, or by direct isolation from cells and tissues containing the gene, using standard techniques. Alternatively, the gene of interest can be produced synthetically rather than cloned.

[0346] The expression of natural or synthetic nucleic acid is typically achieved by: the nucleic acid encoding the target gene is operably linked to a promoter, and the construct is incorporated into an expression vector. The expression vector can be suitable for replication and expression in bacteria. The expression vector can also be suitable for replication and integration in eukaryotes. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters, which can be used for the expression of the desired nucleotide sequence.

[0347] In some embodiments, the promoter element of the present invention is located in the region of 30-110 base pairs (bp) upstream of the start site, although many promoters have recently been shown to contain functional elements downstream of the start site. The interval between the promoter elements is normally flexible, so that when the inversion element or the element is moved relative to each other, the promoter function can be retained. In the thymidine kinase (tk) promoter, before the activity begins to decline, the interval between the promoter elements can be increased to 50bp. Depending on the promoter, it seems that a single element can function jointly or independently to activate transcription.

[0348] An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high-level expression of any polynucleotide sequence operably linked thereto. Another example of a suitable promoter is elongation growth factor-1α (EF-1α). However, other constitutive promoter sequences may also be used, including but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV), long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukosis virus promoter, Epstein-Barr virus immediate early promoter, Rous sarcoma virus promoter, as well as human gene promoters (such as but not limited to actin promoter, myosin promoter, hemoglobin promoter, and creatine kinase promoter).

[0349] Alternatively, the promoter can be an inducible promoter. The use of an inducible promoter provides a molecular switch that can turn on expression of a polynucleotide sequence operably linked to the promoter when such expression is desired, or turn off expression when expression is not desired. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.

[0350] The expression vector to be introduced may also contain a selective marker gene or a reporter gene or both, thereby facilitating the identification and selection of expressing cells from a population of cells to be transfected or infected by a viral vector. In other aspects, the selective marker can be carried on a separate DNA and used in a co-transfection procedure. Both the selective marker and the reporter gene can be flanked by appropriate regulatory sequences to enable expression in the host cell. Useful selective markers include, for example, antibiotic resistance genes such as neo.

[0351] Reporter gene can be used to identify cells of potential conversion and for evaluating the functionality of regulatory sequences. Generally, reporter gene is not present in receptor source or is not expressed by receptor source, and encodes a gene for a polypeptide whose expression is demonstrated by some easy detection characteristics (such as enzymolysis activity). After DNA is introduced into the recipient cell, the expression of reporter gene is measured at the appropriate time. Suitable reporter gene can include the gene encoding luciferase, beta-galactosidase, chloramphenicol acetyltransferase, secretory alkaline phosphatase, or green fluorescent protein gene (for example, Ui-Tei et al., FEBS Letters [Federation of European Biochemical Societies Express] 479:79-82,2000). Suitable expression system is well known and can be prepared or commercially obtained using known technology. Generally, the construct with the minimum 5' flanking region showing the highest expression level of reporter gene is identified as promoter. This type of promoter region can be connected to reporter gene and is used to evaluate the ability of medicament regulating promoter-driven transcription.

[0352] In some cases, organism can be genetically modified thereby change the expression of one or more proteins.The expression of one or more proteins can be modified for specific time, for example the growth or differentiation state of organism.In one case, the present invention includes the composition that is used to change the expression of one or more proteins (for example affecting active, structure or function protein).The expression of one or more proteins can be limited to one or more specific positions, or spread throughout the whole organism.

[0353] (b) Synthetic mRNA

[0354] The PMP composition can include synthetic mRNA molecules, such as synthetic mRNA molecules encoding polypeptides. The synthetic mRNA molecules can be modified, such as chemically modified. The mRNA molecules can be chemically synthesized or transcribed in vitro. The mRNA molecules can be arranged on plasmids, such as viral vectors, bacterial vectors, or eukaryotic expression vectors. In some instances, the mRNA molecules can be delivered to cells by transfection, electroporation, or transduction (e.g., adenovirus or lentivirus transduction).

[0355] In some cases, the modified RNA agents of interest described herein have modified nucleosides or nucleotides. Such modifications are known and described in, for example, WO 2012 / 019168. Additional modifications are described in, for example, WO 2015 / 038892; WO 2015 / 038892; WO 2015 / 089511; WO 2015 / 196130; WO 2015 / 196118 and WO 2015 / 196128 A2.

[0356] In some cases, the modified RNA encoding the polypeptide of interest has one or more terminal modifications, such as a 5' cap structure and / or a poly A tail (e.g., 100-200 nucleotides in length). The 5' cap structure can be selected from the group consisting of CapO, Capl, ARCA, inosine, N1-methyl-guanosine, 2' fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine. In some cases, the modified RNA also contains a 5'UTR (which includes at least one Kozak sequence) and a 3'UTR. Such modifications are known and are described in, for example, WO 2012 / 135805 and WO 2013 / 052523. Additional terminal modifications are described in, for example, WO 2014 / 164253 and WO 2016 / 011306, WO 2012 / 045075, and WO 2014 / 093924. Chimeric enzymes for synthesizing capped RNA molecules (e.g., modified mRNAs) that may include at least one chemical modification are described in WO 2014 / 028429.

[0357] In some cases, the modified mRNA can be cyclized or concatenated to produce a translationally competent molecule, thereby facilitating the interaction between the poly A binding protein and the 5'-end binding protein. The cyclization or concatenation mechanism can occur via at least three different pathways: 1) chemical, 2) enzymatic, and 3) ribozyme-catalyzed. The newly formed 5' / 3' bond can be intramolecular or intermolecular. Such modifications are described, for example, in WO 2013 / 151736.

[0358] Methods for making and purifying modified RNA are known in the art and have been disclosed in the art. For example, modified RNA can be made using only in vitro transcription (IVT) enzymatic synthesis. Methods for making IVT polynucleotides are known in the art and described in WO 2013 / 151666, WO 2013 / 151668, WO 2013 / 151663, WO 2013 / 151669, WO 2013 / 151670, WO 2013 / 151664, WO 2013 / 151665, WO 2013 / 151671, WO 2013 / 151672, WO 2013 / 151667, and WO 2013 / 151736. The purification method includes purifying RNA transcripts comprising a poly A tail by contacting the sample with a surface attached to multiple thymidines or derivatives thereof and / or multiple uracils or derivatives thereof (poly T / U) under conditions that allow the RNA transcripts to bind to the surface and elute the purified RNA transcripts from the surface (WO 2014 / 152031); using ion (e.g., anion) exchange chromatography that allows for the separation of longer RNAs up to 10,000 nucleotides in length via a scalable method (WO 2014 / 144767); and subjecting the modified mRNA sample to DNase treatment (WO 2014 / 152030).

[0359] Formulations of modified RNA are known and described, for example, in WO 2013 / 090648. For example, the formulation can be, but is not limited to, nanoparticles, poly(lactic-co-glycolic acid) (PLGA) microspheres, lipidoids, lipoplexes, liposomes, polymers, carbohydrates (including simple sugars), cationic lipids, fibrin gels, fibrin hydrogels, fibrin glues, fibrin sealants, fibrinogen, thrombin, rapidly eliminated lipid nanoparticles (reLNPs), and combinations thereof.

[0360] In the fields of human diseases, antibodies, viruses and various in vivo environments, modified RNAs encoding polypeptides are known and disclosed, for example, in Table 6 of International Publication Nos. WO 2013 / 151666, WO 2013 / 151668, WO 2013 / 151663, WO 2013 / 151669, WO 2013 / 151670, WO 2013 / 151664, WO 2013 / 151665, WO 2013 / 151736; Tables 6 and 7 of International Publication No. WO 2013 / 151672; Tables 6, 178 and 179 of International Publication No. WO 2013 / 151671; and Tables 6, 185 and 186 of International Publication No. WO 2013 / 151667. Any of the above can be synthesized as an IVT polynucleotide, a chimeric polynucleotide, or a circular polynucleotide, and each can include one or more modified nucleotides or terminal modifications.

[0361] (c) Inhibitory RNA

[0362] In some cases, the PMP composition comprises an inhibitory RNA molecule, for example, the inhibitory RNA molecule plays a role via RNA interference (RNAi) approach. In some cases, the inhibitory RNA molecule reduces the gene expression level in the plant and / or reduces the protein level in the plant. In some cases, the inhibitory RNA molecule inhibits the expression of plant genes. For example, the inhibitory RNA molecule can include short interfering RNA or its precursor, short hairpin RNA and / or microRNA or its precursor, which targets the gene in the plant. Some RNA molecules can inhibit gene expression by the biological process of RNA interference (RNAi). RNAi molecules include RNA or RNA-like structures, which typically contain 15-50 base pairs (such as about 18-25 base pairs) and have the same (or complementary) or nearly the same (or substantially complementary) core base sequence as the coding sequence in the target gene of expression in the cell. RNAi molecules include, but are not limited to, short interfering RNA (siRNA), double-stranded RNA (dsRNA), short hairpin RNA (shRNA), partial duplex (meroduplex), dicer enzyme substrates, and polyvalent RNA interference (U.S. Patent Nos. 8,084,599, 8,349,809, 8,513,207, and 9,200,276). shRNA is an RNA molecule comprising a hairpin bend (hairpin bend) that reduces target gene expression via RNAi. shRNA can be delivered to cells in the form of a plasmid, for example, a viral or bacterial vector, for example, by transfection, electroporation, or transduction. MicroRNA is a non-coding RNA molecule typically having a length of about 21 or 22 nucleotides. MiRNA binds to a target site on an mRNA molecule and silences the mRNA, for example, by causing the cutting of the mRNA, destabilizing the mRNA, or inhibiting the translation of the mRNA. In some cases, inhibitory RNA molecules reduce the level and / or activity of negative functional regulatory factors. In other cases, the inhibitory RNA molecule reduces the level and / or activity of an inhibitor of a positive function regulator.The inhibitory RNA molecule can be chemically synthesized or transcribed in vitro.

[0363] In some cases, nucleic acid is DNA, RNA or PNA. In some cases, RNA is inhibitory RNA. In some cases, inhibitory RNA suppresses gene expression in plant. In some cases, nucleic acid is mRNA, modified mRNA or DNA molecule, which increases the following expression in plant: enzyme (for example, metabolic recombinase, helicase, integrase, RNA enzyme, DNA enzyme or ubiquitinated protein), pore-forming protein, signal transduction ligand, cell penetration peptide, transcription factor, receptor, antibody, nanobody, gene editing protein (for example, CRISPR-Cas system, TALEN or zinc finger), riboprotein, protein aptamer or chaperone protein. In some cases, the nucleic acid is an mRNA, a modified mRNA, or a DNA molecule that increases expression of an enzyme (e.g., a metabolic enzyme, a recombinase, a helicase, an integrase, an RNase, a DNase, or a ubiquitinated protein), a pore-forming protein, a signaling ligand, a cell-penetrating peptide, a transcription factor, a receptor, an antibody, a nanobody, a gene editing protein (e.g., a CRISPR-Cas system, TALEN, or a zinc finger), a riboprotein, a protein aptamer, or a chaperone. In some aspects, the nucleic acid encodes an enzyme, a pore-forming protein, a signaling ligand, a cell-penetrating peptide, a transcription factor, a receptor, an antibody, a nanobody, a gene editing protein, a riboprotein, a protein aptamer, or a chaperone. In some cases, the increase in expression in the plant is an increase in expression of about 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100% relative to a reference level (e.g., expression in an untreated plant). In some cases, the increase in expression in a plant is about 2x-fold, about 4x-fold, about 5x-fold, about 10x-fold, about 20x-fold, about 25x-fold, about 50x-fold, about 75x-fold, or about 100x-fold or greater increase in expression relative to a reference level (e.g., expression in an untreated plant).

[0364] In some cases, the nucleic acid is an antisense RNA, dsiRNA, siRNA, shRNA, miRNA, aiRNA, PNA, morpholino, LNA, piRNA, ribozyme, DNAzyme, aptamer (DNA, RNA), circRNA, gRNA, or DNA molecule (e.g., plasmid) that acts to reduce expression of, for example, an enzyme (metabolic enzyme, recombinase, helicase, integrase, RNase, DNase, polymerase, ubiquitinated protein, superoxide management enzyme, or energy production enzyme), transcription factor, secreted protein, structural factor (actin, kinesin, or tubulin), riboprotein, protein aptamer, chaperone protein, receptor, signaling ligand, or transporter in a plant. In some cases, the reduction in expression in a plant is about 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100% relative to a reference level (e.g., expression in an untreated plant). In some cases, the reduction in expression in a plant is about 2x-fold, about 4x-fold, about 5x-fold, about 10x-fold, about 20x-fold, about 25x-fold, about 50x-fold, about 75x-fold, or about 100x-fold or greater reduction in expression relative to a reference level (e.g., expression in an untreated plant).

[0365] RNAi molecules include sequences that are substantially complementary or fully complementary to the whole or fragment of the target gene. RNAi molecules can be complementary to the sequence at the boundary between introns and exons, thereby preventing the newly generated nuclear RNA transcript of the specific gene from maturing into the mRNA for transcription. The RNAi molecules complementary to the specific gene can hybridize with the mRNA of the target gene and prevent it from being translated. Antisense molecules can be DNA, RNA or its derivatives or hybrids. Examples of such derivative molecules include, but are not limited to, peptide nucleic acids (PNA) and thiophosphate-based molecules, such as deoxyribonucleic acid guanidine (DNG) or ribonucleic acid guanidine (RNG).

[0366] RNAi molecules can be provided as ready-to-use RNA synthesized in vitro, or as sense and antisense RNA sequences (or DNA encoding sense and antisense RNA sequences) transfected into cells, which, after transcription, will produce RNAi molecules. The hybridization of RNA molecules, for example, with target mRNA results in the degradation of the hybridized complex by RNase H, and / or the inhibition of the formation of translation complexes. Both result in the inability to produce the product of the original gene.

[0367] The length of the RNAi molecule that hybridizes to the target transcript can be about 10 nucleotides, between about 15 or 30 nucleotides, or about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more nucleotides. In embodiments, the RNAi molecule hybridizes to the target transcript to form a fully or nearly fully double-stranded region of at least about 17 base pairs; in embodiments, the double-stranded region includes at least about 10 consecutive base pairs. The degree of identity of the antisense sequence to the targeted transcript can be at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%.

[0368] RNAi molecules can also include overhangs, i.e., typically unpaired, overhanging nucleotides that do not directly participate in the double helical structure formed by the core sequences of the sense and antisense strands defined herein. RNAi molecules can contain 3' and / or 5' overhangs of approximately 1-5 bases independently located on each sense and antisense strand. In some cases, both the sense and antisense strands contain 3' and 5' overhangs. In some cases, one or more 3' overhang nucleotides of a strand are base-paired with one or more 5' overhang nucleotides of the other strand. In other cases, one or more 3' overhang nucleotides of a strand are not base-paired with one or more 5' overhang nucleotides of the other strand. The sense and antisense strands of an RNAi molecule may or may not contain the same number of nucleotide bases. The antisense and sense strands can form a duplex, wherein only the 5' end has a blunt end, only the 3' end has a blunt end, both the 5' and 3' ends are blunt ends, or neither the 5' end nor the 3' end is a blunt end. In another aspect, one or more nucleotides in the overhang contain phosphorothioates, phosphorothioates, inverted deoxynucleotides (3' to 3' linked) nucleotides, or are modified ribonucleotides or deoxynucleotides.

[0369] Small interfering RNA (siRNA) molecules include a nucleotide sequence that is identical to about 15 to about 25 consecutive nucleotides of a target mRNA. In some cases, the siRNA sequence begins with the dinucleotide AA, includes a GC content of 30%-70% (about 30%-60%, about 40%-60%, or about 45%-55%), and does not have a high percent identity with any nucleotide sequence other than the target in the genome into which it is to be introduced, e.g., as determined by a standard BLAST search.

[0370] siRNA and shRNA are similar to intermediates in the processing pathway of endogenous microRNA (miRNA) genes (Bartel, Cell 116: 281-297, 2004). In some cases, siRNA can act as miRNA, and vice versa (Zeng et al., Mol. Cell 9: 1327-1333, 2002; Doench et al., Genes Dev. 17: 438-442, 2003). Exogenous siRNA downregulates mRNA with seed complementarity to the siRNA (Birmingham et al., Nat. Methods 3: 199-204, 2006). Multiple target sites within the 3'UTR give stronger downregulation (Doench et al., Genes Dev. 17: 438-442, 2003).

[0371] Known effective siRNA sequences and cognate binding sites are also well presented in the relevant literature. RNAi molecules are easy to design and produce using techniques known in the art. In addition, there are computational tools that increase the chances of discovering effective and specific sequence motifs (Pei et al., Nat. Methods 3(9):670-676, 2006; Reynolds et al., Nat. Biotechnol. 22(3):326-330, 2004; Khvorova et al., Nat. Struct. Biol. 10(9):708-712, 2003; Schwarz et al., Cell 115(2):199-208, 2003; Ui-Tei et al., Nucleic Acids Res. 32(3):936-948, 2004; Heale et al., Nucleic Acids Res. [Nucleic Acids Research] 33(3):e30, 2005; Chalk et al., Biochem. Biophys. Res. Commun. [Biochemical and Biophysical Research Communications] 319(1):264-274, 2004; and Amarzguioui et al., Biochem. Biophys. Res. Commun. [Biochemical and Biophysical Research Communications] 316(4):1050-1058, 2004).

[0372] RNAi molecules regulate the expression of the RNA of gene encoding.Because a plurality of genes may share a certain degree of sequence homology each other, so in some cases, RNAi molecules can be designed to have a class gene of sufficient sequence homology with targeting.In some cases, RNAi molecules can contain and be the sequence shared in different gene targets or be that unique sequence has the sequence of complementarity for specific gene target.In some cases, RNAi molecules can be designed to have the conserved region of the RNA sequence of homology between some genes with targeting, some genes (such as, different gene isoforms, splice variants, mutant genes etc.) in a gene family of targeting thus.In some cases, RNAi molecules can be designed to be unique sequence for the specific RNA sequence of individual genes with targeting.

[0373] Inhibitory RNA molecules can be modified, for example, to contain modified nucleotides, such as 2'-fluoro, 2'-o-methyl, 2'-deoxy, unlocked nucleic acid, 2'-hydroxy, phosphorothioate, 2'-thiouridine, 4'-thiouridine, 2'-deoxyuridine. Without wishing to be bound by theory, it is believed that such modifications can increase nuclease resistance and / or serum stability, or reduce immunogenicity.

[0374] In some cases, the RNAi molecule or its precursor is connected to the delivery polymer via a physiologically unstable bond or linker. The physiologically unstable linker is selected so that when present under certain physiological conditions, it undergoes chemical transformation (e.g., cleavage) (e.g., under the reducing environment of the cytoplasm, through disulfide bond cleavage). By cleaving the physiologically unstable connection, the molecule is released from the polymer, which promotes the interaction of the molecule with the appropriate cellular components for activity.

[0375] RNAi molecule-polymer conjugates can be formed by covalently linking the molecule to a polymer. The polymer is polymerized or modified so that it contains a reactive group A. The RNAi molecule is also polymerized or modified so that it contains a reactive group B. Reactive groups A and B are selected so that they can be linked via reversible covalent bonds using methods known in the art.

[0376] In the presence of an excess of polymer, the RNAi molecule can be coupled to the polymer. Because the RNAi molecule and the polymer can have opposite charges during coupling, the presence of an excess of polymer can reduce or eliminate the aggregation of the conjugate. Alternatively, an excess of a carrier polymer, such as a polycation, can be used. Excess polymer can be removed from the coupled polymer before administering the conjugate. Alternatively, an excess of polymer can be co-administered with the conjugate.

[0377] The preparation and use of inhibitors based on non-coding RNA, such as ribozymes, RNase P, siRNA, and miRNA, are also known in the art, for example, as described in Sioud, RNA Therapeutics: Function, Design, and Delivery (Methods in Molecular Biology). Humana Press (2010).

[0378] (d) Gene editing

[0379] The PMP compositions described herein may include components of a gene editing system. For example, a medicament may introduce changes (e.g., insertions, deletions (e.g., knockouts), translocations, inversions, single point mutations, or other mutations) into a gene in a plant. Exemplary gene editing systems include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly spaced short palindromic repeats (CRISPR) systems. Methods based on ZFNs, TALENs, and CRISPRs are described in the following literature: for example, Gaj et al., Trends Biotechnol. [Biotechnology Trends] 31(7): 397-405, 2013.

[0380] In a typical CRISPR / Cas system, an endonuclease is directed to a target nucleotide sequence (e.g., a site in a genome to be sequence-edited) by a sequence-specific, non-coding "guide RNA" targeting a single-stranded or double-stranded DNA sequence. Three classes (I-III) of CRISPR systems have been identified. Class II CRISPR systems use a single Cas endonuclease (rather than multiple Cas proteins). A Class II CRISPR system includes Class II Cas endonucleases, such as Cas9, CRISPR RNA (crRNA), and trans-activating crRNA (tracrRNA). CrRNA contains a guide RNA, i.e., typically, an RNA sequence of about 20 nucleotides corresponding to a target DNA sequence. CrRNA also includes a region bound to tracrRNA to form a partial double-stranded structure cut by RNase III, producing a crRNA / tracrRNA hybrid. RNA acts as a guide to instruct Cas proteins to silence specific DNA / RNA sequences, depending on the spacer sequence. See, e.g., Horvath et al., Science 327:167-170, 2010; Makarova et al., Biology Direct 1:7, 2006; Pennisi, Science 341:833-836, 2013. The target DNA sequence must generally be adjacent to a protospacer adjacent motif (PAM) specific for a given Cas endonuclease; however, PAM sequences appear to be distributed throughout a given genome. CRISPR endonucleases identified from different prokaryotic species have unique PAM sequence requirements; examples of PAM sequences include 5'-NGG (SEQ ID NO: 1) (Streptococcus pyogenes), 5'-NNAGAA (SEQ ID NO: 2) (Streptococcus thermophilus CRISPR1), 5'-NGGNG (SEQ ID NO: 3) (Streptococcus thermophilus CRISPR3), and 5'-NNNGATT (SEQ ID NO: 4) (Neisseria meningiditis). Some endonucleases, such as the Cas9 endonuclease, associate with G-rich PAM sites (e.g., 5'-NGG (SEQ ID NO: 1)) and perform blunt-end cleavage of the target DNA at a position 3 nucleotides upstream (5' from the PAM site) of the PAM site.Another Class II CRISPR system includes the V-type endonuclease Cpf1, which is smaller than Cas9; examples include AsCpf1 (from Acidaminococcus sp.) and LbCpf1 (from Lachnospiraceae sp.). Cpf1-associated CRISPR arrays are processed into mature crRNAs without the need for tracrRNA; in other words, the Cpf1 system only requires the Cpf1 nuclease and crRNA to cleave the target DNA sequence. The Cpf1 endonuclease is associated with T-rich PAM sites, for example, 5'-TTN (SEQ ID NO: 5). Cpf1 can also recognize the 5'-CTA (SEQ ID NO: 6) PAM motif. Cpf1 cuts the target DNA by introducing a misplaced or staggered double-strand break with a 5' overhang of 4 or 5 nucleotides, for example, cutting the target DNA where the misplaced or staggered cut of 5 nucleotides is located 18 nucleotides downstream (3') of the PAM site on the coding strand and 23 nucleotides downstream of the PAM site on the complementary strand; the 5 nucleotide overhangs generated by this misplaced cut allow DNA insertion by homologous recombination to be more accurately edited than insertion of DNA cut at the blunt end. See, for example, Zetsche et al., Cell 163:759-771, 2015.

[0381] For the purpose of gene editing, a CRISPR array can be designed to contain one or more guide RNA sequences corresponding to a desired target DNA sequence; see, for example, Cong et al., Science 339:819-823, 2013; Ran et al., Nature Protocols 8:2281-2308, 2013. For DNA cleavage to occur, Cas9 requires at least about 16 or 17 nucleotides of the gRNA sequence; for Cpf1, at least about 16 nucleotides of the gRNA sequence are required to achieve detectable DNA cleavage. In practice, guide RNA sequences are typically designed to have a length between 17-24 nucleotides (e.g., 19, 20, or 21 nucleotides) and are complementary to the targeted gene or nucleic acid sequence. Custom gRNA generators and algorithms are commercially available for designing effective guide RNAs. Gene editing has also been achieved using a chimeric single guide RNA (sgRNA), an engineered (synthetic) single RNA molecule that mimics the naturally occurring crRNA-tracrRNA complex and contains tracrRNA (for binding nuclease) and at least one crRNA (to guide the nuclease to the editing target sequence). Chemically modified sgRNAs have also been shown to be effective in genome editing; see, for example, Hendel et al., Nature Biotechnol. 985-991, 2015.

[0382] While wild-type Cas9 generates double-strand breaks (DSBs) at specific DNA sequences targeted by gRNAs, many CRISPR endonucleases with modified functionality are available, for example: the nickase form of Cas9 only generates single-strand breaks; catalytically inactive Cas9 (dCas9) does not cut the target DNA, but interferes with transcription by steric hindrance. dCas9 can be further fused to effectors to repress (CRISPRi) or activate (CRISPRa) the expression of target genes. For example, Cas9 can be fused to transcription repressors (e.g., KRAB domains) or transcription activators (e.g., dCas9-VP64 fusions). Catalytically inactive Cas9 (dCas9) fused to the FokI nuclease (dCas9-FokI) can be used to generate DSBs at target sequences homologous to two gRNAs. See, for example, the numerous CRISPR / Cas9 plasmids disclosed and publicly available in the Addgene repository (Addgene, 75 Sidney St., Suite 550A, Cambridge, MA 02139; addgene.org / crispr / ). The double-nickase Cas9 that introduces two separate double-strand breaks (each guided by a separate guide RNA) is described by Ran et al., Cell 154: 1380-1389, 2013 to achieve more precise genome editing.

[0383] CRISPR technology for editing genes in eukaryotic organisms is disclosed in U.S. Patent Application Publication Nos. 2016 / 0138008A1 and 2015 / 0344912A1, as well as U.S. Patents 8,697,359, 8,771,945, 8,945,839, 8,999,641, 8,993,233, 8,895,308, 8,865,406, 8,889,418, 8,871,445, 8,889,356, 8,932,814, 8,795,965, and 8,906,616. The Cpf1 endonuclease and corresponding guide RNA and PAM site are disclosed in U.S. Patent Application Publication No. 2016 / 0208243A1.

[0384] In some cases, the desired genome modification relates to homologous recombination, wherein one or more double-stranded DNA breaks in the target nucleotide sequence are produced by the nuclease guided by RNA and one or more guide RNAs, and then the one or more breaks are repaired using a homologous recombination mechanism (homologous directed repair). In such a case, a donor template encoding the desired nucleotide sequence to be inserted or knocked into at a double-stranded break is provided to a cell or subject; The example of a suitable template includes a single-stranded DNA template and a double-stranded DNA template (for example, connected to a polypeptide as described herein). Typically, in the form of single-stranded DNA, a donor template encoding nucleotide changes in a region less than about 50 nucleotides is provided; Larger donor templates (for example, more than 100 nucleotides) are typically provided as double-stranded DNA plasmids. In some cases, with enough to achieve desired homologous directed repair, but after a given time period (for example, after one or more cell division cycles), the amount not retained in a cell or subject is provided to a cell or subject. In some cases, the donor template has a core nucleotide sequence that differs from the target nucleotide sequence (e.g., a homologous endogenous genomic region) by at least 1, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, or more nucleotides. This core sequence is flanked by homology arms or regions with a high degree of sequence identity to the targeted nucleotide sequence; in some cases, the regions with a high degree of identity include at least 10, at least 50, at least 100, at least 150, at least 200, at least 300, at least 400, at least 500, at least 600, at least 750, or at least 1000 nucleotides on each side of the core sequence. In some cases, where the donor template is in the form of single-stranded DNA, the core sequence is flanked by homology arms that include at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, or at least 100 nucleotides on each side of the core sequence. In various cases, wherein the donor template is in the form of double-stranded DNA, the core sequence is flanked by homology arms comprising at least 500, at least 600, at least 700, at least 800, at least 900, or at least 1000 nucleotides on each side of the core sequence. In one case, two separate double-strand breaks are introduced into the target nucleotide sequence of a cell or subject using the double-nickase Cas9 (see Ran et al., Cell 154: 1380-1389, 2013), followed by delivery of the donor template.

[0385] In some cases, the composition includes a gRNA and a targeted nuclease, e.g., Cas9, e.g., wild-type Cas9, nickase Cas9 (e.g., Cas9 D10A), inactivated Cas9 (dCas9), eSpCas9, Cpf1, C2C1, or C2C3, or a nucleic acid encoding such a nuclease. The selection of the nuclease and one or more gRNAs is determined by whether the targeted mutation is a deletion, substitution, or addition of nucleotides, e.g., a deletion, substitution, or addition of nucleotides of the targeted sequence. A fusion of a catalytically inactive endonuclease, e.g., inactivated Cas9 (dCas9, e.g., D10A, H840A) linked to all or a portion (e.g., a biologically active portion) of (one or more) effector domains produces a chimeric protein that can be linked to a polypeptide, thereby guiding the composition to a specific DNA site via one or more RNA sequences (sgRNAs), thereby modulating the activity and / or expression of one or more target nucleic acid sequences.

[0386] In many cases, the agent includes a guide RNA (gRNA) for a CRISPR system for gene editing. In some cases, the agent includes a zinc finger nuclease (ZFN) or an mRNA encoding a ZFN that targets (e.g., cuts) a nucleic acid sequence (e.g., a DNA sequence) of a gene in a plant. In some cases, the agent includes a TALEN or an mRNA encoding a TALEN that targets (e.g., cuts) a nucleic acid sequence (e.g., a DNA sequence) of a gene in a plant.

[0387] For example, gRNA can be used for the CRISPR system to engineer the change of the gene in the plant. In other examples, ZFN and / or TALEN can be used for the change of the gene in the plant. Exemplary changes include insertion, deletion (for example, knockout), translocation, inversion, single point mutation or other sudden change. Changes can be introduced into the gene in the cell, for example, in vitro, in vitro or in vivo. In some instances, the change increases the level and / or activity of the gene in the plant. In other examples, the change reduces the level and / or activity of the gene in the plant (for example, strikes low or knocks out). In another example again, the change corrects the defect in the gene in the plant (for example, causing a sudden change of a defect).

[0388] In some cases, the CRISPR system is used to edit (e.g., add or delete base pairs) target genes in plants. In other cases, the CRISPR system is used to introduce premature termination codons, such as thereby reducing the expression of the target gene. Still in other cases, the CRISPR system is used to turn off the target gene in a reversible manner, such as similar to RNA interference. In some cases, the CRISPR system is used to guide Cas to the promoter of the gene, thereby blocking RNA polymerase in a steric manner.

[0389] In some cases, CRISPR systems can be generated to edit genes in plants using techniques described in, for example, U.S. Publication No. 20140068797, Cong, Science 339:819-823, 2013; Tsai, Nature Biotechnol. 32:6 569-576, 2014; U.S. Patent Nos. 8,871,445; 8,865,406; 8,795,965; 8,771,945; and 8,697,359.

[0390] In some cases, CRISPR interference (CRISPRi) technology can be used to transcriptionally repress specific genes in plants. In CRISPRi, engineered Cas9 proteins (e.g., dCas9 or dCas9 fusion proteins without nucleases, e.g., dCas9-KRAB or dCas9-SID4X fusions) can be paired with sequence-specific guide RNA (sgRNA). The Cas9-gRNA complex can block RNA polymerase, thereby interfering with transcriptional extension. The complex can also bind to and block transcription initiation by interfering with transcription factors. The CRISPRi method is specific, has minimal off-target effects, and can be multi-channel shared, for example, more than one gene (e.g., using multiple gRNAs) can be repressed simultaneously. Moreover, the CRISPRi method allows reversible gene suppression.

[0391] In some cases, CRISPR-mediated gene activation (CRISPRa) can be used for transcriptional activation of genes in plants. In CRISPRa technology, dCas9 fusion proteins recruit transcriptional activators. For example, dCas9 can be fused to a polypeptide (e.g., an activation domain) (e.g., VP64 or p65 activation domain (p65D)) and used together with sgRNA (e.g., a single sgRNA or multiple sgRNAs) to activate one or more genes in a plant. A variety of sgRNAs can be used to recruit a variety of activators-this can increase activation efficacy. A variety of activation domains and single or multiple activation domains can be used. In addition to engineering dCas9 to recruit activators, sgRNAs can also be engineered to recruit activators. For example, RNA aptamers can be incorporated into sgRNA to recruit proteins (e.g., activation domains), such as VP64. In some instances, a synergistic activation mediator (SAM) system can be used for transcriptional activation. In SAM, an MS2 aptamer is added to the sgRNA. MS2 recruits the MS2 coat protein (MCP) fused to p65AD and heat shock factor 1 (HSF1).

[0392] The following literature describes CRISPRi and CRISPRa technology in more detail, for example, Dominguez et al., Nat. Rev. Mol. Cell Biol. [Nature Review Molecular Cell Biology] 17: 5-15, 2016, which is incorporated herein by reference. In addition, dCas9-mediated epigenetic modification and simultaneous activation and repression using the CRISPR system (as described by Dominguez et al.) can be used to regulate genes in plants.

[0393] D. Xenologous Therapeutic Agents

[0394] The PMPs produced herein can include heterologous therapeutic agents (e.g., agents that affect animals (e.g., mammals, such as humans), animal pathogens, or their pathogen vectors, and can be loaded into the PMP), such as therapeutic peptides, therapeutic nucleic acids (e.g., therapeutic RNA), therapeutic small molecules, or pathogen control agents (e.g., antifungals, antibacterials, viricides, antivirals, insecticides, nematicides, antiparasitics, or insect repellents). PMPs loaded with such agents can be formulated with a pharmaceutically acceptable carrier for delivery to animals, animal pathogens, or their pathogen vectors.

[0395] i. Antibacterial agents

[0396] The PMP compositions described herein may further comprise an antibacterial agent. For example, a PMP composition comprising an antibiotic as described herein may be administered to an animal in an amount and for a time sufficient to: achieve a target level (e.g., a predetermined or threshold level) of antibiotic concentration in or on the animal; and / or treat or prevent bacterial infection in the animal. The antibacterial agents described herein may be formulated in a PMP composition for any of the methods described herein, and in some cases, may be associated with its PMP. In some cases, the PMP composition comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different antibacterial agents.

[0397] As used herein, the term "antibacterial agent" refers to a material that kills or inhibits the growth, proliferation, division, reproduction, or spread of bacteria (such as plant pathogenic bacteria), and includes bactericides (e.g., disinfecting compounds, antibacterial compounds, or antibiotics) or bacteriostatics (e.g., compounds or antibiotics). Bactericidal antibiotics kill bacteria, while bacteriostatic antibiotics only slow their growth or reproduction.

[0398] Bactericides may include disinfectants, antimicrobials, or antibiotics. The most commonly used disinfectants may include: active chlorine (i.e., hypochlorites (e.g., sodium hypochlorite), chloramines, dichloroisocyanurates and trichloroisocyanurates, wet chlorine, chlorine dioxide, etc.), active oxygen (peroxides such as peracetic acid, potassium persulfate, sodium perborate, sodium percarbonate, and urea perhydrate), iodine (iodine povidone (povidone iodine, Betadine), Lugol's solution (Lugol's solution), and the like. solution), iodine tincture, iodinated nonionic surfactants), concentrated alcohols (mainly ethanol, 1-propanol (also called n-propanol) and 2-propanol (called isopropanol), and mixtures thereof; further, 2-phenoxyethanol and 1-phenoxypropanol and 2-phenoxypropanol are used), phenolic substances (such as phenol (also called carbolic acid), cresol (combined with liquid potassium soap to be called Lysol), halogenated (chlorinated, brominated) phenols, such as hexachlorophene, triclosan, trichlorophenol, tribromophenol, pentachlorophenol, dibromophenol and their salts), cationic surfactants, such as some quaternary ammonium cations (such as benzalkonium chloride, cetyltrimethylammonium bromide or cetyltrimethylammonium chloride, didecyldimethyl The following are some of the following: 1) alkylammonium chloride, cetylpyridinium chloride, benzethonium chloride) and other non-quaternary compounds such as chlorhexidine, saccharin protamine, octenidine dihydrochloride, etc.; 2) strong oxidants such as ozone and permanganate solution; 3) heavy metals and their salts such as colloidal silver, silver nitrate, mercuric chloride, phenylmercuric salts, copper sulfate, copper oxychloride, copper hydroxide, copper octoate, copper oxychloride sulfate, copper sulfate, copper sulfate pentahydrate, etc. Heavy metals and their salts are the most toxic and environmentally harmful bactericides, and therefore, their use has been strongly suppressed or eliminated; 4) in appropriately concentrated form strong acids (phosphoric acid, nitric acid, sulfuric acid, sulfamic acid, toluenesulfonic acid) and alkalis (sodium hydroxide, potassium hydroxide, calcium hydroxide).

[0399] As antimicrobial agents (i.e., antiseptics that can be used on the human or animal body, skin, mucous membranes, wounds, etc.), the above-mentioned disinfectants can be used under appropriate conditions (mainly concentration, pH, temperature and toxicity to humans / animals). Important among these are: appropriately diluted chlorine preparations (i.e., Daquin's solution, 0.5% sodium or potassium hypochlorite solution (pH adjusted to pH 7-8), or 0.5%-1% solution of benzenesulfonyl chloride sodium salt (chloramine B)); some iodine preparations, such as iodine povidone in various galenical preparations (ointments, solutions, wound plasters) and, in the past, Lugol's solution; peroxides as urea perhydrate solutions and pH-buffered 0.1%-0.25% peracetic acid solutions; alcohols with or without antimicrobial additives, primarily for skin antiseptics; weak organic acids, such as sorbic acid, benzoic acid, lactic acid, and salicylic acid; some phenolic compounds, such as hexachlorophene, triclosan, and Dibromol; and cationically active compounds, such as 0.05%-0.5% benzalkonium, 0.5%-4% chlorhexidine, 0.1%-2% octenidine solutions.

[0400] The PMP compositions described herein may include an antibiotic. Any antibiotic known in the art may be used. Antibiotics are generally classified based on their mechanism of action, chemical structure, or spectrum of activity.

[0401] Antibiotics described herein can target the function or growth process of any bacteria and can be bacteriostatic (for example, slowing down or preventing bacterial growth) or bactericidal (for example, killing bacteria). In some cases, antibiotic is a bactericidal antibiotic. In some cases, bactericidal antibiotic is a bactericidal antibiotic (for example, penicillin and cephalosporin) targeting bacterial cell wall;Bactericidal antibiotic (for example, polymyxin) targeting cell membrane;Or bactericidal antibiotic (for example, rifamycin, lipiarmycins, quinolones and sulfonamides) that suppresses essential bacterial enzymes. In some cases, bactericidal antibiotic is aminoglycoside (for example, kasugamycin). In some cases, antibiotic is a bacteriostatic antibiotic. In some cases, bacteriostatic antibiotic targets protein synthesis (for example, macrolides, lincosamides and tetracyclines). The antibiotic of other classes that can be used herein includes cyclic lipopeptides (such as daptomycin), glycylcycline (such as tigecycline), oxazolidinones (such as linezolid) or lipiarmycins (such as fidaxomicin). Examples of antibiotics include rifampicin, ciprofloxacin, doxycycline, ampicillin, and polymyxin B. Antibiotics described herein can have any level of target specificity (e.g., narrow spectrum or broad spectrum). In some cases, antibiotics are narrow spectrum antibiotics and therefore target specific types of bacteria, such as gram-negative bacteria or gram-positive bacteria. Alternatively, antibiotics can be broad spectrum antibiotics targeting a wide range of bacteria.

[0402] Examples of antibacterial agents suitable for treating animals include penicillins (amoxicillin, ampicillin, bacampicillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, nafcillin, oxacillin, penicillin G, procaine penicillin 300 A.S., penicillin G potassium (Pentids), Permapen, Pfizerpen, Pfizerpen-AS, Wycillin, penicillin V, piperacillin, pivampicillin, pivmecillin, ticarcillin), cephalosporins (cefacetrile), cefadroxil, ... cefadroxyl), Cefalexin (cephalexin), Cefaloglycin (cephaloglycin), Cefalonium (cephalonium), Cefaloridine (cephaloradine), Cefalotin (cephalothin), Cefapirin (cephapirin), Ceftriaxone, Cefazolin, Cefazolin, Cefazolin, Cefazolin Cefazolin (cephazolin), Cefradine (cephradine), Cefoxadine, Cefotezole, Cefaclor, Cefdazole, Cefmetazole, Cefonicid, Cefotetan, Cefoxetine, Cefprozil (cefproxil), Cefuroxime, Cefazolin, Cefcaprine, Cefdoxime, Cefdinir, Cefditoren, Cefetamet, Cefixime, Cefmenoxime, Cefodizime, Cefotaxime, Cefmidazole, Cefpodoxime, Cefditoren, Cefbutane, Ceftiofur, Ceftiolin, Cefazolin, Ceftriaxone, Cefoperazone, Ceftazidime, Cefixime, Cefpodoxime, Cefditoren, Ceftibuten, Ceftiofur, Ceftiolin, Cefazolin, Ceftriaxone, Cefoperazone, Ceftazidime, Cefixime, Cefuroxime Ceftriaxone, Cefuroxime, Ceftriaxone, Cefazolin, Cefoperazone, Cefpirome, Cefquinome, Ceftobiprole, Cefuroxime, Cefuroxime, Cefuroxime, Cefdrol, Cefoperazone, Cefcanel, Cefdrolol, Cefoperazone, Ceftriaxone, Ceftriaxone, Cefavirenz, Cefmepidium, Cefavirin, Cefoxazole, Cefrothirin, Cefsumabucil, Cefuroxime, Ceftioxime, Combinations (ceftazidime / avibactam, ceftolozane / tazobactam)), Monobactam (aztreonam), Carbapenems (imipenem, imipenem / cilastatin, doripenem, ertapenem, meropenem, meropenem / vaborbactam), Macrolides (azithromycin, erythromycin, clarithromycin, dirithromycin,erythromycin, telithromycin), lincosamides (clindamycin, lincomycin), streptogramins (primamicin, quinupristin / dalfopristin), aminoglycosides (amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin, tobramycin), quinolones (flumequine, nalidixic acid, oxolinic acid, piromidic acid, pipemidic acid, rosofloxacin (second generation), ciprofloxacin, enoxacin, lomefloxacin, nadifloxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, gatifloxacin, grefloxacin, levofloxacin, moxifloxacin, pazufloxacin, sparfloxacin, temafloxacin, tosufloxacin, besifloxacin, delafloxacin, clinfloxacin Star, gemifloxacin, prulifloxacin, sitafloxacin, trovafloxacin), sulfonamides (sulfamethizole, sulfamethoxazole, sulfisoxazole, trimethoprim-sulfamethoxazole), tetracyclines (demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, tigecycline), others (lipopeptides, fluoroquinolones, lipoglycopeptides, cephalosporins, macrocycles, chloramphenicol, metronidazole, sulfamethoxazole, nitrofurantoin, glycopeptides, vancomycin, teicoplanin, lipoglycopeptides, telavancin, oxazolidinone, linezolid, cycloserine 2, rifamycin, rifampicin, rifabutin, rifapentine, rifalazil, polypeptides, bacitracin, polymyxin B, tuberculin, viomycin, capreomycin).

[0403] One skilled in the art will recognize that the appropriate concentration of each antibiotic in the composition depends on factors such as the potency, stability of the antibiotic, the number of different antibiotics, the formulation, and the method of application of the composition.

[0404] ii. Antifungal agents

[0405] The PMP compositions described herein may further comprise an antifungal agent. For example, a PMP composition comprising an antifungal agent as described herein can be administered to an animal in an amount and for a time sufficient to achieve a target level (e.g., a predetermined or threshold level) of antifungal agent concentration in or on the animal; and / or to treat or prevent fungal infections in animals. The antifungal agents described herein can be formulated in the PMP compositions for any of the methods described herein, and in some cases, can be associated with their PMPs. In some cases, the PMP composition comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different antifungal agents.

[0406] As used herein, the term "fungicide" or "antifungal agent" refers to a substance that kills or inhibits the growth, proliferation, division, reproduction or spread of fungi (such as fungi that are pathogens for animals). Many different types of antifungals have been produced commercially. Non-limiting examples of antifungals include: allylamines (Amorolfine, Butenafine, Nathifon, Terbinafine), imidazoles ((Bifonazole, Butoconazole, Clotrimazole, Econazole, Fenticonazole, Ketoconazole, Isoconazole, Luliconazole, Miconazole, Omoconazole, Oxiconazole, Sertaconazole, Sulficonazole, Tioconazole, Terconazole); triazoles (Albaconazole, Efinaconazole, Fluconazole, Isavuconazole, Itraconazole, Posaconazole, Ravuconazole, Terconazole, Voriconazole); The present invention also includes but is not limited to: azoles, thiazoles (abafungin), polyenes (amphotericin B, nystatin, natamycin, trichostatin), echinocandins (anidulafungin, caspofungin, micafungin), others (tolnaftate, flucytosine, butenafine, griseofulvin, ciclopirox, selenium sulfide, tavaborole). It will be appreciated by those skilled in the art that the appropriate concentration of each antifungal agent in the composition depends on factors such as efficacy, stability of the antifungal agent, the amount of the different antifungal agents, formulation, and method of application of the composition.

[0407] iii. Insecticides

[0408] The PMP compositions described herein may further comprise an insecticide. For example, an insecticide may reduce (e.g., reduce the growth of or kill) the fitness of an insect vector of an animal pathogen. A PMP composition comprising an insecticide as described herein may be brought into contact with an insect in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of insecticide concentration in or on the insect; and (b) reduce the fitness of the insect. In some cases, an insecticide may reduce (e.g., reduce the growth of or kill) the fitness of a parasitic insect. A PMP composition comprising an insecticide as described herein may be brought into contact with a parasitic insect or an animal infected therewith in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of insecticide concentration in or on the parasitic insect; and (b) reduce the fitness of the parasitic insect. The insecticides described herein may be formulated in a PMP composition for use in any of the methods described herein, and in some cases, may be associated with a PMP thereof. In some cases, the PMP composition comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different insecticides.

[0409] As used herein, the term "insecticide" or "insecticidal agent" refers to a substance that kills or inhibits the growth, proliferation, reproduction, or spread of insects, such as insect vectors of animal pathogens or parasitic insects. Non-limiting examples of insecticides are shown in Table 4. Additional non-limiting examples of suitable insecticides include biological agents, hormones or pheromones (such as azadirachtin), Bacillus species (e.g., Bacillus thuringiensis), Beauveria species, codlemone, Metarrhizium species, Paecilomyces species, Saccharopolyspora species, and Verticillium species; as well as active compounds with unknown or unspecified mechanisms of action, such as fumigants (such as aluminum phosphide, methyl bromide, and sulfuryl fluoride), and selective feeding inhibitors (such as cryolite, flonicamid, and pymetrozine). Those skilled in the art will recognize that the appropriate concentration of each insecticide in the composition depends on factors such as efficacy, stability of the insecticide, the amount of the different insecticides, the formulation, and the method of application of the composition.

[0410] Table 4. Examples of insecticides

[0411]

[0412]

[0413] iv. Nematicides

[0414] The PMP compositions described herein may further comprise a nematocide. In some cases, the PMP compositions comprise two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different nematocides. For example, a nematocide can reduce (e.g., reduce growth or kill) the fitness of a parasitic nematode. A PMP composition comprising a nematocide as described herein can be contacted with a parasitic nematode or an animal infected therewith in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of nematocide concentration in or on the target nematode; and (b) reduce the fitness of the parasitic nematode. The nematocide described herein can be formulated in a PMP composition for any of the methods described herein and, in some cases, can be associated with its PMP.

[0415] As used herein, the term "nematicide" or "nematicidal agent" refers to a substance that kills or inhibits the growth, proliferation, reproduction, or spread of nematodes (e.g., parasitic nematodes). Non-limiting examples of nematicides are shown in Table 5. One skilled in the art will recognize that the appropriate concentration of each nematicide in the composition depends on factors such as efficacy, stability of the nematicide, the amount of the different nematicides, the formulation, and the method of application of the composition.

[0416] Table 5. Examples of nematicides

[0417]

[0418] v. Antiparasitic agents

[0419] The PMP compositions described herein may further comprise an antiparasitic agent. For example, an antiparasitic agent can reduce (e.g., reduce growth or kill) the fitness of a parasitic protozoan. A PMP composition comprising an antiparasitic agent as described herein can be brought into contact with a protozoan in an amount and for a time sufficient to: (a) achieve a target level (e.g., predetermined or threshold level) of antiparasitic agent concentration in or on the protozoan or an animal infected therewith; and (b) reduce the fitness of the protozoan. This can be used to treat or prevent parasites in animals. For example, a PMP composition comprising an antiparasitic agent as described herein can be administered to an animal in an amount and for a time sufficient to: achieve a target level (e.g., predetermined or threshold level) of antiparasitic agent concentration in or on the animal; and / or treat or prevent parasites (e.g., parasitic nematodes, parasitic insects, or protozoa) infection in an animal. The antiparasitic agent described herein can be formulated in a PMP composition for any of the methods described herein and, in some cases, can be associated with its PMP. In some cases, a PMP composition comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different antiparasitic agents.

[0420] As used herein, the term "antiparasitic or antiparasitic agent" refers to a substance that kills or inhibits the growth, proliferation, reproduction, or spread of parasites (such as parasitic protozoa, parasitic nematodes, or parasitic insects). Examples of antiparasitic agents include anthelmintics (benzimidazole, diethylcarbamazine, ivermectin, niclosamide, piperazine, praziquantel, pyrantel, pyrantel, pyrvinium, benzimidazole, albendazole, flubendazole, mebendazole, thiabendazole, levamisole, nitazoxanide, Monopantel, emodepside, spiroindole), scabicides (benzyl benzoate, benzyl benzoate / disulfiram, lindane, marathon, permethrin), pediculicides (piperonyl butoxide / pyrethrin, spinosad, moxidectin), scabicides (crotamiton), tapeworms (niclosamide, pranziquantel, albendazole), amoebicides (rifampicin, amphotericin B); or antiprotozoal agents (melarsoprol, ilonexide, metronidazole, tinidazole, miltefosine, artemisinin). In some cases, antiparasitic agents can be used to treat or prevent infections in livestock animals, such as levamisole, fenbendazole, oxfendazole, albendazole, moxidectin, eprinomectin, doramectin, ivermectin, or clorsulon. One skilled in the art will recognize that the appropriate concentration of each antiparasitic agent in the composition depends on factors such as efficacy, stability of the antiparasitic agent, the amount of the different antiparasitic agents, the formulation, and the method of application of the composition.

[0421] vi. Antiviral agents

[0422] The PMP compositions described herein may further comprise an antiviral agent. A PMP composition comprising an antiviral agent as described herein can be administered to an animal in an amount and for a time sufficient to achieve a target level (e.g., a predetermined or threshold level) of antiviral concentration in or on the animal; and / or to treat or prevent viral infection in an animal. The antiviral agents described herein can be formulated in a PMP composition for any of the methods described herein, and in some cases, can be associated with its PMP. In some cases, the PMP composition comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different antiviral agents.

[0423] As used herein, the term "antiviral agent" or "virucide" refers to a substance that kills or inhibits the growth, proliferation, reproduction, development, or spread of viruses (e.g., viral pathogens that infect animals). Many agents can be used as antiviral agents, including chemicals or biological agents (e.g., nucleic acids, such as dsRNA). Examples of antiviral agents useful herein include abacavir, acyclovir (Aciclovir), adefovir, amantadine, amprenavir (Agenerase), ampligen, arbidol, atazanavir, lipitor, balavir, cidofovir, compivir, dolutegravir, darunavir, delavirdine, didanosine, docosinol, edoxuridine, efavirenz, emtricitabine, enfuvirtide, entecavir, ecoliever, famciclovir, fomivirsen, fosamprenavir, foscarnet, fosfonet, fusion inhibitors, ganciclovir, ibacitabine, Imunov ir, herpes net, imiquimod, indinavir, inosine, integrase inhibitors, type III interferon, type II interferon, type I interferon, interferon, lamivudine, lopinavir, loviride, maraviroc, morphine, methylthiazone, nelfinavir, nevirapine, sorafenib (Nexavir), nitazoxanide, nucleoside analogs, novir, oseltamivir (Tamiflu), pegylated interferon α-2a, penciclovir, peramivir, praconazole, podophyllotoxin, raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, sofosbuvir, stavudine, synergistic enhancers (antiretroviral agents), telaprevir, tenofovir, tenofovir disoproxil fumarate (Tenofovir

[00145] The present invention relates to a pharmaceutical composition comprising: ...

[0424] vii. Repellent

[0425] The PMP compositions described herein may further comprise a repellent. For example, a repellent may repel vectors of animal pathogens, such as insects. The repellents described herein may be formulated in a PMP composition for use in any of the methods described herein, and in some cases, may be associated with a PMP. In some cases, a PMP composition comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) different repellents.

[0426] For example, a PMP composition comprising a repellent as described herein can be contacted with an insect vector or a habitat of the vector in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of repellent concentration; and / or (b) reduce the level of insects near or on the animal relative to a control. Alternatively, a PMP composition comprising a repellent as described herein can be contacted with an animal in an amount and for a time sufficient to: (a) achieve a target level (e.g., a predetermined or threshold level) of repellent concentration; and / or (b) reduce the level of insects near or on the animal relative to an untreated animal.

[0427] Some examples of well-known insect repellents include: benzil; benzyl benzoate; 2,3,4,5-bis(but-2-ene)tetrahydrofurfural (MGK Repellent 11); butoxypolypropylene glycol; N-butylacetanilide; n-butyl-6,6-dimethyl-5,6-dihydro-1,4-pyrone-2-carboxylate (Bifurcon); dibutyl adipate; dibutyl phthalate; di-n-butyl succinate (Bifurcon); N,N-diethyl-m-toluamide (DEET); Bifurcon (endo, endo)-dimethylbicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate); dimethyl phthalate; 2-ethyl-2-butyl-1,3-propanediol; 2-ethyl-1,3-hexanediol (Rutgers 612); di-n-propyl isooctanoate (MGK Repellent 326); 2-phenylcyclohexanol; p-methane-3,8-diol, and n-propyl N,N-diethylsuccinamate. Other repellents include citronella oil, dimethyl phthalate, n-butyl mesitylene oxide oxalate, and 2-ethylhexanediol-1,3-diol (see Kirk-Othmer Encyclopedia of Chemical Technology, 2nd ed., Vol. 11: 724-728; and The Condensed Chemical Dictionary, 8th ed., p. 756).

[0428] In some cases, the repellent is an insect repellent, including synthetic or non-synthetic insect repellents. Examples of synthetic insect repellents include methyl anthranilate and other anthranilate-based insect repellents, benzaldehyde, DEET (N,N-diethyl-m-toluamide), chlorpyrifos, dimethyl phthalate, icaridin (i.e., picaridin), Bayrepel, and KBR 3023), dimethoate (e.g., as used in a "6-2-2" mixture (60% dimethyl phthalate, 20% dimethoate, 20% ethyl hexanediol), IR3535 (3-[N-butyl-N-acetyl]-aminopropionic acid, ethyl ester), metofluthrin, permethrin, SS220, or tricyclodecenyl allyl ether. Examples of natural insect repellents include callicarpa (Callicarpa) leaves, birch bark, mentha (Myrica Gale), catnip oil (e.g., nepetalactone), citronella oil, essential oils of lemon eucalyptus (Corymbia citriodora; e.g., p-menthane-3,8-diol (PMD)), neem oil, lemongrass, tea tree oil from Melaleuca alternifolia leaves, tobacco, or extracts thereof.

[0429] III. How to use

[0430] The PMPs herein can be used in a variety of agricultural or therapeutic methods. Examples of methods of using PMPs (eg, including the modified PMPs described herein) are further described below.

[0431] A. Delivery to Plants

[0432] Provided herein are methods for delivering a PMP composition (e.g., comprising a modified PMP described herein) to a plant, e.g., by contacting the plant or part thereof with the PMP composition. In some cases, the plant can be treated with a PMP that does not contain a heterologous functional agent. In other cases, the PMP comprises a heterologous functional agent (e.g., a pesticide (e.g., an antibacterial agent, an antifungal agent, a nematicide, a molluscicide, a viricide, a herbicide)), a pest control agent (e.g., a repellent), a fertilizer, or a plant modifier.

[0433] In one aspect, provided herein is a method of increasing the fitness of a plant, comprising delivering to the plant a PMP composition described herein (e.g., in an amount and for a duration effective to increase the fitness of the plant relative to an untreated plant (e.g., a plant to which the PMP composition is not delivered).

[0434] The increase in plant fitness caused by delivering the PMP composition can be manifested in many ways, such as resulting in better production of plants, such as increased yield, improved plant vigor (e.g., improved tolerance to abiotic or biotic stress or improved resistance to harmful organisms), or improved quality of products harvested from plants. Improved plant yields relate to an increase in the yield of a measurable amount of a plant's product relative to the yield of the same product produced under the same conditions but without the application of the composition of the present invention, or compared to the application of conventional agricultural agents (e.g., as measured by plant biomass, grain, seed or fruit yield, protein content, carbohydrate or oil content, or leaf area). For example, the yield can be increased by at least about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, or greater than 100%. Yield can be expressed as a weight or volumetric measurement of the plant or plant product on a certain basis. The basis can be expressed in terms of time, growth area, weight of the plant produced, or the amount of raw materials used. For example, such methods can increase the yield of plant tissues including, but not limited to, seeds, fruits, kernels, pods, tubers, roots, and leaves.

[0435] The increase in plant fitness due to delivery of the PMP composition can also be measured by other methods, such as an increase or improvement in vigor level, stand (number of plants per unit area), plant height, culm girth, culm length, number of leaves, leaf size, plant canopy, visual appearance (such as greener leaf color), root level, emergence, protein content, increase in tillers, larger leaves, more leaves, fewer dead basal leaves, stronger tillers, less fertilizer required, fewer seeds required, more productive tillers, earlier flowering, earlier grain or seed maturity, fewer plant verses (lodging), increase in bud growth, earlier germination, or any combination of these factors, relative to the same factors in plants produced under the same conditions but without application of the composition of the invention or with application of conventional agricultural agents.

[0436] Provided herein are methods for modifying or increasing the fitness of a plant, the methods comprising delivering to the plant an effective amount of a PMP composition provided herein, wherein the method modifies the plant and thereby introduces or increases a beneficial trait in the plant relative to an untreated plant (e.g., an increase of about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%). In particular, the method can increase the fitness of the plant relative to an untreated plant (e.g., an increase of about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%).

[0437] In some cases, the increase in plant fitness is an increase (e.g., an increase of about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%) in disease resistance, drought tolerance, heat tolerance, cold tolerance, salt tolerance, metal tolerance, herbicide tolerance, chemical tolerance, water use efficiency, nitrogen utilization, resistance to nitrogen stress, nitrogen fixation, pest resistance, herbivore resistance, pathogen resistance, yield, yield under water-limiting conditions, vigor, growth, photosynthetic capacity, nutrition, protein content, carbohydrate content, oil content, biomass, shoot length, root length, root structure, seed weight, or amount of harvestable product.

[0438] In some cases, the increase in fitness is an increase in development, growth, yield, resistance to an abiotic stress source, or resistance to a biotic stress source (e.g., an increase of about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%). Abiotic stress refers to environmental stress conditions to which a plant or plant part is subjected, including, for example, drought stress, salt stress, heat stress, cold stress, and low nutrient stress. Biotic stress refers to environmental stress conditions to which a plant or plant part is subjected, including, for example, nematode stress, herbivorous insect stress, fungal pathogen stress, bacterial pathogen stress, or viral pathogen stress. Stress can be temporary, e.g., for a few hours, a few days, a few months, or permanent, e.g., lasting the lifetime of the plant.

[0439] In some cases, the increase in plant fitness is an increase in the quality of a product harvested from the plant (e.g., an increase of about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%). For example, the increase in plant fitness can be an improvement in a commercially advantageous characteristic (e.g., taste or appearance) of a product harvested from the plant. In other cases, the increase in plant fitness is an increase in the shelf life of a product harvested from the plant (e.g., an increase of about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%).

[0440] Alternatively, the increase in fitness can be a change in a trait that is beneficial to human or animal health, such as a reduction in allergen production. For example, the increase in fitness can be a reduction in the production of an allergen (e.g., pollen) that stimulates an immune response in an animal (e.g., a human) (e.g., a reduction of about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%).

[0441] The modification of a plant (e.g., an increase in fitness) may result from modification of one or more plant parts. For example, a plant can be modified by contacting leaves, seeds, pollen, roots, fruits, buds, flowers, cells, protoplasts, or tissues (e.g., meristems) of the plant. Thus, in another aspect, provided herein is a method for increasing the fitness of a plant, the method comprising contacting pollen of the plant with an effective amount of a PMP composition of the present invention, wherein the method increases the fitness of the plant relative to an untreated plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%).

[0442] In yet another aspect, provided herein is a method of increasing the fitness of a plant, the method comprising contacting a seed of the plant with an effective amount of a PMP composition disclosed herein, wherein the method increases the fitness of the plant relative to an untreated plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%).

[0443] In another aspect, provided herein is a method comprising contacting protoplasts of a plant with an effective amount of a PMP composition herein, wherein the method increases the fitness of the plant relative to an untreated plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%).

[0444] In additional aspects, provided herein is a method of increasing the fitness of a plant, the method comprising contacting a plant cell of the plant with an effective amount of a PMP composition herein, wherein the method increases the fitness of the plant relative to an untreated plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%).

[0445] In another aspect, provided herein is a method of increasing the fitness of a plant, comprising contacting a meristem of the plant with an effective amount of a PMP composition herein, wherein the method increases the fitness of the plant relative to an untreated plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%).

[0446] In another aspect, provided herein is a method of increasing the fitness of a plant, comprising contacting an embryo of the plant with an effective amount of a PMP composition herein, wherein the method increases the fitness of the plant relative to an untreated plant (e.g., by about 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%).

[0447] In the case where PMP or its composition comprises a herbicide, the method can further be used to reduce the fitness of weeds or kill weeds. In such cases, compared with untreated weeds (e.g., weeds to which the PMP composition is not applied), the method can effectively reduce the fitness of weeds by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more. For example, the method can effectively kill weeds, thereby reducing the weed population by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more compared with untreated plants. In some cases, the method significantly eliminates weeds. Examples of weeds that can be processed according to the method of the present invention are further described herein.

[0448] i. Plants

[0449] A variety of plants can be delivered to or treated with the PMP compositions described herein. Plants to which the PMP compositions can be delivered (i.e., "treated") according to the methods of the present invention include whole plants and parts thereof, including but not limited to bud vegetative organs / structures (e.g., leaves, stems, and tubers), roots, flowers and floral organs / structures (e.g., bracts, sepals, petals, stamens, carpels, anthers, and ovules), seeds (including embryos, endosperms, cotyledons, and embryos), and fruits (mature ovaries), plant tissues (e.g., meristems, vascular tissues, ground tissues, etc.), and cells (e.g., guard cells, egg cells, etc.), and their progeny. Plant parts can further refer to plant parts such as buds, roots, stems, seeds, stipules, leaves, petals, flowers, ovules, bracts, branches, petioles, internodes, bark, pubescence, tillers, rhizomes, fronds, leaves, pollen, stamens, etc.

[0450] Classes of plants that can be treated in the methods disclosed herein include higher and lower plant classes, including angiosperms (monocots and dicots), gymnosperms, ferns, horsetails, gymnosperms, lycophytes, bryophytes, and algae (e.g., multicellular or unicellular algae). Plants that can be treated according to the methods of the present invention further include any vascular plant, such as monocots or dicots or gymnosperms, including but not limited to alfalfa, apple, Arabidopsis, banana, barley, canola, castor bean, chrysanthemum, clover, cocoa, coffee, cotton, cottonseed, corn, crambe, cranberry, crucifers, cucumber, dendrobium, yam, eucalyptus, fescue, flax, gladiolus, lily family, linseed, millet, melon, mustard, oats, oil palm, canola or rapeseed, papaya, peanut, pineapple, ornamentals, beans, potatoes, rapeseed, rice, rye, ryegrass, safflower, sesame, sorghum, soybean, sugar beet, sugarcane, sunflower, strawberry, tobacco, tomato, Turfgrass, wheat, and vegetable crops (e.g., lettuce, celery, broccoli, cauliflower, gourds); fruit and nut trees, such as apples, pears, peaches, oranges, grapefruits, lemons, limes, almonds, pecans, walnuts, and hazelnuts; vines, such as grapes (e.g., vineyards), kiwifruit, and hops; hemp, fruit shrubs, and raspberries, such as raspberries, blackberries, and currants; forest trees, such as ash, pine, fir, maple, oak, chestnut, and poplar (popular); and alfalfa, canola, castor bean, corn, cotton, crambe, flax, linseed, mustard, oil palm, rapeseed, peanuts, potatoes, rice, safflower, sesame, soybeans, sugar beets, sunflowers, tobacco, tomatoes, and wheat. Plants that can be treated according to the methods of the present invention include any crop plants, for example, forage crops, oilseed crops, cereal crops, fruit crops, vegetable crops, fiber crops, spice crops, spice crops, turf crops, sugar crops, beverage crops, and forest crops. In some cases, the crop plants treated in this method are soybean plants. In other certain cases, the crop plants are wheat. In some cases, the crop plants are corn. In some cases, the crop plants are cotton. In some cases, the crop plants are alfalfa. In some cases, the crop plants are sugar beets. In some cases, the crop plants are rice. In some cases, the crop plants are potatoes. In some cases, the crop plants are tomatoes.

[0451] In some cases, the plant is a crop. Examples of such crop plants include, but are not limited to, monocots and dicots, including, but not limited to, feed or forage legumes, ornamentals, food crops, trees, or shrubs selected from Acer spp., Allium spp., Amaranthus spp., Ananascomosus, Apium graveolens, Arachis spp., Asparagus officinalis, Beta vulgaris, Brassica spp. (e.g., Brassica napus, Brassica rapa ssp.) (canola, rapeseed, turnip rape), Camellia sinensis, Canna indica, Cannabis sativa, Capsicum spp., Castanea spp. spp.), cultivated chicory (Cichorium endivia), watermelon (Citrullus lanatus), citrus species (Citrus spp.), coconut species (Cocos spp.), coffee species (Coffea spp.), cilantro (Coriandrum sativum), hazelnut species (Corylus spp.), hawthorn species (Crataegus spp.), pumpkin species (Cucurbita spp.), cucumber species (Cucumis spp.), carrot (Daucus carota), beech species (Fagus spp.), fig (Ficus carica), strawberry species (Fragaria spp.), ginkgo (Ginkgo biloba), Glycines spp. (e.g., soybean (Glycine max), soybean (Soja hispida), or soybean (Soja max)), upland cotton (Gossypium hirsutum), sunflower species (Helianthus spp.) (e.g., sunflower), Hibiscus spp., Hordeum spp. (e.g., Hordeum vulgare), Ipomoea batatas, Juglans spp.), lettuce (Lactuca sativa), flax (Linumus itatissimum), litchi (Litchi chinensis), lotus species (Lotus spp.), angular loofah (Luffa acutangula), lupinus species (Lupinus spp.), tomato species (Lycopersicon spp.) (e.g., tomato (Lycopersicon esculenturn)), cherry tomatoes (Lycopersicon lycopersicum), pear-shaped tomatoes (Lycopersicon pyriforme), apple species (Malus spp.), alfalfa (Medicago sativa), mint species (Mentha spp.), awn (Miscanthus sinensis), black mulberry (Morus nigra), banana species (Musa spp.), tobacco species (Nicotiana spp.), Olea spp., Oryza spp. (e.g., Oryza sativa), broadleaf wild rice (Oryza latifolia), millet (Panicum miliaceum), switchgrass (Panicum virgatum), passionflower (Passiflora edulis), parsley (Petroselinum crispum), bean species (Phaseolus spp.), pine species (Pinus spp.), pistachio (Pistacia vera), pea species (Pisum spp.), bluegrass species (Poa spp.), poplar species (Populus spp.), plum species (Prunus spp.), pear (Pyrus communis), oak species (Quercus spp.), radish (Raphanus sativus), rhubarb (Rheum rhabarbarum), ribes species (Ribes spp.), castor (Ricinus communis), Rubus species (Rubus spp.), Saccharum spp., Salix sp., Sambucus spp., Secale cereale, Sesamum spp., Sinapis spp., Solanum spp.) (e.g., Solanum tuberosum, Solanum integrifolium, or Solanum lycopersicum), Sorghum bicolor, Sorghum halepense, Spinacia spp., Tamarindus indica, Theobroma cacao, Trifolium spp., Triticosecale rimpaui, Triticum spp. (e.g., Triticum aestivum), Triticum durum, Triticum turgidum, Triticum hybernum, Triticum macha, Triticum sativum, or Triticum vulgare), Vaccinium spp., Vicia spp., Vigna spp.), Viola odorata, Vitis spp., and Zea mays. In certain embodiments, the crop plant is rice, rapeseed, canola, soybean, corn (maize), cotton, sugarcane, alfalfa, sorghum, or wheat.

[0452] In some cases, these compositions and methods can be used to treat post-harvest plants or plant parts, food or feed products. In some cases, the food or feed product is a non-plant food or feed product (e.g., a product edible to humans, veterinary animals, or livestock (e.g., mushrooms)).

[0453] Plants or plant parts used in the present invention include plants in any plant development stage. In some cases, delivery can be carried out in the stages of germination, seedling growth, vegetative growth, and reproductive growth. In some cases, delivery to the plant is carried out during the vegetative growth and reproductive growth stages. Alternatively, delivery to the seed can be carried out. The vegetative growth and reproductive growth stages are also referred to as "mature plants" or "mature" plants in this article.

[0454] ii. Weeds

[0455] In the case where PMP or its composition comprises a herbicide, the method can further be used to reduce the fitness of weeds or kill weeds. In such cases, compared with untreated weeds (e.g., weeds to which the PMP composition is not applied), the method can effectively reduce the fitness of weeds by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more. For example, the method can effectively kill weeds, thereby reducing the weed population by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more compared with untreated plants. In some cases, the method significantly eliminates weeds. Examples of weeds that can be processed according to the method of the present invention are further described herein.

[0456] As used herein, the term "weeds" refers to plants that grow in places where they are not desired. Such plants are typically invasive and sometimes harmful or at risk of becoming harmful. Weeds can be treated with the PMP compositions of the present invention to reduce or eliminate the presence, viability, or reproduction of the plants. For example, and without limitation, these methods can be used to target weeds that are known to damage plants. For example, and without limitation, the weeds can be any member of the following family groups: Gramineae, Umbelliferae, Papilionaceae, Cruciferae, Malvaceae, Eufhorbiaceae, Compositae, Chenopodiaceae, Fumariaceae, Charyophyllaceae, Primulaceae , Geraniaceae, Polygonaceae, Juncaceae, Cyperaceae, Aizoaceae, Asteraceae, Convolvulaceae, Cucurbitaceae, Euphorbiaceae, Polygonaceae, Portulaceae, Solanaceae, Rosaceae eae), Simaroubaceae, Lardizabalaceae, Liliaceae, Amaranthaceae, Vitaceae, Fabaceae, Primulaceae, Apocynaceae, Araliaceae, Caryophyllaceae, Asclepiadaceae, Celastraceae , Papaveraceae, Onagraceae, Ranunculaceae, Lamiaceae, Commelinaceae, Scrophulariaceae, Dipsacaceae, Boraginaceae, Equisetaceae, Geraniaceae, Rubiaceae, Cannabaceae,Hyperiacaceae, Balsaminaceae, Lobeliaceae, Caprifoliaceae, Nyctaginaceae, Oxalidaceae, Vitaceae, Urticaceae, Polypodiaceae, Anacardiaceae, Smilacaceae, Araceae, Campanulaceae, Typhaceae, Valerianaceae, Verbenaceae, and Violaceae. For example, and without limitation, the weeds may be any member of the group consisting of: Lolium rigidum, Amaramthus palmeri, Abutilon theopratsi, Sorghum halepense, Conyza canadensis, Setaria verticillata, Capsella pastoris, and Cyperus rotundas. Additional weeds include, for example, Mimos apigra, salvinia, hyptis, senna, noogoora, burr, Jatropha gossypifolia, Parkinsonia aculeate, Chromolaena odorata, Cryptoslegia grandiflora, or Andropogon gayanus. Weeds may include monocots (e.g., Agrostis, Alopecurus, Avena, Bromus, Cyperus, Digitaria, Echinochloa, Lolium, Monochoria, Rottboellia, Sagittaria, Scirpus, Setaria, Sida, or Sorghum) or dicots (Abutilon), Amaranthus,Chenopodium, Chrysanthemum, Conyza, Galium, Ipomoea, Nasturtium, Sinapis, Solanum, Stellaria, Veronica, Viola, or Xanthium.

[0457] The compositions and related methods can be used to prevent infestation by pathogens or pathogen vectors or to reduce the number of pathogens or pathogen vectors in any habitat they inhabit (e.g., external to an animal, such as on a plant, plant part (e.g., roots, fruits and seeds); in soil, water or on; or in another pathogen or pathogen vector habitat. Thus, these compositions and methods can reduce the damaging effects of pathogen vectors by, for example, killing, injuring or slowing the activity of the vectors, and can thereby control the spread of pathogens to animals. The compositions disclosed herein can be used to control, kill, injure, paralyze, or reduce the activity of any one or more of any pathogens or pathogen vectors in any developmental stage (e.g., their eggs, nymphs, instars, larvae, adults, juveniles, or dried forms). Details of each of these methods are further described below.

[0458] B. Delivery of plant pests

[0459] Provided herein are methods for delivering a PMP composition (e.g., comprising a modified PMP described herein) to a plant pest, e.g., by contacting the plant pest with the PMP composition. In some cases, a PMP that does not contain a heterologous functional agent can be used to treat the plant pest. In other cases, the PMP comprises a heterologous functional agent (e.g., a pesticide (e.g., an antibacterial agent, an antifungal agent, a nematicide, a molluscicide, a viricide, or a herbicide)), a pest control agent (e.g., a repellent). For example, the method can be used to reduce the fitness of the pest, e.g., to prevent or treat an infestation of the pest as a result of delivering the PMP composition.

[0460] In one aspect, provided herein is a method of reducing the fitness of a pest, the method comprising delivering to the pest a PMP composition described herein (e.g., in an effective amount and for an effective duration) to reduce the fitness of the pest relative to an untreated pest (e.g., a pest to which the PMP composition is not delivered).

[0461] In one aspect, provided herein is a method of reducing (eg, treating) a fungal infection in a plant having a fungal infection, wherein the method comprises delivering to the plant pest a PMP composition comprising a plurality of PMPs (eg, a PMP composition described herein).

[0462] On the other hand, there is provided herein a method for reducing (e.g., processing) a fungal infection in a plant having a fungal infection, wherein the method includes delivering a PMP composition (e.g., a PMP composition described herein) comprising multiple PMPs to the plant pest, and wherein the multiple PMPs include an antifungal agent. In some cases, the antifungal agent is a nucleic acid that suppresses the expression of genes (e.g., dcl1 and dcl2 (i.e., dcl1 / 2)) in the fungus causing the fungal infection. In some cases, the fungal infection is caused by a fungus belonging to a species of Sclerotinia spp. (e.g., Sclerotinia sclerotiorum), a species of Botrytis spp. (e.g., Botrytis cinerea), an Aspergillus species (Aspergillus spp.), a species of Fusarium spp., or a species of Penicillium spp.). In some cases, the composition includes the PMPs produced from an Arabidopsis apoplast EV. In some cases, the method reduces or significantly eliminates fungal infection.

[0463] In another aspect, provided herein is a method of reducing (eg, treating) a bacterial infection in a plant having a bacterial infection, wherein the method comprises delivering a PMP composition comprising a plurality of PMPs (eg, a PMP composition described herein) to the plant pest.

[0464] On the other hand, there is provided herein a method for reducing (e.g., treating) a bacterial infection in a plant with a bacterial infection, wherein the method includes delivering a PMP composition comprising multiple PMPs to the plant pest, and wherein the multiple PMPs include an antibacterial agent. In some cases, the antibacterial agent is streptomycin. In some cases, the bacterial infection is caused by a bacterium that belongs to Pseudomonas species (Pseudomonas spp) (e.g., Pseudomonas syringae). In some cases, the composition includes PMPs produced from Arabidopsis apoplast EVs. In some cases, the method reduces or significantly eliminates bacterial infection.

[0465] In another aspect, provided herein is a method of reducing the fitness of an insect plant pest, wherein the method comprises delivering to the insect plant pest a PMP composition comprising a plurality of PMPs (eg, a PMP composition described herein).

[0466] In another aspect, provided herein is a method for reducing the fitness of an insect plant pest, wherein the method comprises delivering a PMP composition comprising a plurality of PMPs (e.g., a PMP composition described herein) to the plant pest, and wherein the plurality of PMPs comprises an insecticide. In some cases, the insecticide is a peptide nucleic acid. In some cases, the insect plant pest is an aphid. In some cases, the insect plant pest is a lepidopteran insect (e.g., fall armyworm). In some cases, the insect plant pest is an arachnid, e.g., a mite. In some cases, the method reduces the fitness of the insect plant pest relative to an untreated insect plant pest.

[0467] In another aspect, provided herein is a method of reducing the fitness of a nematode plant pest, wherein the method comprises delivering to the nematode plant pest a PMP composition comprising a plurality of PMPs (eg, a PMP composition described herein).

[0468] In another aspect, provided herein is a method for reducing the fitness of a nematode plant pest, wherein the method comprises delivering a PMP composition comprising a plurality of PMPs (e.g., a PMP composition described herein) to the nematode plant pest, and wherein the plurality of PMPs comprises a nematode. In some cases, the nematode plant pest is a neuropeptide (e.g., Mi-NLP-15b). In some cases, the nematode plant pest is a root-knot nematode. In some cases, the method reduces the fitness of the nematode plant pest relative to an untreated nematode plant pest.

[0469] In another aspect, provided herein is a method of reducing the fitness of a weed, wherein the method comprises delivering to the weed a PMP composition comprising a plurality of PMPs (eg, a PMP composition described herein).

[0470] In another aspect, provided herein is a method for reducing the fitness of a weed, wherein the method comprises delivering a PMP composition comprising a plurality of PMPs (e.g., a PMP composition described herein) to the weed, and wherein the plurality of PMPs comprises a herbicide (e.g., glufosinate). In some cases, the weed is Indian goosegrass (Eleusine indica). In some cases, the method reduces the fitness of the weed relative to untreated weeds.

[0471] The reduction in the fitness of a pest as a result of delivering a PMP composition can be manifested in many ways. In some cases, the reduction in the fitness of a pest as a result of delivering a PMP composition can be manifested as a deterioration or decline in the physiology of the pest (e.g., reduced health or survival). In some cases, the fitness of an organism can be measured by one or more parameters, including but not limited to reproductive rate, fertility, lifespan, viability, mobility, fecundity, pest development, weight, metabolic rate or activity, or survival, compared to a pest to which a PMP composition is not applied. For example, the methods or compositions provided herein can effectively reduce the overall health of a pest or reduce the overall survival of a pest. In some cases, the survival of the pest is reduced by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%, relative to a reference level (e.g., a level found in a pest that has not received a PMP composition). In some cases, the methods and compositions are effective in reducing pest reproduction (e.g., reproduction rate, fertility) compared to pests to which the PMP composition has not been applied. In some cases, the methods and compositions are effective in reducing other physiological parameters (such as motility, body weight, lifespan, fecundity, or metabolic rate) by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100% relative to a reference level (e.g., a level found in pests that have not received the PMP composition).

[0472] In some cases, the reduction in pest fitness can be manifested as a reduction in the production of one or more nutrients (e.g., vitamins, carbohydrates, amino acids, or polypeptides) in the pest compared to the pest to which the PMP composition has not been applied. In some cases, the methods or compositions provided herein can be effective in reducing the production of a nutrient (e.g., vitamin, carbohydrate, amino acid, or polypeptide) in the pest by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100% relative to a reference level (e.g., a level found in a pest that has not received the PMP composition).

[0473] In some cases, the reduction in pest fitness can be manifested as an increase in the pest's sensitivity to the pesticide and / or a decrease in the pest's resistance to the pesticide compared to the pest to which the PMP composition is not applied. In some cases, relative to a reference level (e.g., a level found in pests that have not received the PMP composition), the methods or compositions provided herein can effectively increase the pest's sensitivity to the pesticide by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%. The pesticide can be any pesticide known in the art, including insecticides. In some cases, compared to pests to which the PMP composition is not applied, the methods or compositions provided herein can increase the pest's sensitivity to the pesticide by reducing the pest's ability to metabolize or degrade the pesticide into a usable substrate.

[0474] In some cases, the reduction in pest fitness can be manifested as an increase in the sensitivity of the pest to the allelopathic agent and / or a reduction in the resistance of the pest to the allelopathic agent compared to the pest to which the PMP composition is not applied. In some cases, relative to a reference level (e.g., a level found in pests that have not received the PMP composition), the method or composition provided herein can effectively reduce the resistance of the pest to the allelopathic agent by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%. In some cases, the allelopathic agent is caffeine, soy cysteine ​​protease inhibitor (soyacystatin), fenitrothion, monoterpenes, diterpenoids, or phenolic compounds (e.g., tannins, flavonoids). In some cases, compared to pests to which the PMP composition is not applied, the method or composition provided herein can increase the sensitivity of the pest to the allelopathic agent by reducing the ability of the pest to metabolize or degrade the allelopathic agent into a usable substrate.

[0475] In some cases, the methods or compositions provided herein can be effective in reducing a pest's resistance to a parasite or pathogen (e.g., a fungal, bacterial, or viral pathogen or parasite) compared to a pest to which the PMP composition has not been applied. In some cases, the methods or compositions provided herein can be effective in reducing a pest's resistance to a pathogen or parasite (e.g., a fungal, bacterial, or viral pathogen; or a parasitic mite) by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100% relative to a reference level (e.g., a level found in a pest that has not received the PMP composition).

[0476] In some cases, the methods or compositions provided herein can be effective in reducing the ability of a pest to carry or transmit a plant pathogen (e.g., a plant virus (e.g., TYLCV) or a plant bacterium (e.g., Agrobacterium spp.)) compared to a pest to which the PMP composition is not applied. For example, the methods or compositions provided herein can be effective in reducing the ability of a pest to carry or transmit a plant pathogen (e.g., a plant virus (e.g., TYLCV) or a plant bacterium (e.g., Agrobacterium spp.)) by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100% relative to a reference level (e.g., a level found in a pest that has not received a PMP composition).

[0477] Additionally or alternatively, in the case where a PMP or its composition comprises a herbicide, the method can further be used to reduce the fitness of weeds or kill weeds. In such cases, the method can effectively reduce the fitness of weeds by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more compared to untreated weeds (e.g., weeds to which the PMP composition has not been applied). For example, the method can effectively kill weeds, thereby reducing the weed population by about 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more compared to untreated plants. In some cases, the method significantly eliminates weeds. Examples of weeds that can be processed according to the methods of the present invention are further described herein.

[0478] In some cases, the reduction in pest fitness can be manifested as other fitness disadvantages, such as reduced tolerance to certain environmental factors (e.g., high or low temperature tolerance), reduced ability to survive in certain habitats, or reduced ability to maintain a certain diet, compared to pests to which the PMP composition is not applied. In some cases, the methods or compositions provided herein can effectively reduce pest fitness in any of the various ways described herein. In addition, the PMP composition can reduce the fitness of pests in any number of classes, orders, families, genera, or species (e.g., 1 pest species, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 200, 250, 500, or more pest species). In some cases, the PMP composition acts on a single pest class, order, family, genus, or species.

[0479] Any standard method in the art can be used to assess pest fitness. In some cases, pest fitness can be assessed by evaluating individual pests. Alternatively, pest fitness can be assessed by evaluating a pest population. For example, a decrease in pest fitness can manifest as a decrease in successful competition with other insects, thereby resulting in a decrease in the size of the pest population.

[0480] i. Fungi

[0481] PMP compositions and related methods can be used to reduce the fitness of fungi, for example, to prevent or treat fungal infections in plants. Methods for delivering the PMP composition to a fungus by contacting the fungus with the PMP composition are included. Additionally or alternat...

Claims

1. A method for preparing a lipid-reconstituted plant messenger package (LPMP), the method comprising reconstructing a membrane comprising purified PMP lipids in the presence of a synthetic charged lipid, thereby producing a LPMP comprising the synthetic charged lipid, wherein the synthetic charged lipid is selected from 1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), DLin-MC3-DMA (MC3), dioleoyl-3-trimethylammonium propane (DODAP), DC-cholesterol, DOTAP, ethyl PC, GL67, DLin-KC2-DMA (KC2), MD1 (cKK-E12), OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5, cationic sulfonamide amino lipid, amphiphilic zwitterionic amino lipid, DODAC, DOBAQ, YSK05, DOBAT, DOBAQ, DOPAT, DOMPAQ, DOAAQ, DMAP-BLP, DLinDMA, DODMA, DOTMA, DSDMA, DOSPA, DODAC, DOBAQ, DMRIE, DOTAP-cholesterol, GL67A, and 98N12-5, or a combination thereof.

2. The method of claim 1, wherein the synthetic charged lipid is selected from C12-200, MC3, DODAP, DC-cholesterol, DOTAP, ethyl PC, GL67, KC2, MD1, OF2, EPC, ZA3-Ep10, TT3, LP01, 5A2-SC8, lipid 5, cationic sulfonamide amino lipids, and amphiphilic zwitterionic amino lipids, or a combination thereof.

3. The method of claim 2, wherein the synthetic charged lipid is selected from C12-200, MC3, DODAP, and DC-cholesterol, or a combination thereof.

4. The method of claim 1, wherein the reconstitution is performed in the presence of a sterol, thereby producing a LPMP comprising a synthetic charged lipid and a sterol.

5. The method of claim 4, wherein the sterol is cholesterol or sitosterol.

6. The method of claim 1, wherein the reconstitution is performed in the presence of a PEGylated lipid, thereby producing a LPMP comprising a synthetic charged lipid and a PEGylated lipid.

7. The method of claim 6, wherein the PEGylated lipid is C14-PEG2k, C18-PEG2k, or DMPE-PEG2k.

8. The method of claim 1, wherein the reconstitution is performed in the presence of a sterol and a pegylated lipid, thereby producing a LPMP comprising a synthetic charged lipid, a sterol, and a pegylated lipid.

9. The method of claim 8, wherein the synthetic charged lipids, purified PMP lipids, sterols, and PEGylated lipids account for 30%-75%, 10%-20%, 35%-50%, and 1%-3% of the lipids in the modified PMP, respectively.

10. The method of claim 9, wherein the synthetic charged lipid, purified PMP lipid, sterol, and PEGylated lipid are formulated in a molar ratio of 50:10:38.5:1.

5.

11. The method of claim 1, wherein the LPMPs comprise heterologous polynucleotides.

12. The method of claim 11, wherein the heterologous polynucleotide is mRNA, siRNA or a precursor thereof, micro RNA (miRNA) or a precursor thereof, viral RNA, or a plasmid.

13. The method of claim 11, wherein the LPMP has an encapsulation efficiency of at least 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or more than 99% for the heterologous polynucleotide.

14. The method of claim 1, wherein the LPMP is formulated for delivery to an animal.

15. The method of claim 1, wherein the LPMP is formulated for delivery to a plant.